Therapeutics Advisory Group CCG and NHS Trusts in Norfolk and Waveney Index of TAG recommendations Generic name Indication BNFclass Trafficlight IQoro euromuscular training Hiatus hernia - improving symptoms No BNF entry - device Double Red Not recommended for device routine use / Not commissioned

(L-) Carnitine Carnitine Deficiency 9.8.1 Drugs used in Red Hospital / Specialist metabolic disorders only

(Para-)aminosalicylic acid Tuberculosis 5.1.9 Antituberculosis Double Red Not recommended for drugs - routine use / Not Antimycobacterials commissioned

5-fluorouracil + salicyclic acid Hyperkeratotic actinic keratosis 13.8.1 Photodamage Double-GreenSuitable for GPs to topical solution initiate and prescribe

5-fluorouracil 5% w/w cream Non-hypertrophic actinic keratosis 13.8.1 Photodamage Double-GreenSuitable for GPs to initiate and prescribe

Abacavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Abacavir + dolutegravir + HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist lamivudine antiretroviral drugs only

Abacavir and lamivudine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Abaloparatide Male and juvenile osteoporosis 6.6.1 Calcitonin and Double Red Not recommended for Calcitonin and routine use / Not parathyroid hormone commissioned

Abatacept Rheumatoid arthritis - 1st line biologic 10.1.3 Drugs that suppress Red Hospital / Specialist after failure of non-biologic DMARDs - the rheumatic disease only as per NICE TA 280 process

Abatacept Treatment of Juvenile Idiopathic 10.1.3 Drugs that suppress Red Hospital / Specialist Arthritis (JIA) as per NICE TA 373 the rheumatic disease only process

Abatacept Rheumatoid arthritis - after other 10.1.3 Drugs that suppress Red Hospital / Specialist DMARDs including a TNF inhibitor - as the rheumatic disease only per NICE TA 195 process

Abatacept Psoriatic arthritis after DMARDs as 10.1.3 Drugs that suppress Double Red Not recommended for per NICE TA 568 terminated appraisal the rheumatic disease routine use / Not process commissioned

Abatacept moderate rheumatoid arthritis after 10.1.3 Drugs that suppress Double Red Not recommended for conventional DMARDs have failed as the rheumatic disease routine use / Not per TA715 process commissioned

Abatacept (subcutaneous) First line biologic option for moderate 10.1.3 Drugs that suppress Red Hospital / Specialist to severe active rheumatoid arthritis in the rheumatic disease only adults who responded inadequately to process one or more DMARDS (including MTX) Abciximab Prevention of MI during PCTA - as per 2.9 Antiplatelet drugs Red Hospital / Specialist NICE TA 47 only

Abemaciclib Locally advanced or metastic hormone 8.1.5 Other antineoplastic Red Hospital / Specialist receptor-positive, human epidermal drugs only growth factor receptor 2 (HER2)- negative breast cancer as first endocrine-based therapy in adults - as per NICE TA 563 Abiraterone Metastatic hormone-relapsed prostate 8.3.4 Hormone antagonists Red Hospital / Specialist cancer before chemotherapy is only indicated (in combination with prednisone or prednisolone) - as per NICE TA 387

Abiraterone acetate Castration resistant metastatic 8.3.4 Hormone Antagonists Red Hospital / Specialist prostate cancer previously treated with only docetaxel - as per NICE TA 259

Printed: 14 September 2021 Page 1 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Acalabrutinib chronic lymphocytic leukaemia as per 8.1.5 Protein kinase Red Hospital / Specialist TA689 inhibitors only

Acamprosate Maintenance of abstinence in alcohol- 4.10.1 Drugs used in Red Hospital / Specialist dependent patients substance misuse only

ACE inhibitors with Angiontensin-II Receptor 2.5.5.1 Angiotensin- Double red Not recommended for Antagonists (ARBs) - NICE Do Not Do converting enzyme routine use / Not inhibitors commissioned

ACE Inhibitors - various Treatment of cor pulmonale - as per 2.5.5.1 Angiotensin- Double Red Not recommended for NICE CG 101 - NICE Do Not Do converting enzyme routine use / Not inhibitors commissioned Acitretin All indications 13.5.2 Oral retinoids for Red Hospital / Specialist psoriasis only

Aclidinium bromide (Eklira Inhaled treatment for Chronic 3.1.2 Antimuscarinic Double-GreenSuitable for GPs to Genuair®) ▼ Obstructive Pulmonary Disease bronchodilators initiate and prescribe (COPD)

Acne treatment - Aknicare® Treatment of acne Not listed Double Red Not recommended for products routine use / Not commissioned ActiPatch® Relief of musculoskeletal pain Not listed - pulsed Double Red Not recommended for electromagnetic routine use / Not stimulator commissioned

Adalimumab Treatment of (non-radiographic) axial 10.1.3 Drugs that suppress Red Hospital / Specialist spondyloarthritis - as per local the rheumatic disease only treatment pathway process

Adalimumab Juvenile idiopathic rheumatoid arthritis 10.1.3 Cytokine modulators Red Hospital / Specialist (JIA) - option in children with chronic only anterior uveitis - as per NHS England policy

Adalimumab Behcet's syndrome 10.1.3 Drugs that affect the Red Hospital / Specialist rheumatic disease only process

Adalimumab Anti-TNF treatment option for adult 10.1.3 Drugs that suppress Double Red Not recommended for patients with severe refractory uveitis - the rheumatic disease routine use / Not as per NHS England policy and NICE process commissioned TA 460 Adalimumab Treatment of adults with psoriasis - as 10.1.3 Drugs that suppress Red Hospital / Specialist per NICE TA 146 and the local the rheumatic disease only treatment pathway process

Adalimumab 2nd line anti-TNF in patients with joint 10.1.3 Drugs that suppress Red Hospital / Specialist or skin autoimmune disease who the rheumatic disease only develop IBD on etanercept - as per process local treatment pathway

Adalimumab Rheumatoid arthritis - after other 10.1.3 Drugs which suppress Red Hospital / Specialist DMARDs including a TNF inhibitor - as the rheumatic disease only per local treatment pathway process

Adalimumab moderate rheumatoid arthritis after 10.1.3 Drugs that suppress Red Hospital / Specialist conventional DMARDs have failed as the rheumatic disease only per TA715 process

Adalimumab Plaque psoriasis in children and young 10.1.3 Drugs that suppress Red Hospital / Specialist people - as per NICE TA 455 the rheumatic disease only process

Adalimumab Severe active Crohn's disease which 1.5.3 Drugs affecting the Red Hospital / Specialist has not responded to conventional immune response only therapy - as per NICE TA 187

Adalimumab Ankylosing spondilitis - as per local 10.1.3 Drugs that suppress Red Hospital / Specialist treatment pathway the rheumatic disease only process

Adalimumab Anti-TNF Alpha treatment option for 10.1.3 Drugs that suppress Double Red Not recommended for paediatric patients with severe the rheumatic disease routine use / Not refractory uveitis process commissioned

Printed: 14 September 2021 Page 2 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Adalimumab Moderate to severe hidradenitis 10.1.3 Drugs that suppress Red Hospital / Specialist suppurativa - as per NICE TA 392 the rheumatic disease only process

Adalimumab Moderate to severe ulcerative colitis 1.5.3 Drugs affecting the Red Hospital / Specialist (primary) - as per NICE TA 329 immnune response only

Adalimumab Treatment of children and young 10.1.3 Cytokine modulators Red Hospital / Specialist people with polyarticular juvenile only idiopathic arthritis and for enthesitis- related juvenile idiopathic arthritis as per NICE TA 373

Adalimumab Children with Severe Refractory 10.1.3 Cytokine modulators Red Hospital / Specialist Uveitis with onset in childhood (age 2 only or more up to 18 or less) - as per NHS England policy

Adalimumab Treatment of psoriatic arthritis 10.1.3 Drugs which suppress Red Hospital / Specialist (including switching between the rheumatic disease only treatments) - as per local treatment process pathway Adalimumab (biosimilar) Peripheral spondyloarthritis - following 10.1.3 Drugs that suppress Red Hospital / Specialist use of 3 DMARDs, as per NNUH the rheumatic disease only application process

ADHD drugs - various First-line use in children and 4.4 CNS stimulants and Double Red Not recommended for adolescents with ADHD - as per NICE drugs for ADHD routine use / Not CG 72 - Do Not Do commissioned

ADHD drugs - various Use in pre-school children - as per 4.4 CNS stimulants and Double Red Not recommended for NICE CG 72 - Do Not Do drugs used for ADHD routine use / Not commissioned

Afatinib ▼ Advanced squamous non-small-cell 8.1.5 Protein Kinase Double Red Not recommended for lung cancer after platinum-based Inhibitors routine use / Not chemotherapy - as per NICE TA 444 commissioned

Afatinib ▼ Treatment of epidermal growth factor 8.1.5 Protein kinase Red Hospital / Specialist receptor mutation-positive locally inhibitors only advanced or metastatic non-small-cell lung cancer - as per NICE TA 310

Aflibercept Treatment of visual impairment due to 11.8.2 Ocular diagnostic and Red Hospital / Specialist myopic choroidal neovascularisation in peri-operative only adults - as per NICE TA 486 preparations

Aflibercept Visual impairment caused by macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist oedema after branch retinal vein peri-operative only occlusion - as per NICE TA 409 and preparations local treatment pathway Aflibercept Treatment of Diabetic Macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist Oedema (DMO) as part of a treat and peri-operative only extend regimen in line with the locally preparations commissioned treatment pathway

Aflibercept Treatment of metastatic colorectal 8.1.5 Other antineoplastic Double Red Not recommended for cancer that has progressed following drugs routine use / Not prior oxaliplatin-based chemotherapy commissioned (along with irinotecan and fluorouracil- based therapy) - as per NICE TA 307 - NICE Do Not Do Aflibercept Wet Age-related Macular 11.8.2 Ocular diagnostic & Red Hospital / Specialist Degeneration (AMD) in patients peri-operative only requiring frequent doses with preparations ranibizumab (around eight or more injections per eye per year required to maintain the condition)

Aflibercept Treatment of Wet Age-related Macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist Degeneration (AMD) as part of a treat peri-operative only and extend regimen in line with the preparations locally commissioned treatment pathway

Printed: 14 September 2021 Page 3 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Aflibercept Wet Age-related Macular 11.8.2 Ocular diagnostic & Red Hospital / Specialist Degeneration (AMD) in new patients peri-operative only preparations

Aflibercept Visual impairment caused by macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist oedema secondary to central retinal peri-operative only vein occlusion - as per NICE TA 305 preparations and local treatment pathway

Aflibercept Treatment of Wet Age-related Macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist Degeneration in patients unresponsive peri-operative only to or intolerant of ranibizumab - as per preparations locally commissioned pathway

Aflibercept Treatment of visual impairment 11.8.2 Ocular diagnostic and Red Hospital / Specialist caused by diabetic macular oedema peri-operative only (DMO) as per NICE TA 346 and local preparations treatment pathway Aflibercept (switched to Switching between products in the 11.8.2 Ocular diagnostic & Red Hospital / Specialist Ranibizumab (Lucentis®) treatment of Wet Age-related Macular peri-operative only Degeneration (AMD) in previously preparations treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - as per locally commissioned pathway

Agalsidase alfa and beta Fabry disease (α-galactosidase A Enzymes Red Hospital / Specialist deficiency) only

Agomelatine 4th line use in depression where other 4.3.4 Other antidepressant Double red Not recommended for treatments have failed or not been drugs routine use / Not tolerated commissioned

Albutrenpenonacog alfa Haemophilia B - as per NHS England Not listed in BNF Red Hospital / Specialist policy SSC1652 only

Albutropin Adult onset growth hormone deficiency 6.5.1 Hypothalamic & Double Red Not recommended for anterior pituitary routine use / Not hormones commissioned

Aldesleukin Cancer - metastatic renal cancer Not listed Double Red Not recommended for routine use / Not commissioned

Alectinib Untreated ALK-positive advanced non- 8.1.5 Anti-neoplastic agents; Red Hospital / Specialist small-cell lung cancer - as per NICE protein kinase inhibitor only TA 536

Alectinib ▼ Previously treated anaplastic 8.1.5 Anti-neoplastic agents; Double Red Not recommended for lymphoma kinase-positive advanced protein kinase inhibitor routine use / Not non-small-cell lung cancer - as per commissioned NICE TA 438

Alemtuzumab Pre-transplant immunosuppression 8.2.3 Anti-lymphocyte Red Hospital / Specialist monoclonal antibodies only

Alemtuzumab Behcet's syndrome 8.2.3 Anti-lymphocyte Red Hospital / Specialist monoclonal antibodies only

Alemtuzumab Chronic lymphocytic leukaemia 8.2.3 Anti-lymphocyte Red Hospital / Specialist (CLL) - as per NHS England policy monoclonal antibodies only

Alemtuzumab ▼ Treatment of adults with relapsing- 8.2.3 Anti-lymphocyte Red Hospital / Specialist remitting multiple sclerosis (RRMS) - monoclonal antibodies only as per NICE TA 312

Alendronate / Vitamin D3 Treatment of post menopausal 6.6.2 Bisphosphonates & Double Red Not recommended for combination osteoporosis in women at risk of other drugs affecting routine use / Not vitamin D deficiency - as per N&W bone metab commissioned DROP List Alendronic acid (sodium Primary prevention of osteoporotic 6.6.2 Bisphosphonates Double-GreenSuitable for GPs to alendronate) fragility fractures in postmenopausal (drugs affecting bone initiate and prescribe women as per NICE criteria metabolism)

Alendronic acid (sodium Secondary prevention of osteoporotic 6.6.2 Bisphosphonates Double-GreenSuitable for GPs to alendronate) fragility fractures in postmenopausal (drugs affecting bone initiate and prescribe women - as per NICE criteria metabolism)

Printed: 14 September 2021 Page 4 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Alfacalcidol Preparation for 9.6.4 Vitamin D Green GP prescribable at hyperparathyroidectomy request of Consultant/Specialist

Alglucosidase alfa Pompe disease (a lysosomal storage Enzyme replacement Red Hospital / Specialist disorder caused by deficiency of acid therapy only alpha-glucosidase) - as per NHS England

Alimemazine (Trimeprazine) Sedative in children / general 3.2 Sedating Double Red Not recommended for antihistamine antihistamines routine use / Not commissioned

Alipogene tiparvovec (Gene therapy treatment for ) Not listed in BNF Double Red Not recommended for Lipoprotein lipase deficiency - as per routine use / Not NHSE policy commissioned

Alirocumab ▼ Treating primary 2.12 Lipid-regulating drugs Red Hospital / Specialist hypercholesterolaemia and mixed only dyslipidaemia - as per NICE TA 393

Aliskiren ▼ Treatment of essential hypertension - 2.5.5 Drugs affecting the Double red Not recommended for as per NICE CG 127 and N&W DROP renin-angiotensin routine use / Not List system commissioned

Alisporivir Viral Hepatitis C - as per NHSE policy 5.3.3 Not listed in BNF - Double Red Not recommended for cylcophilin inhibitor routine use / Not commissioned

Alitretinoin Treatment of severe chronic hand 13.5.1 Preparations for Red Hospital / Specialist eczema - as per NICE TA 177 eczema only

Alpelisib with fulvestrant for treating hormone- 8.1 Cytotoxic drugs Double Red Not recommended for receptor positive, HER2-negative, routine use / Not PIK3CA-positive advanced breast commissioned cancer (terminated appraisal) TA652

Alpha blockers - various Treatment of cor pulmonale - as per 2.5 Alpha-adrenoceptor Double Red Not recommended for NICE CG 101 blocking drugs routine use / Not commissioned

Alpha-mannosidase - Alpha Mannosidase deficiency - as Not listed in BNF - Double Red Not recommended for recombinant human per NHSE policy enyzyme replacement routine use / Not therapy commissioned

Alprostadil cream Erectile dysfunction (as per SLS 7.4.5 Drugs for erectile Double-GreenSuitable for GPs to conditions only) dysfunction initiate and prescribe

Alteplase Treatment of acute ischaemic stroke - 2.10.2 Fibrinolytic drugs Red Hospital / Specialist as per NICE TA 264 only

Amantadine Hydrochloride Treatment of influenza 5.3.4 Influenza Double red Not recommended for routine use / Not commissioned

Amantadine Hydrochloride Prophylaxis of influenza 5.3.4 Influenza Double red Not recommended for routine use / Not commissioned

Ambrisentan Pulmonary Arterial Hypertension - 2.5.1 Vasodilator Red Hospital / Specialist specialist centre only antihypertensive drugs only

Ambrisentan Pulmonary Arterial Hypertension - 2.5.1 Vasodilator Special Special contract - not specialist centre only antihypertensive drugs for GP prescribing

Amifampridine (phosphate) ▼ Treatment of myasthenias - Lambert- 10.2.1 Drugs that enhance Double red Not recommended for Eaton syndrome - as per NHS neuromuscular routine use / Not England policy transmission commissioned

Amikacin - liposomal for Gram-negative bacterial infection in 5.1 Aminoglycoside Double Red Not recommended for inhalation Cystic Fibrosis antibacterials routine use / Not commissioned

Amikacin (for inhalation) Gram-negative bacterial infection in 5.1 Aminoglycoside Double Red Not recommended for Cystic Fibrosis antibacterials routine use / Not commissioned

Aminobenzoic acid (capsules Peyronie's disease, Scleroderma 6 Vitamins and trace Double Red Not recommended for and powder) elements - B group routine use / Not commissioned

Printed: 14 September 2021 Page 5 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Amiodarone Supraventricular and ventricular 2.3.2 Drugs for arrhythmias Green GP prescribable at arrhythmias request of Consultant/Specialist

Amorolfine Fungal nail infections - as per N&W 13.10.2 Antifungal preparations Double Red Not recommended for DROP List routine use / Not commissioned

Amphotericin B, itraconazole Chronic Pulmonary Aspergillosis 5.2 Antifungal drugs Special Special contract - not & voriconazole (CPA) - specialist centre only for GP prescribing

Anagrelide ▼ Thrombocythaemia 9.4.1 Drugs used in platelet Amber Option for Shared disorders Care Prescribing

Anakinra Still’s disease as per TA685 10.1.3 Drugs that suppress Double Red Not recommended for the rheumatic disease routine use / Not process commissioned

Anakinra Rheumatoid arthritis - as per NICE 10.1.3 Drugs which suppress Double red Not recommended for CG79 - Do Not Do the rheumatic disease routine use / Not process commissioned

Anakinra Treatment of Juvenile Idiopathic 10.1.3 Drugs that suppress Red Hospital / Specialist Arthritis (JIA) - as per NHS England the rheumatic disease only policy process

Anakinra Cryopyrin-associated periodic 10.1.3 Drugs that suppress Red Hospital / Specialist syndrome (CAPS) - as per NHSE the rheumatic disease only policy process

Anastrozole Breast cancer - as per NICE CG81 8.3.4 Hormone antagonists Green GP prescribable at request of Consultant/Specialist

Andexanet alfa reversing anticoagulation from 2.8.3 Anticoagulant reversal Double Red Not recommended for apixaban or rivaroxaban as per TA697 agents routine use / Not commissioned Angiotensin-II receptor with ACE inhibitors 2.5.5.2 Angiotensin-II receptor Double red Not recommended for antagonists antagonists routine use / Not commissioned

Anidulafungin Fungal infection - invasive candidiasis 5.2 Antifungal agents Red Hospital / Specialist only

Antacids - various Long term frequent use in functional 1.1.1 Antacids and Double Red Not recommended for dyspepsia - as per NICE CG 184 - Do simeticone routine use / Not Not Do commissioned

Antibiotic prophylaxis Infective endocarditis and 5.1 Antibacterial drugs Double Red Not recommended for interventional procedure (dental/non routine use / Not dental) - as per NICE CG 64 commissioned

Antibiotics - intravenous / Cystic fibrosis 5.1 Antibacterial drugs Red Hospital / Specialist inhalation only

Antibiotics (oral for children)) Fever in children without apparent 5.1 Antibacterial drugs Double Red Not recommended for source - as per NICE CG 160 - Do Not routine use / Not Do commissioned

Anticoagulant monitoring self Anticoagulant self testing Not listed in the BNF Double-GreenSuitable for GPs to test strips initiate and prescribe

Anti-D immunoglobulin Routine anti-D prophylaxis (RAADP) - 14.5 Immunoglobulins Red Hospital / Specialist as per NICE TA 156 only

Antidepressants (including (Routine use) for the treatment of 4.3 Antidepressant drugs Double Red Not recommended for SSRIs) alcohol misuse alone - as per NICE routine use / Not CG 115 - Do Not Do commissioned

Antihaemophilic Factor As per BCSH Guidelines Blood glycoprotein Red Hospital / Specialist (coagulation Factor only VIII)

Antihistamines (oral) (Routine use) for Atopic eczema in 3.4.1 Antihistamines Double Red Not recommended for children - as per NICE CG 57 routine use / Not commissioned

Antioxidant - ubiquinone aka Any indication - as per N&W DROP Not listed in the BNF Double red Not recommended for ubidecarenone List routine use / Not commissioned

Printed: 14 September 2021 Page 6 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Antioxidant nutritional Eye health - including to prevent or Not listed in the BNF Double red Not recommended for supplements (many brands) slow the progression of AMD, or routine use / Not prevent cataracts - as per N&W DROP commissioned List - brands include Ocuvite PreserVision ICAPS MacuLEH Viteyes Vitalux Anti-Pseudomonas aeruginosa Cystic fibrosis - NHSE policy - IFR Not listed in BNF Double Red Not recommended for antibody approval routine use / Not commissioned

Antipsychotics Treatment of ADHD in children, young 4.2.1 Antipsychotic drugs Double Red Not recommended for people and adults - as per NICE CG routine use / Not 72 - Do Not Do commissioned

Antipsychotics Borderline personality disorder 4.2.1 Antipsychotics Double Red Not recommended for (medium to long term treatment) - as routine use / Not per NICE CG 78 - Do Not Do commissioned

Antipsychotics Loading doses of antipsychotic 4.2.1 Antipsychotics Double Red Not recommended for medication (aka 'rapid routine use / Not neuroleptisation') commissioned

Antipsychotics Combined use (except for short 4.2.1 Antipsychotics Double Red Not recommended for periods) - as per NICE CG 178 routine use / Not commissioned

Antipsychotics Generalised Anxiety Disorder - as per 4.2.1 Antipsychotics Double Red Not recommended for NICE CG 113 - Do Not Do routine use / Not commissioned

Antiretroviral therapy (ART) Treatment as Prevention (TasP) - as 5.3.1 HIV Infection Red Hospital / Specialist per NHS England policy only

Antithrombin III As per BCSH Guidelines No listed in BNF Red Hospital / Specialist only

Antithymocyte immunoglobulin Aplastic anaemia, organ transplant - Immunoglobulins Red Hospital / Specialist as per BCSH guidelines only

Antivirals Chronic fatigue syndrome/myalgic 5.3 Antiviral drugs Double Red Not recommended for encephalomyelitis (or routine use / Not encephalopathy) - as per NICE CG commissioned 53 - Do Not Do

Apixaban Treatment and secondary prevention 2.8.2 Oral anticoagulants Green GP prescribable at of deep vein thrombosis in adults in request of specified patient groups (see full Consultant/Specialist guidance)

Apixaban Anticoagulation in DC Cardioversion of 2.8.2 Oral anticoagulants In progress Prescribing Atrial Fibrillation / Atrial Flutter responsibility yet to be confirmed

Apixaban Treatment of calf vein deep vein 2.8.2 Oral anticoagulants Red Hospital / Specialist thrombosis (as per NICE TA 341) only

Apixaban Treatment and secondary prevention 2.8.2 Oral anticoagulants Green GP prescribable at of pulmonary embolism as per NICE request of TA 341 (where warfarin is not Consultant/Specialist appropriate - see Full Guidance) Apixaban Thromboprophylaxis post hip and 2.8.2 Oral anticoagulants Red Hospital / Specialist knee surgery (as per NICE TA 245) only

Apixaban Prevention of stroke and systemic 2.8.2 Oral antocoagulants Double-GreenSuitable for GPs to embolism in people with non-valvular initiate and prescribe atrial fibrillation - as per NICE TA 275 and local policy

Apixaban Combined use with dual antiplatelet 2.8.2 Oral anticoagulants Double Red Not recommended for therapy in people who otherwise need routine use / Not anticoagulation, who have had an MI - commissioned as per NICE CG 172 - Do Not Do

Apomorphine Patients with Parkinson's disease with 4.9.1 Dopaminergic drugs Red Hospital / Specialist disabling motor fluctuations used in parkinsonism only

Printed: 14 September 2021 Page 7 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Apraclonidine eye drops Short-term adjunctive therapy of Alpha2-adrenoceptor Red Hospital / Specialist chronic glaucoma in patients on agonists only maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery. Apremilast Paediatric indications - NHSE policy 10.1.3 Drugs that suppress Double Red Not recommended for the rheumatic disease routine use / Not process commissioned

Apremilast ▼ Treatment of moderate to severe 10.1.3 Drugs that suppress Red Hospital / Specialist plaque psoriasis that has not the rheumatic disease only responded to systemic therapy, or process where systemic therapy is contraindicated or not tolerated - as per NICE TA 419 and the local treatment pathway

Apremilast ▼ Active psoriatic arthritis in adults - as 10.1.3 Drugs that suppress Red Hospital / Specialist per NICE TA 433 the rheumatic disease only process

Aprepitant Prevention of nausea and vomiting in 4.6 Drugs used in nausea Red Hospital / Specialist patients on highly emetogenic and vertigo only chemotherapy - as per NHS England policy Aripiprazole Schizophrenia and bipolar mood 4.2.1 Second-generation Green GP prescribable at disorder - as per NICE CG 82 and TA antipsychotic drugs request of 213 Consultant/Specialist

Aripiprazole Moderate to severe manic episodes in 4.2.1 Antipsychotic drugs Green GP prescribable at adolescents with bipolar I disorder - as request of per NICE TA 292 Consultant/Specialist

Armour Thyroid / any Any indication Not listed in BNF Double Red Not recommended for unlicensed thyroid products routine use / Not commissioned

Aromatase inhibitors (Various) Adjuvant hormonal treatment of early 8.3.4.1 Hormone antagonists - Green GP prescribable at oestrogen-receptor-positive breast breast cancer request of cancer in post menopausal women - Consultant/Specialist as per local protocol Arsenic trioxide Acute promyelocytic leukaemia 8.1.5 Other antineoplastic Red Hospital / Specialist (characterised by the presence of the drugs only t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526

Artificial saliva or salivary Xerostomia from any cause where 12.3.5 Treatment of dry mouthDouble-GreenSuitable for GPs to stimulants simple measures alone have been initiate and prescribe ineffective

Asfotase alfa ▼ Paediatric-onset hypophosphatasia Not listed Red Hospital / Specialist only

Aspirin Primary prevention of CVD in T1 or T2 2.9 Antiplatelet drugs Double Red Not recommended for Diabetes - as per NG17 and NG 28 Do routine use / Not Not Do's commissioned

Asunaprevir (with Daclatasvir) Viral Hepatitis (B&C) and Respiratory 5.3.3.2 Not listed in BNF Double Red Not recommended for Syncytial Virus routine use / Not commissioned

Atacicept Systemic Lupus Erythematosus (SLE) B Cell Differentiation Double Red Not recommended for into Plasma Cells routine use / Not blockers commissioned

Ataluren ▼ Duchenne muscular dystrophy with a Not listed in the BNF Red Hospital / Specialist nonsense mutation in the dystrophin only gene in people aged ≥5 years who can walk - as per NHS England policy

Atazanavir HIV infection in combination with other 5.3.1 HIV infection Red Hospital / Specialist antiretroviral drugs - as per BHIVA only Guidelines

Printed: 14 September 2021 Page 8 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Atazanavir and Cobicistat HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs - as per BHIVA only guidelines

Atezolimumab ▼ Untreated PD-L1-positive locally 8.1.5 Other antineoplastic Red Hospital / Specialist advanced or metastatic urothelial drugs only cancer when cisplatin is unsuitable - as per NICE TA 492

Atezolizumab with nab-paclitaxel for untreated PD- 8.1.5 Other antineoplastic Red Hospital / Specialist L1-positive, locally advanced or drugs only metastatic, triple-negative breast cancer Atezolizumab Locally advanced or metastatic non- 8.1.5 Other antineoplastic Red Hospital / Specialist small-cell lung cancer after drugs only chemotherapy - as per NICE TA 520

Atezolizumab with carboplatin and etoposide for 8.1.5 Other antineoplastic Red Hospital / Specialist untreated extensive-stage small-cell drugs only lung cancer as per TA638

Atezolizumab with bevacizumab for treating 8.1.5 Other antineoplastic Red Hospital / Specialist advanced or unresectable drugs only hepatocellular carcinoma as per TA666

Atezolizumab with carboplatin and nab-paclitaxel for 8.1.5 Other antineoplastic Double Red Not recommended for untreated advanced non-squamous drugs routine use / Not non-small-cell lung cancer (terminated commissioned appraisal) as per NICE TA618 - Jan 2020

Atezolizumab Locally advanced or metastatic 8.1.5 Other antineoplastic Red Hospital / Specialist urothelial carcinoma after platinum- drugs only containing chemotherapy - as per NICE TA 525

Atezolizumab▼ Cancer - various 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Atomoxetine Attention Deficit Hyperactivity Disorder 4.4 Drugs used for ADHD Amber Option for Shared in Children & Adolescents Care Prescribing

Atomoxetine Attention Deficit Hyperactivity Disorder 4.4 CNS stimulants and Amber Option for Shared in Adults for new treatment of drugs used for ADHD Care Prescribing symptoms that can be confirmed from childhood

Atypical antipsychotics As per NICE CG 178 4.2.1 Antipsychotic drugs Green GP prescribable at (except clozapine) request of Consultant/Specialist

Auto inflation device (Otovent) Considered use for equalisation of Not listed Double-GreenSuitable for GPs to pressure in the middle ear: in otitis initiate and prescribe media with effusion (glue ear) in children who are able to cooperate with treatment. Autologous anti-CD19- relapsed or refractory mantle cell 16.1 Other items Red Hospital / Specialist transduced CD3+ cells lymphoma as per TA677 only

Autologous chondrocyte For treating symptomatic articular Not listed Red Hospital / Specialist implantation cartilage defects of the knee only

Autologous chondrocyte For treating symptomatic articular Not listed Red Hospital / Specialist implantation cartilage defects of the knee - as per only NICE TA 508

Autologous serum eye drops Dry eye Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Avanafil ▼ Use of regular, daily doses for penile 7.4.5 Drugs for erectile Double Red Not recommended for rehabilitation in prostate cancer/post dysfunction routine use / Not radical prostatectomy commissioned

Avatrombopag Treating thrombocytopenia in people 9.1.4 Drugs used in platelet Double Red Not recommended for with chronic liver disease needing a disorders routine use / Not planned invasive procedure as per commissioned TA626 (June 2020)

Printed: 14 September 2021 Page 9 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Avelumab with axitinib for untreated advanced 8.1.5 Other antineoplastic Red Hospital / Specialist renal cell carcinoma as per TA645 drugs only

Avelumab Metastatic Merkel cell carcinoma - as 8.1.5 Other antineoplastic Red Hospital / Specialist per NICE TA 517 drugs only

Avelumab untreated metastatic Merkel cell 8.1.5 other antineoplastic Red Hospital / Specialist carcinoma as per TA691 drugs only

Avoralstat Hereditary angioedema 3.4.3 Allergic emergencies Double Red Not recommended for (not listed in BNF) routine use / Not commissioned

Axicabtagene ciloleucel Relapsed or refractory diffuse large B- No BNF entry Red Hospital / Specialist cell lymphoma or primary mediastinal only large B-cell lymphoma in adults after 2 or more systemic therapies - as per NICE TA 559

Axitinib Advanced renal cell carcinoma after 8.1.5 Other antineoplastic Red Hospital / Specialist failure of prior systemic treatment - as drugs only per NICE TA 331 Axonics sacral Overactive bladder and faecal Not listed in the BNF Double Red Not recommended for neuromodulation system incontinence routine use / Not commissioned

Azacitidine Acute myeloid leukaemia with more 8.1.3 Antimetabolites Double Red Not recommended for than 30% bone marrow blasts in routine use / Not people of 65 years or older who are commissioned not eligible for haematopoietic stem cell transplant - as per NICE TA 399

Azacitidine Myelodysplastic syndromes, chronic 8.1.3 Antimetabolites Red Hospital / Specialist myelomonocytic leukaemia and acute only myeloid leukaemia - as per NICE 218

Azathioprine As a steroid-sparing effect in patients 8.2.1 Antiproliferative Amber Option for Shared with Autoimmune Diseases in whom immunosuppressants Care Prescribing steroids cannot be reduced or are contraindicated, and for maintaining remission in vasculitis

Azathioprine Steroid-sparing effect in ulcerative 8.2.1 Antiproliferative Amber Option for Shared colitis and Crohn's disease immunosuppressants Care Prescribing

Azilsartan Essential hypertension - as per N&W 2.5.5.2 Angiotensin II receptor Double Red Not recommended for DROP List antagonists routine use / Not commissioned

Aztreonam (nebulised) Gram negative infections in cystic 5.1.2.3 Other beta-lactam Special Special contract - not fibrosis - as per NHS England policy antibiotics for GP prescribing

Baclofen (via intrathecal pump) Muscle spasm in neurological 10.2.2 Skeletal muscle Special Special contract - not conditions as per NICE guidance relaxants for GP prescribing

Bamboo bedding (incl sheets, Care of very disabled patients with Not listed Double Red Not recommended for pillow cases) severe physical needs - as per N&W routine use / Not DROP List commissioned

Baricitinib moderate to severe atopic dermatitis 10.1.3 Drugs that suppress Double Red Not recommended for as per TA681 the rheumatic disease routine use / Not process commissioned

Baricitinib ▼ (with or without methotrexate) for 10.1.3 Drugs that suppress Red Hospital / Specialist active moderate to severe rheumatoid the rheumatic disease only arthritis in adults - as per NICE TA 466 process and locally commissioned treatment pathway Basiliximab Option for induction therapy in the 8.2.2 Corticosteroids and Red Hospital / Specialist prophylaxis of acute organ rejection in other only adults, children and adolescents immunosuppressants undergoing renal transplantation - as per NICE TAs 481 and 482

Bazedoxifene plus conjugated Management of oestrogen deficiency 8.1 Female sex hormone Double Red Not recommended for oestrogens symptoms in postmenopausal women responsive conditions routine use / Not with a uterus for whom treatment with commissioned progestin-containing therapy is not appropriate

Printed: 14 September 2021 Page 10 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Beclabuvir Hepatitis C 5.3.3 Viral hepatitis Double Red Not recommended for routine use / Not commissioned

Beclometasone dipropionate Second-line oral corticosteroid option 1.5.2 Corticosteroids for Green GP prescribable at 5mg MR tablets in the treatment of flares in mild- inflammatory bowel request of moderate ulcerative colitis in adults - disease Consultant/Specialist as per local pathway

Bedaquiline ▼ Multidrug-Resistant and Extensively 5.1.9 Antituberculosis drugs Red Hospital / Specialist Drug-Resistant Tuberculosis - as per only NHS England policy

Bee and Wasp allergen Bee and wasp venom allergy - as per 3.4.2 Allergen Special Special contract - not extracts NICE TA 246 - specialist centre only immunotherapy for GP prescribing

Bee and wasp venom Bee and wasp venom allergy - as per 3.4.2 Allergen Red Hospital / Specialist NICE TA 246 - specialist centre only immunotherapy only

Begelomab Graft versus Host Disease (GvHD) Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Belatacept Initial treatment to prevent organ Class t-cell activation Double Red Not recommended for rejection in adults, children and young inhibitors routine use / Not people having a kidney transplant - as commissioned per NICE TAs 481 & 482

Belimumab ▼ Active autoantibody-positive systemic 10.1.3 Drugs that suppress Red Hospital / Specialist lupus erythematosus (add-on the rheumatic disease only treatment) - as per NICE TA 397 process

Belladonna adhesive plaster As a counter irritant for pain relief Not listed Double Red Not recommended for routine use / Not commissioned Bempedoic acid with ezetimibe for treating primary 2.12 lipid-regulating drugs Double Red Not recommended for hypercholesterolaemia or mixed routine use / Not dyslipidaemia as per TA694 commissioned

Bendamustine First-line treatment of chronic 8.1.1 Alkylating drugs Red Hospital / Specialist lymphocytic leukaemia (binet stage B only or C) - as per NICE TA 216 / NHS England policy

Bendamustine Treatment of indolent (low grade) non- 8.1.1 Alkylating drugs Red Hospital / Specialist Hodgkin’s lymphoma that is refractory only to rituximab - as per NICE TA 206 / NHS England policy

Benralizumab Severe eosinophilic asthma (specialist 3.4.2 Monoclonal Red Hospital / Specialist use only) - as per NICE TA 565 antibodies - allergen only (NHSE commissioning responsibility) immunotherapy

Benzodiazepines Panic disorder - as per NICE CG 113 - 4.1.2 Benzodiazepines Double Red Not recommended for Do Not Do routine use / Not commissioned Benzodiazepines Augmentation of an antidepressant 4.1.2 Anxiolytics Double Red Not recommended for with a benzodiazepine for more than 2 routine use / Not weeks - as per NICE CG 90 - Do Not commissioned Do

Benzodiazepines Generalised Anxiety Disorder (long 4.1.2 Benzodiazepines Double Red Not recommended for term use) - as per NICE CG 113 - Do routine use / Not Not Do commissioned

Benzodiazepines Ongoing treatment of alcohol 4.1.2 Benzodiazepines Double Red Not recommended for dependence - as per NICE CG 115 routine use / Not commissioned

Beractant Respiratory distress syndrome Children's BNF - Red Hospital / Specialist neonates pulmonary surfactants only

Beta-carotene (supplements Secondary prevention of MI / reduce Not listed Double Red Not recommended for containing) cardiovsacular risk post MI - as per routine use / Not NICE CG 172 - Do Not Do commissioned

Betaine Homocystinuria Adjunctive treatment Red Hospital / Specialist of homocystinuria only

Printed: 14 September 2021 Page 11 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Betamethasone plasters Treatment of inflammatory skin 13.4 Topical Corticosteroids Double Red Not recommended for disorders that do not respond to less routine use / Not potent corticosteroids commissioned

Bevacizumab Treatment for relapsed, platinum 8.1.5 Other antineoplastic Double Red Not recommended for resistant epithelial ovarian, fallopian drugs routine use / Not tube or primary peritoneal cancer - as commissioned per NICE TA 353

Bevacizumab Choroidal neovascularisation (CNV) 8.1.5 Other antineoplastic Red Hospital / Specialist secondary to conditions other than drugs only age-related macular degeneration (AMD) or pathological myopia (PM) - as per local agreement during 2014-15

Bevacizumab Treatment of metastatic colorectal 8.1.5 Other antineoplastic Red Hospital / Specialist cancer after 1st-line chemotherapy - drugs only as per NHS England policy

Bevacizumab Early (pre-NICE criteria) treatment of 11.8.2 Ocular diagnostic and Double red Not recommended for wet AMD and related conditions peri-operative routine use / Not preparations commissioned

Bevacizumab (with paclitaxel & carboplatin) 1st-line 8.1.5 Other antineoplastic Red Hospital / Specialist for advanced ovarian cancer - as per drugs only NHS England policy

Bevacizumab (with gemcitabine & carboplatin) - 8.1.5 Other antineoplastic Red Hospital / Specialist treatment of the first recurrence of drugs only platinum-sensitive advanced ovarian cancer - as per NHS England policy Bevacizumab With oxaliplatin and either 5-FU plus 8.1.5 Other antineoplastic Red Hospital / Specialist folinic acid or capecitabine for drugs only metastatic colorectal cancer - as NHS England policy

Bevacizumab (Short term) treatment of neovascular 8.1.5 Other antineoplastic Red Hospital / Specialist glaucoma in rubeosis iridis - as per drugs only locally commissioned agreement

Bevacizumab Epidermal growth factor receptor 8.1.5 Other antineoplastic Double Red Not recommended for mutation-positive non-small-cell lung drugs routine use / Not cancer - as per NICE TA 436 commissioned

Bevacizumab Neurofibromatosis 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Bevacizumab First-line treatment of metastatic 8.1.5 Other antineoplastic Double red Not recommended for breast cancer drugs routine use / Not commissioned

Bevacizumab Treatment of non-small-cell lung 8.1.5 Other antineoplastic Double red Not recommended for cancer - as per NHS England policy drugs routine use / Not commissioned

Bevacizumab First-line treatment of metastatic 8.1.5 Other antineoplastic Red Hospital / Specialist breast cancer (in combination with a drugs only taxane) - as per NHS England policy Bevacizumab Radiation retinopathy macular oedema 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Bevacizumab (with carboplatin, gemcitabine and 8.1.5 Other antineoplastic Double Red Not recommended for paclitaxel) for first recurrence of drugs routine use / Not platinum-sensitive advanced ovarian commissioned cancer - as per NICE TA 560 Bevacizumab First-line treatment of advanced 8.1.5 Other antineoplastic Double red Not recommended for and/or metastatic renal cell drugs routine use / Not carcinoma - as per NHS England commissioned

Bexarotene All indications 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Bezafibrate Prevention of CVD - as per NICE CG 2.12 Lipid-regulating Double Red Not recommended for 181 "Do Not Do" drugs - Fibrates routine use / Not commissioned

Printed: 14 September 2021 Page 12 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Bezlotoxumab Prevention of recurrent clostridium Antitoxins Double Red Not recommended for defficile infection routine use / Not commissioned

Bimagrumab Inclusion body myositis Human monoclonal Double Red Not recommended for antibodies - not listed routine use / Not in BNF commissioned

Binimetinib (with encorafenib (Braftovi®)) for 8.1.5 Other antineoplastic Red Hospital / Specialist treating unresectable or metastatic drugs only BRAF V600 mutation-positive melanoma in adults - as per NICE TA 562

Bioidentical HRT Menopausal symptoms - as per N&W Not listed Double Red Not recommended for DROP List routine use / Not commissioned

Biotin (vitamin H) Multiple sclerosis 9.6 Vitamins Double Red Not recommended for routine use / Not commissioned

Bivalirudin Treatment of ST-segment-elevation 2.8.1 Parenteral Red Hospital / Specialist myocardial infarction - as per NICE TA anticoagulants only 230

Blinatumomab previously treated Philadelphia- 8.2.3 Other Double Red Not recommended for chromosome-positive acute immunomodulating routine use / Not lymphoblastic leukaemia as per drugs commissioned TA686 (terminated appraisal) Blinatumomab Acute lymphoblastic leukaemia in 8.2.4 Other Red Hospital / Specialist remission with minimal residual immunomodulating only disease activity drugs

Blinatumomab ▼ Philadelphia-chromosome-negative 8.2.3 Anti-lymphocyte Red Hospital / Specialist relapsed or refractory precursor B-cell monoclonal antibodies only acute lymphoblastic leukaemia in adults - as per NICE TA 450

Blisibimod Systemic lupus erythematosus (SLE) B-cell activating factor Double Red Not recommended for (BAFF) inhibitor routine use / Not commissioned

Boceprevir Treatment of genotype 1 chronic 5.3.3 Viral hepatitis Red Hospital / Specialist hepatitis C - as per NICE TA 253 only

Bortezomib Treatment of refractory antibody 8.1.5 Other antineoplastic Double Red Not recommended for mediated rejection post kidney drugs routine use / Not transplant - as per NHS England policy commissioned

Bortezomib Induction therapy in multiple myeloma 8.1.5 Other antineoplastic Red Hospital / Specialist before high-dose chemotherapy and drugs only autologous stem cell transplantation - as per NICE TA 311

Bortezomib Relapsed Multiple Myeloma - as per 8.1.5 Other antineoplastic Double Red Not recommended for NHS England policy & NICE TA 453 drugs routine use / Not commissioned

Bortezomib Multiple myeloma (first line) - as per 8.1.5 Other antineoplastic Red Hospital / Specialist NICE 228 agents only

Bortezomib Previously untreated mantle cell 8.1.5 Other antineoplastic Red Hospital / Specialist lymphoma in adults for whom drugs only haematopoietic stem cell transplantation is unsuitable as per NICE TA 370

Bosentan Pulmonary arterial hypertension - - as 2.5.1 Vasodilator Special Special contract - not per NHS England policy - specialist antihypertensive drugs for GP prescribing centres only

Bosentan Treatment of digital ulceration in 2.5.1 Vasodilator Red Hospital / Specialist systemic sclerosis - as per NHS antihypertensive drugs only England policy

Bosutinib Untreated chronic myeloid leukaemia 8.1.5 Protein kinase Double Red Not recommended for in adults - as per NICE TA 576 inhibitors routine use / Not (terminated appraisal) commissioned

Printed: 14 September 2021 Page 13 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Bosutinib Previously treated chronic myeloid 8.1.5 Protein kinase Red Hospital / Specialist leukaemia - as per NHS England inhibitors only policy

Botulinum neurotoxin type A Chronic sialorrhoea Neurotoxins Red Hospital / Specialist only

Botulinum Toxin Type A Overactive bladder / detrusor 4.9.3 Drugs for essential Red Hospital / Specialist overactivity - as per locally agreed tremor, chorea, tics etc only policy

Botulinum Toxin Type A (severe) Focal hyperhidrosis - as per 13.12 Antiperspirants Red Hospital / Specialist locally agreed policy only

Botulinum Toxin Type A Neurogenic and non neurogenic 4.9.3 Drugs used in Red Hospital / Specialist detrusor overactivity in paediatric essential tremor, only patients who have not responded to chorea, tics etc antimuscarinic treatment - as per locally agreed policy

Botulinum Toxin Type A Oesophageal spasm and nutcracker 4.9.3 Drugs used in Red Hospital / Specialist oesophagus - as per locally agreed essential tremor, only policy chorea, tics etc

Botulinum Toxin Type A Muscle spasticity in neuromuscular 4.9.3 Drugs used in Red Hospital / Specialist conditions - cerebral palsy - as per essential tremor, only locally agreed policy chorea, tics etc

Botulinum Toxin Type A Prophylaxis of headaches in adults 4.7.4.2 Antimigraine drugs Red Hospital / Specialist with chronic migraine - as per locally only agreed policy

Botulinum Toxin Type A Chronic anal fissure - as per locally 4.9.3 Drugs used in Red Hospital / Specialist agreed policy essential tremor, only chorea, tics etc

Botulinum Toxin Type A Treatment of focal spasticity in 4.9.3 Drugs used in Red Hospital / Specialist Multiple Sclerosis or following stroke essential tremor, only or brain injury - as per locally agreed chorea, tics etc policy

Botulinum Toxin Type A Treatment of achalasia and 4.9.3 Drugs for essential Red Hospital / Specialist gastroparesis - as per locally agreed tremor, chorea, tics etc only policy

Braun Diveen Women with stress urinary Devices Double Red Not recommended for incontinence routine use / Not commissioned

Brentuximab vedotin in combination for untreated systemic 8.1.5 Malignant disease and Red Hospital / Specialist anaplastic large cell lymphoma as per immunosuppression only TA641

Brentuximab vedotin CD30-positive Hodgkin lymphoma in 8.1.5 Malignant disease and Red Hospital / Specialist adults with relapsed or refractory immunosuppression only disease - as per NICE TA 524

Brentuximab vedotin Treating CD30-positive cutaneous T- 8.1.5 Other antineoplastic Red Hospital / Specialist cell lymphoma (CTCL) after at least 1 drugs only systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE commissioning responsibility)

Brentuximab vedotin Untreated advanced Hodgkin 8.1.5 Malignant disease and Double Red Not recommended for lymphoma immunosuppression routine use / Not commissioned

Brentuximab vedotin ▼ CD30-positive Hodgkin lymphoma - as 8.1.5 Malignant disease and Red Hospital / Specialist per NICE TA 446 immunosuppression only

Brentuximab vedotin ▼ For treating relapsed or refractory 8.1.5 Other antineoplastic Red Hospital / Specialist systemic anaplastic large cell drugs - monoclonal only lymphoma in adults, only if they have antibodies an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478

Printed: 14 September 2021 Page 14 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Brigatinib For treating ALK-positive advanced 8.1.5 Tyrosine kinase Red Hospital / Specialist non-small-cell lung cancer in adults, inhibitor only after crizotinib - as per NICE TA 571 (NHSE commissioning responsibility) Brigatinib ALK-positive advanced non-small-cell 8.1.5 Tyrosine kinase Red Hospital / Specialist lung cancer that has not been inhibitor only previously treated with an ALK inhibitor as per TA670

Brimonidine tartrate gel Treatment of facial erythema (rosacea) 13.6.3 Topical preparations Double Red Not recommended for for rosacea routine use / Not commissioned

Brincidofovir CMV infection Experimental antiviral Double Red Not recommended for drug - not listed in BNF routine use / Not commissioned

Brodalumab Moderate to severe plaque psoriasis - 13.5.3 Drugs affecting the Red Hospital / Specialist as per NICE TA 511 immune response only

Brolucizumab wet age-related macular degeneration 11.8.2 Ocular diagnostic Red Hospital / Specialist as per TA672 preparations only

Bromocriptine Pharmacological neuroprotective 4.9.1 Dopamine-receptor Double Red Not recommended for therapy in Parkinson's disease agonists routine use / Not commissioned

Bromocriptine mesilate First-line use in Parkinson's disease - 6.7.1 Ergot-derived Double Red Not recommended for as per NICE NG 17 dopamine agonists routine use / Not commissioned

Budenofalk Crohn's disease in adults 1.5.2 Corticosteroids for Green GP prescribable at inflammatory bowel request of disease Consultant/Specialist

Budenofalk (Budesonide 3mg Collagenous colitis in adults 1.5.2 Corticosteroids for Green GP prescribable at caps & 9mg granules) inflammatory bowel request of disease Consultant/Specialist

Budesonide orodispersible Eosinophilic oesophagitis in adults 8.2.2 Corticosteroids (used Green GP prescribable at tablets (GP may issue a SINGLE follow-up in GORD) request of treatment (NOT for repeat) only if Consultant/Specialist deemed necessary following assessment of response to initial treatment by given the hospital)

Budesonide orodispersible Eosinophilic oesophagitis in adults 8.2.2 Corticosteroids (used Red Hospital / Specialist tablets (first treatment with follow-up in GORD) only assessment of effectiveness by the hospital)

Buprenorphine (sublingual & Opioid dependence (for use by 4.10 Drugs used in Double-GreenSuitable for GPs to oral lyophilisate) prescribers with competence in substance dependence initiate and prescribe treating opioid dependence)

Buprenorphine (transdermal) Patients with renal impairment (eGFR 4.7.2 Opioid analgesics Green GP prescribable at 15-30, CKD 4) who have an request of accumulation of opiates and a Consultant/Specialist resulting potential for toxicity

Buprenorphine long-acting opioid substitution treatment 4.10.3 Opioid substitution Double Red Not recommended for injection therapy routine use / Not commissioned

Bupropion Adjunct to smoking cessation 4.10 Drugs used in Double-GreenSuitable for GPs to substance dependence initiate and prescribe

Burosumab X-linked hypophosphataemia (XLH) Recombinant IgG1 Red Hospital / Specialist with radiographic evidence of bone monoclonal antibody only disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Buspirone Augmentation of an antidepressant - 4.1.2 Anxiolytics Double Red Not recommended for as per NICE CG 90 - Do Not Do routine use / Not commissioned

Busulfan All indications 8.1.1 Alkylating drugs Red Hospital / Specialist only

Printed: 14 September 2021 Page 15 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Butyrophenones (benperidol NICE Do Not Do - Use in Parkinson's 4.2.1 First-generation Double Red Not recommended for and haloperidol) disease - as per NG 71 antipsychotic drugs routine use / Not commissioned

Cabazitaxel Metastatic hormone relapsed prostate 8.1.5 Other antineoplastic Red Hospital / Specialist cancer in people whose disease has drugs only progressed during or after docetaxel chemotherapy - as per NICE TA 391

Cabazitaxel Hormone-refractory metastatic 8.1.5 Other antineoplastic Double red Not recommended for prostate cancer previously treated with drugs routine use / Not a docetaxel-containing regimen - as commissioned per NICE TA 255 Cabergoline First-line use in Parkinson's disease - 6.7.1 Ergot-derived Double Red Not recommended for as per NICE NG 71 dopamine agonists routine use / Not commissioned

Cabergoline Pharmacological neuroprotective 4.9.1 Dopamine-receptor Double Red Not recommended for therapy in Parkinson's disease agonists routine use / Not commissioned

Cabozantinib Untreated advanced renal cell 8.1.5 Other antineoplastic Red Hospital / Specialist carcinoma in adults under defined drugs only circumstances - as per NICE TA 541

Cabozantinib For treating medullary thyroid cancer - 8.1.5 Other antineoplastic Double Red Not recommended for as per NICE TA 516 drugs routine use / Not commissioned

Cabozantinib ▼ Previously treated advanced renal cell 8.1.5 Other antineoplastic Red Hospital / Specialist carcinoma in adults after vascular drugs only endothelial growth factor (VEGF)- targeted therapy - as per NICe TA 463

Calcium and Ergocalciferol Prevention of osteoporosis-related 9.6.4 Vitamin D Double Red Not recommended for combi tablets fractures and falls - as per N&W routine use / Not DROP List commissioned

Calcium channel blockers - Treatment of cor pulmonale - as per 2.6.2 Calcium-channel Double Red Not recommended for various NICE CG 101 - NICE Do Not Do blockers routine use / Not commissioned

Canagliflozin ▼ As a 4th monotherapy option for 6.1.2.3 Other antidiabetic Green GP prescribable at treating type 2 diabetes - as per NICE drugs request of TA 390 Consultant/Specialist

Canagliflozin ▼ In combination therapy for treating 6.1.2.3 Other antidiabetic Green GP prescribable at type 2 diabetes - as per NICE TA 315 drugs request of (Prescriber's Rating "Possibly helpful" Consultant/Specialist in certain patients)

Canakinumab Treatment of gouty arthritis attacks 8.2.4 Other Double red Not recommended for and reducing the frequency of immunomodulating routine use / Not subsequent attacks - as per NICE TA drugs commissioned 281 Canakinumab Treatment of systemic juvenile 8.2.4 Other Double Red Not recommended for idiopathic arthritis - - as per NHS immunomodulating routine use / Not England policy drugs commissioned

Cangrelor ▼ Treatment for reducing 2.9 Antiplatelet drug - Double Red Not recommended for atherothrombotic events in people P2Y12 recepter routine use / Not undergoing percutaneous coronary blocker commissioned intervention or awaiting surgery requiring interruption of anti platelet therapy - as per NICE TA 351

Cannabidiol with clobazam Seizures associated with Dravet 4.8.1 Control of epilepsy Red Hospital / Specialist syndrome only

Cannabidiol with clobazam Seizures associated with 4.8.1 Control of epilepsy Red Hospital / Specialist Lennox–Gastaut syndrome only

Cannabis (all forms, including All indications - as per local policy 10.2.2 Skeletal muscle Double Red Not recommended for nabilone) (July 2011) relaxants routine use / Not commissioned

Cannabis Extract Spray ▼ All indications - as per local policy 10.2.2 Skeletal muscle Double red Not recommended for relaxants routine use / Not commissioned

Printed: 14 September 2021 Page 16 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Cannabis-based medicinal All indications as per PAC guidance 10.2.2 Skeletal muscle Double Red Not recommended for preparations - unlicenced statement Jan 2020 relaxants routine use / Not commissioned

Capecitabine All indications 8.1.3 Antimetabolites Red Hospital / Specialist only

Caplacizumab with plasma exchange and 9.1.4 Drugs used in Red Hospital / Specialist immunosuppression for treating acute autoimmune only acquired thrombotic thrombocytopenic thrombocytopenic purpura as per TA667 purpura

Capsaicin transdermal Peripheral neuropathic pain in non- 10.3.2 Plant alkaloids - Red Hospital / Specialist patches (Qutenza®) diabetic patients (specialist use only) rubefacient only

Carbamazepine Augmentation of an antidepressant - 4.2.3 Drugs used for mania Double Red Not recommended for as per NICE CG 90 - Do Not Do and hypomania routine use / Not commissioned

Carfilzomib previously treated multiple myeloma 8.1.5 Other antineoplastic Red Hospital / Specialist as per TA657 drugs only

Carfilzomib 8.1.5 other antineoplastic Red Hospital / Specialist drugs only

Carfilzomib ▼ (with dexamethasone) for previously 8.1.5 Other antineoplastic Red Hospital / Specialist treated multiple myeloma where the drugs only patient has had only 1 previous therapy, which did not include bortezomib - as per NICE 457 Carglumic acid Treatment hyperammonaemia in urea 9.8.1 Drugs used in Red Hospital / Specialist cycle disorder metabolic disorders only

Carmustine implants Treatment of recurrent glioblastoma 8.1.1 Alkylating drugs Double red Not recommended for multiforme - as per NICE TA 149 and routine use / Not NHS England policy commissioned

Caspofungin Systemic candidiasis - - as per NHS 5.2.4 Echinocandin Red Hospital / Specialist England policy antifungals only

Catridecacog Congenital factor XIII A-subunit Not lisited in BNF Double Red Not recommended for deficiency routine use / Not commissioned

Ceftriaxone Cellulitis - as per local policy 5.1.2 Cephalosporins, Red Hospital / Specialist cephamycins, & other only beta-lactams

Cemiplimab Metastatic or locally advanced 8.2.4 Other Red Hospital / Specialist cutaneous squamous cell carcinoma immunomudoulating only drugs

Cenegermin eye drops ▼ Treatment of moderate or severe Not listed Double Red Not recommended for neurotrophic keratitis - as per NICE routine use / Not TA 532 commissioned

Ceralifimod Multiple sclerosis No listed in BNF Double Red Not recommended for routine use / Not commissioned

Cerebrotech Visor For detecting stroke Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Ceritinib Anaplastic lymphoma kinase positive 8.1.5 Other antineoplastic Red Hospital / Specialist non-small-cell lung cancer in adults drugs only previously treated with crizotinib - as per NICE TA 395

Ceritinib ▼ Untreated ALK-positive non-small-cell 8.1.5 Other antineoplastic Red Hospital / Specialist lung cancer in adults drugs only

Cerliponase Neuronal Ceroid Lipofuscinosis, type 2 Not listed in BNF Double Red Not recommended for (CLN2) from birth, also known as routine use / Not tripeptidyl peptidase 1 (TPP1) commissioned deficiency

Printed: 14 September 2021 Page 17 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Certolizumab Pegol Treatment of severe (non- 10.1.3 Drugs that supress the Red Hospital / Specialist radiographic) axial spondyloarthritis - rheumatic disease only as per NICE TA 383 and locally process agreed pathway Certolizumab pegol For treating moderate to severe 10.1.3 Drugs that suppress Red Hospital / Specialist plaque psoriasis in adults - as per the rheumatic disease only NICE TA 574 and local treatment process pathway

Certolizumab pegol Treatment of rheumatoid arthritis - as 10.1.3 Drugs that suppress Red Hospital / Specialist per NICE TA 186 and locally agreed the rheumatic disease only pathway process

Certolizumab pegol Ankylosing spondylitis - as per NICE 10.1.3 Drugs that suppress Red Hospital / Specialist TA 383 and locally agreed pathway the rheumatic disease only process

Certolizumab pegol (with and Active rheumatoid arthritis in adults 10.1.13 Drugs that suppress Red Hospital / Specialist without MTX) after inadequate response or the rheumatic disease only intolerance to other disease-modifying process antirheumatic drugs (DMARDs) including at least one tumour necrosis factor-alpha (TNF-alpha) inhibitor

Certolizumab pegol (with or Psoriatic arthritis (including switching 10.1.3 Drugs that suppress Red Hospital / Specialist without MTX) between treatments) after inadequate the rheumatic disease only response to DMARDs - as per NICE process TA 445 and locally agreed pathway

Cetuximab Recurrent or metastatic squamous cell 8.1.5 Other antineoplastic Red Hospital / Specialist head and neck cancer in adults only if drugs only started in the mouth - as per NICE TA 473 and NHS England policy

Cetuximab First-line treatment of metastatic 8.1.5 Other antineoplastic Red Hospital / Specialist colorectal cancer under specified drugs only circumstances - as per NICE TA 176 and NHS England policy

Cetuximab Treatment of metastatic colorectal 8.1.5 Other antineoplastic Red Hospital / Specialist cancer after 1st-line chemotherapy - drugs only as per NICE TA 242 and NHS England policy Cetuximab Locally advanced squamous cell 8.1.5 Antineoplastic drugs Red Hospital / Specialist cancer of the head and neck - as per only NICE TA 145 and NHS England policy

Chenodeoxycholic acid Cerebrotendinous xanthomatosis 9.8.1 Drugs used in Double Red Not recommended for (CTX) metabolic disorders routine use / Not commissioned

Chenodeoxycholic acid Primary biliary cirrhosis 9.8.1 Drugs used in Double Red Not recommended for metabolic disorders routine use / Not commissioned

Chlorambucil All indications 8.1.1 Alkylating drugs Red Hospital / Specialist only

Chlorhexidine Mouthwash prophylaxis against 12.3.4 Mouthwashes, Double Red Not recommended for infective endocarditis to people at risk gargles, and dentifrices routine use / Not of infective endocarditis undergoing commissioned dental procedures - as per NICE CG 64 - Do Not Do Chlorpropamide Type 2 diabetes mellitus 6.1.2 Oral antidiabetic drugs Double red Not recommended for routine use / Not commissioned

Cholestyramine Prevention of CVD, alone or added to 2.12 Lipid-regulating Double Red Not recommended for a statin - as per NICE CG 181 - Do drugs - Bile Acid routine use / Not Not Do Sequestrants commissioned

Cholic acid Inborn errors in primary bile acid 9.8.1 Drugs used in Double Red Not recommended for synthesis metabolic disorders routine use / Not commissioned Chondroitin Osteoarthritis - as per NICE CG 177 - 10.1.5 Other drugs used for Double Red Not recommended for Do Not Do rheumatic diseases routine use / Not commissioned

Printed: 14 September 2021 Page 18 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Ciclosporin Rheumatic and dermatological 8.2.2 Corticosteroids and Amber Option for Shared diseases. other Care Prescribing immunosuppressants

Ciclosporin Severe keratitis in adult patients with Not listed Green GP prescribable at dry eye disease that has not improved request of despite treatment with tear substitutes Consultant/Specialist (Consultant recommendation only) - as per NICE TA 369 Cidofovir Cytomegalovirus (CMV) infection 5.3.1 HIV Infection Red Hospital / Specialist only

Cilostazol Treatment of intermittent claudication 2.6.4 Peripheral Double red Not recommended for in people with peripheral arterial vasodilators and routine use / Not disease - as per NICE TA 223 related drugs commissioned

Cinacalcet Refractory secondary 9.5.1.2 Hypercalcaemia & Red Hospital / Specialist hyperparathyroidism in patients with hypercalciuria only end-stage renal disease under specific criteria - as per NICE TA 117 and NHS England policy

Cinacalcet Secondary hyperparathyroidism & 9.5.1.2 Hypercalcaemia & Double red Not recommended for parathyroid cancer - as per NHS hypercalciuria routine use / Not England policy commissioned

Cinacalcet Primary Hyperparathyroidism in 9.5.1.2 Hypercalcaemia & Red Hospital / Specialist patients with symptomatic severe hypercalciuria only PHPT where normalisation of calcium is desirable, but in whom surgery is not indicated or is contraindicated for medical reasons - - as per NHS England policy - specialist centre use only

Ciprofibrate Prevention of CVD - as per NICE CG 2.12 Lipid-regulating Double Red Not recommended for 181 "Do Not Do" drugs - Fibrates routine use / Not commissioned

Ciprofloxacin Anthrax exposure - as per Public 5.1.12 Quinolones Double-GreenSuitable for GPs to Health guidance initiate and prescribe

Ciprofloxacin (inhalation) Cystic Fibrosis 5.1.12 Quinolones Double Red Not recommended for routine use / Not commissioned

Ciprofloxacin liposomal Cystic Fibrosis 5.1.12 Quinolones Double Red Not recommended for (inhaled) routine use / Not commissioned

Cladribine Pulmonary Langerhans histiocytosis 8.1.3 Antimetabolites Double Red Not recommended for routine use / Not commissioned

Cladribine Relapsing-remitting multiple 8.1.3 Antimetabolites Red Hospital / Specialist sclerosis - as per NICE TA616 only

Cladribine Relapsing-remitting multiple 8.1.3 Antimetabolites Red Hospital / Specialist sclerosis - as per NICE TA 493 only

Clofarabine Cancer 8.1.3 Antimetabolites Red Hospital / Specialist only

Clomethiazole Community-based assisted alcohol 4.1.1 Hypnotics Double Red Not recommended for withdrawal - as per NICE CG 115 - Do routine use / Not Not Do commissioned

Clopidogrel Primary prevention of CVD in T1 or T2 2.9 Antiplatelet drugs Double Red Not recommended for Diabetes - as per NG17 and NG 28 Do routine use / Not Not Do's commissioned

Clopidogrel Prophylaxis pre-elective PCI 2.9 Antiplatelet drugs Red Hospital / Specialist only

Clopidogrel Prevention of atherosclerotic events 2.9 Anti-platelet drugs Double-GreenSuitable for GPs to initiate and prescribe

Clopidogrel (with low dose Acute Coronary Syndrome without ST- 2.9 Antiplatelet drugs Green GP prescribable at aspirin) segment elevation (NSTEMI) (with request of aspirin) Consultant/Specialist

Printed: 14 September 2021 Page 19 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Clopidogrel (with low dose Post elective percutaneous coronary 2.9 Antiplatelet drugs Green GP prescribable at aspirin) intervention (PCI) - bare metal stent request of Consultant/Specialist

Clopidogrel (with low dose ST-elevation myocardial infarction 2.9 Antiplatelet drugs Green GP prescribable at aspirin) (STEMI) request of Consultant/Specialist

Clozapine Schizophrenia 4.2.1 Antipsychotic drugs Red Hospital / Specialist only

Cobicistat ▼ Use as a booster in treatment of HIV 5.3.1 Pharmacokinetic Red Hospital / Specialist positive adults and adolescents - as enhancers of only per NHS England policy antiretrovirals

Cobimetinib ▼ (in Unresectable or metastatic BRAF 8.1.5 Protein kinase inhibitor Double Red Not recommended for combination with vemurafenib) V600 mutation-positive melanoma - as routine use / Not per NICE TA 414 commissioned

Co-careldopa intestinal gel Severe Parkinson's disease 4.9.1 Dopaminergic drugs Red Hospital / Specialist inadequately controlled by other used for parkinsonism only preparations - as per NHS England policy

Cochlear implants For children and adults with severe to No BNF entry - device Double Red Not recommended for profound deafness - specialist routine use / Not commissioned use only as per NHSE commissioned policy Co-enzyme Q10 All indications - as per N&W DROP Not listed in the BNF Double Red Not recommended for List and NICE NG 71 & 181 Do Not Do routine use / Not commissioned

Colecalciferol (Vitamin D) Treatment of vitamin D deficiency in 9.6.4 Vitamin D Double-GreenSuitable for GPs to adults and children - as per local initiate and prescribe policies

Colecalciferol (Vitamin D) To increase adherence to statin 9.6.4 Vitamin Double Red Not recommended for treatment - as per NICE CG 181 - Do routine use / Not Not Do commissioned

Colesevelam HCl Third-line option for (unlicensed) use 2.12 Bile acid sequestrants Green GP prescribable at in bile salt malabsorption causing request of diarrhoea (for patients under the Consultant/Specialist NNUH only)

Colesevelam HCl ▼ Hypercholesterolaemia - as per N&W 2.12 Bile acid sequestrants Double red Not recommended for DROP List and NICE CG 181 Do Not routine use / Not Do commissioned

Colesevelam hydrochloride Prevention of CVD, alone or added to 2.12 Lipid-regulating Double Red Not recommended for a statin - as per NICE CG 181 - Do drugs - Bile Acid routine use / Not Not Do Sequestrants commissioned

Colestilan Management of hyperphosphataemia 2.12 Bile acid sequestrants Red Hospital / Specialist in adults on renal dialysis only

Colestipol hydrochloride Prevention of CVD, alone or added to 2.12 Lipid-regulating Double Red Not recommended for a statin - as per NICE CG 181 - Do drugs - Bile Acid routine use / Not Not Do Sequestrants commissioned Colistimethate sodium Pseudomonas lung infection in Cystic 5.1.7 Polymyxin antibiotics Red Hospital / Specialist (nebulised) Fibrosis (new patients from 1st April only 2013) - as per NHS England policy

Colistimethate sodium Ps. aeurginosa infection in non-Cystic 5.1.7 Polymyxin antibiotics Amber Option for Shared (Nebulised) Fibrosis bronchiectasis Care Prescribing

Colistimethate sodium Dry Pseudomonas lung infection in cystic 5.1.7 Polymyxins Red Hospital / Specialist Powder Inhaler fibrosis - as per NICE TA 276 and only NHS England policy

Collagenase Clostridium Peyronie’s Disease 10.3.1 Enzymes Double Red Not recommended for Histolyticum routine use / Not commissioned

Collagenase clostridium Dupuytren's contracture with a 10.3.1 Enzymes Double Red Not recommended for histolyticum palpable cord in adults - as per NICE routine use / Not TA 459 commissioned

Printed: 14 September 2021 Page 20 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Combination analgesics with Pain relief Double Red Not recommended for caffeine routine use / Not commissioned

Combination products - new Various Various Double red Not recommended for co-drugs routine use / Not commissioned

Conestat alfa Hereditary angiodema - acute 3.4.3 Allergic emergencies Red Hospital / Specialist treatment only - as per NHS England only policy

Co-proxamol Pain - as per N&W DROP List 4.7.1 Non-opiod analgesics Double Red Not recommended for & compound routine use / Not analgesic preps commissioned

Corneal epithelial cells (Holoclar for) Limbal stem cell No BNF entry Red Hospital / Specialist (human) with stem cells deficiency after eye burns - as per only NICE TA 467

Corticosteroids (Topical) Atopic eczema - as per NICE TA 81 13.4 Topical corticosteroids Double-GreenSuitable for GPs to initiate and prescribe

Cough and cold remedies Cough and cold 4 Cough and congestion Double Red Not recommended for routine use / Not commissioned

COX II Inhibitors Pain and inflammation in osteoarthritis 10.1.1 Non-steroidal anti- Double-GreenSuitable for GPs to or rheumatoid arthritis - as per local inflammatory drugs initiate and prescribe Analgesics Formulary

Creams - tretinoin, Melasma (Chloasma) - as per N&W Not listed Double Red Not recommended for hydroquinone & corticosteroid DROP List routine use / Not commissioned

Crisaborole mild to moderate atopic dermatitis in 13.5.1 Preparations for Double Red Not recommended for people 2 years and older (TA701 - eczema routine use / Not terminated appraisal) commissioned

Crizotinib ROS1-positive advanced non-small- 8.1.5 Other antineoplastic Red Hospital / Specialist cell lung cancer - as per NICE TA 529 drugs only

Crizotinib ▼ Previously treated non-small-cell lung 8.1.5 Other antineoplastic Red Hospital / Specialist cancer associated with an anaplastic drugs only lymphoma kinase fusion gene - as per NICE TA 422

Crizotinib ▼ Untreated anaplastic lymphoma 8.1.5 Anti neoplastic drugs- Red Hospital / Specialist kinase-positive advanced non-small- protein kinase only cell lung cancer - as per NICE TA 406 inhibitors

Cycloidal vibration Therapy for cellulitis, venous leg Not listed Double Red Not recommended for accessories (Vibro-pulse) ulcers and lower limb oedema routine use / Not commissioned

Cyclophosphamide Use in Cancer 8.1.1 Alkylating drugs Red Hospital / Specialist only

Cysteamine (Mercaptamine) Neuropathic cystinosis 9.8.1 Drugs used in Red Hospital / Specialist metabolic disorders only

Dabigatran Anticoagulation in DC Cardioversion of 2.8.2 Oral anticoagulants In progress Prescribing Atrial Fibrillation / Atrial Flutter responsibility yet to be confirmed

Dabigatran Combined use with dual antiplatelet 2.8.2 Oral anticoagulants Double Red Not recommended for therapy in people who otherwise need routine use / Not anticoagulation, who have had an MI - commissioned as per NICE CG 172 - Do Not Do Dabigatran Treatment and prevention of 2.8.2 Oral anticoagulants Green GP prescribable at pulmonary embolism as per NICE TA request of 327 (where warfarin is not Consultant/Specialist appropriate - see Full Guidance)

Dabigatran etexilate Treatment of calf vein deep vein 2.8.2 Oral anticoagulants Red Hospital / Specialist thrombosis (as per NICE TA 327) only

Dabigatran etexilate Stroke and systemic embolism 2.8.2 Oral anticoagulants Double-GreenSuitable for GPs to prevention in non-valvular atrial initiate and prescribe fibrillation -as per NICE TA 249 and local policy

Printed: 14 September 2021 Page 21 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Dabigatran etexilate Prevention of venous 2.8.2 Oral anticoagulants Red Hospital / Specialist thromboembolism after hip or knee only surgery in adults (as per NICE TA 157)

Dabigatran etexilate Treatment and secondary prevention 2.8.2 Oral anticoagulants Green GP prescribable at of proximal deep vein thrombosis in request of specified patient groups asper NICE Consultant/Specialist TA 327 and local policy (see Full TAG Guidance)

Dabrafenib (with trametinib (Mekinist®)) for 8.1.5 Other antineoplastic Double Red Not recommended for treating advanced metstatic BRAF drugs routine use / Not V600E mutation-positive non-small- commissioned cell lung cancer - as per NICE TA 564

Dabrafenib ▼ Treatment of unresectable or 8.1.5 Other antinoplastic Red Hospital / Specialist metastatic BRAF V600 mutation- drugs only positive melanoma (alone or with trametinib) - as per NICE TA 321

Dabrafenib with trametinib Adjuvant treatment of resected BRAF 8.1.5 Other antineoplastic Red Hospital / Specialist V600 mutation-positive melanoma - as drugs only per NICE TA 544

Daclatasvir ▼ For treating chronic hepatitis C in 5.3.3.2 Chronic hepatitis C Red Hospital / Specialist adults (with sofosbuvir or only peginterferon alfa, and with ribavirin) as per NICE TA 364

Daclizumab Relapsing-remitting multiple sclerosis 8.2.4 Other Double Red Not recommended for in adults - as per NICE TA 441 immunomodulating routine use / Not Specialist centre only - currently drugs commissioned suspended Dacomitinib Untreated EGFR mutation-positive 8.1.5 Protein Kinase Red Hospital / Specialist non-small-cell lung cancer Inhibitors only

Danazol Heavy menstrual bleeding - as per 6.7.2 Drugs affecting Double Red Not recommended for NICE CG 44 - Do Not Do gonadotrophins routine use / Not commissioned

Dapagliflozin With insulin for treating type 1 diabetes 6.1.2.3 Other antidiabetic Double Red Not recommended for drugs routine use / Not commissioned

Dapagliflozin Triple therapy for treating type 2 6.1.2.3 Other antidiabetic Green GP prescribable at diabetes in adults - as per NICE TA drugs request of 418 Consultant/Specialist

Dapagliflozin chronic heart failure with reduced 6.1.2.3 Other antidiabetic Double Red Not recommended for ejection fraction as per TA679 drugs routine use / Not commissioned

Dapagliflozin ▼ As monotherapy for treating type 2 6.1.2.3 Other antidiabetic Green GP prescribable at diabetes - as per NICE TA 390 drugs request of Consultant/Specialist

Dapagliflozin ▼ Limited use in Type 2 diabetes 6.1.2.3 Other antidiabetic Green GP prescribable at mellitus - as per NICE TA 288 drugs request of Consultant/Specialist

Dapoxetine For diagnosed premature ejaculation 7.4.6 Drugs for premature Double Red Not recommended for ejaculation routine use / Not commissioned

Daratumumab As monotherapy for treating relapsed 8.1.5 Other antineoplastic Red Hospital / Specialist and refractory multiple myeloma - as drugs only per NICE TA 510

Daratumumab (with Previously treated multiple myeloma 8.1.5 Other antineoplastic Red Hospital / Specialist bortezomib and • in people who have had 1 previous drugs only dexamethasone) treatment - as per NICE TA 573

Daratumumab (with untreated multiple myeloma as per 8.1.5 Other antineoplastic Double Red Not recommended for lenalidomide and TA634 (June 2020 - terminated drugs routine use / Not dexamethasone) appraisal) commissioned

Daratumumab ▼ (with lenalidomide and 8.1.5 Other antineoplastic Double Red Not recommended for dexamethasone) for relapsed or drugs routine use / Not refractory multiple myeloma - as per commissioned NICE TA 454

Printed: 14 September 2021 Page 22 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Darbepoetin alfa treatment of anaemia in chronic 9.1.3 hypopplasmic, Amber Option for Shared kidney disease haemolytic & renal Care Prescribing anaemias

Darbepoetin alfa Treatment of anaemia in people with 9.1.3 Rxs for hypopplasmic, Red Hospital / Specialist cancer having chemotherapy - as per haemolytic & renal only NICE TA 323 anaemias Darolutamide with androgen deprivation therapy for 8.3.4.2 Prostate cancer and Red Hospital / Specialist treating hormone-relapsed non- gonadorelin analogues only metastatic prostate cancer as per TA660

Darunavir HIV infection in combination with other 5.3.1 HIV infection Red Hospital / Specialist antiretroviral drugs - as per BHIVA only Guidelines

Darunavir and Cobicistat HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist (Rezolsta®) antiretroviral drugs - as per BHIVA only Guidelines

Darvadstrocel Complex perianal fistulas in adults No BNF entry Double Red Not recommended for with non-active or mildly active luminal routine use / Not Crohn's disease - as per NICE TA 556 commissioned

Dasabuvir Viral Hepatitis C 5.3.3 Viral hepatitis Double Red Not recommended for routine use / Not commissioned

Dasatinib Chronic myeloid leukaemia (CML) - 8.1.5 Antineoplastic drugs - Red Hospital / Specialist as per NHS England policy protein kinase only inhibitors

Dasatinib Untreated chronic-phase Philadelphia- 8.1.5 Other antineoplastic Red Hospital / Specialist chromosome-positive chronic myeloid drugs only leukaemia in adults - as per NICE TA 426 Decitabine Acute Myeloid Leukaemia - as per 8.1.3 Antimetabolites Double red Not recommended for NICE TA 270 routine use / Not commissioned

Decitabine Untreated acute myeloid leukaemia - 8.1.3 Antimetabolites Double Red Not recommended for as per NICE TA 548 routine use / Not commissioned

Deep Brain Stimulation (DBS) Treatment of refractory epilepsy - as Not listed - procedure Double Red Not recommended for per NHS England policy routine use / Not commissioned

Deep Brain Stimulation (DBS) Treatment of Chronic Neuropathic Not listed - procedure Double Red Not recommended for Pain - as per NHS England policy routine use / Not commissioned

Deferasirox For blood transfusion related iron 9.1.3 Iron chelators Double Red Not recommended for overload in patients with routine use / Not myelodysplastic syndrome (MDS) commissioned

Deferasirox Treatment of chronic iron overload 9.1.3 Drugs in hypoplastic, Red Hospital / Specialist due to frequent blood transfusions (but haemolytic & renal only not for use in MDS) - as per NHS anaemias England policy

Deferiprone Chronic iron overload related to 9.1.3 Drugs used in iron Red Hospital / Specialist frequent blood transfusions (not for overload only use in MDS) - as per NHS England policy Deferiprone For blood transfusion related iron 9.1.3 Iron chelators Double Red Not recommended for overload in patients with routine use / Not myelodysplastic syndrome (MDS) commissioned

Defibrotide Treatment of hepatic veno-occlusive Not listed in the BNF Red Hospital / Specialist disease in adults and children only undergoing haematopoietic stem cell transplant - as per NHS England policy Degarelix Advanced hormone-dependent 8.3.4.2 Gonadotrophin- Red Hospital / Specialist prostate cancer - as per NICE TA 404 releasing hormone only antagonists

Printed: 14 September 2021 Page 23 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Delamanid Multidrug-Resistant and Extensively 5.1.9 Antituberculosis drugs Red Hospital / Specialist Drug-Resistant Tuberculosis - as per only NHS England policy

Denosumab Prevention of osteoporotic fractures in 6.6.2 Bisphosphonates & Amber Option for Shared postmenopausal women as per NICE drugs affecting bone Care Prescribing TA 204 (Shared care in the central metabolism Norfolk and Great Yarmouth & Waveney CCGs)

Denosumab Prevention of osteoporotic fractures in 6.6.2 Bisphosphonates & Green GP prescribable at postmenopausal women as per NICE drugs affecting bone request of TA 204 (Specialist Nurse metabolism Consultant/Specialist recommendation in West Norfolk CCG only)

Denosumab Preventing skeletal-related events in 6.6.2 Bisphosphonates & Double Red Not recommended for multiple myeloma - as per NICE TA drugs affecting bone routine use / Not 549 metabolism commissioned

Denosumab Treatment of therapy-induced bone 6.6.2 Bisphosphonates & Double red Not recommended for loss in non-metastatic prostate drugs affecting bone routine use / Not cancer - as per NICE TA 194 metabolism commissioned

Denosumab ▼ Prevention of skeletal-related events 6.6.2 Bisphosphonates - Red Hospital / Specialist in adults with bone metastases from drugs affecting bone only solid tumours metabolism

Deodorants (stoma) Odour management related to stoma Not listed Double Red Not recommended for routine use / Not commissioned Desferrioxamine For blood transfusion related iron 9.1.3 Iron chelators Double Red Not recommended for overload in patients with routine use / Not myelodysplastic syndrome (MDS) commissioned

Desferrioxamine mesilate Anaemia related to chronic iron 9.1.3 Drugs used in renal Red Hospital / Specialist overload (not for use in MDS) - as per anaemias etc only NHS England policy

Desloratadine Allergy (not for NHS provision - self 3.4.1 Antihistamines Double Red Not recommended for care recommended) routine use / Not commissioned

Dexamethasone To prevent prescribing in primary care 6.3.2 Glucocorticoid therapy Red Hospital / Specialist as a treatment for covid-19 only

Dexamethasone intravitreal Treatment of diabetic macular 11.4.1 Corticosteroids (used Red Hospital / Specialist implant oedema (DMO) in line with NICE TA to treat the eye) only

Dexamethasone intravitreal Non-infectious uveitis in the posterior 11.4.1 Corticosteroids (used Red Hospital / Specialist implant segment of the eye in adults - as per to treat the eye) only NICE TA 460

Dexamethasone intravitreal Macular oedema secondary to retinal 11.4.1 Corticosteroids (used Red Hospital / Specialist implant ▼ vein occlusion - as per NICE TA 229 to treat the eye) only

Dexamfetamine sulfate ▼ Attention Deficit Hyperactivity Disorder 4.4 CNS stimulants and Amber Option for Shared in Adults for new treatment of drugs used for ADHD Care Prescribing symptoms that can be confirmed from childhood Dexamfetamine sulfate ▼ Attention Deficit Hyperactivity Disorder 4.4 CNS stimulants and Amber Option for Shared in children and adolescents drugs used for ADHD Care Prescribing

Dexamfetamine sulphate ▼ Chronic fatigue syndrome/myalgic 4.4 CNS stimulants and Double Red Not recommended for encephalomyelitis (or drugs used for ADHD routine use / Not encephalopathy) - as per NICE CG commissioned 53 - Do Not Do

Dexibuprofen Analgesia / musculoskeletal pain 10.1.1 Non-steroidal anti- Double Red Not recommended for inflammatory drugs routine use / Not commissioned

Dexrazoxane (Cardioxane®) Anthracycline cardiotoxicity 9.1.3 Iron chelators Double Red Not recommended for routine use / Not commissioned

Dexrazoxane (Savene®) Anthracycline extravasation 9.1.3 Iron chelators Red Hospital / Specialist only

Printed: 14 September 2021 Page 24 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Diaminopyridine (-3,4) Treatment of myasthenias - as per 10.2 Not listed Double Red Not recommended for (amifampridine base) NHS England policy routine use / Not commissioned

Diazepam Chronic use for spasticity in adults 4.6 Drugs used in muscle Double Red Not recommended for with cerebral palsy - NICE Do Not Do spasm routine use / Not as per NG 119 commissioned

Dibotermin alfa Complex spinal surgery - as per NHS Not listed in BNF Red Hospital / Specialist England Policy 16063/P only

Dibotermin alfa (RH bone Acute tibial fractures with Grade IIIB Not listed in the BNF Red Hospital / Specialist morphogenetic protein-2) fractures only

Diclofenac Pain relief No BNF entry Double Red Not recommended for routine use / Not commissioned

Diclofenac Pain relief No BNF entry Double Red Not recommended for routine use / Not commissioned

Dicycloverine GI indications 1.2 Antispasmodics & Double Red Not recommended for other drugs altering routine use / Not gut motility commissioned

Didanosine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Dietary supplements (non Various non nutrition-related Various Double red Not recommended for nutritional use) indications - see full entry and N&W routine use / Not DROP List commissioned

Diethylstilboestrol treatment of prostate cancer 8.3.1 Oestrogens Green GP prescribable at request of Consultant/Specialist

Digoxin Cor pulmonale 2.1.1 Cardiac glycosides Double Red Not recommended for routine use / Not commissioned

Dimethyl fumarate Treatment of moderate to severe 8.2.4 Other Red Hospital / Specialist (Skilarence®) plaque psoriasis in adults - as per immunomodulating only NICE TA 475 and locally drugs commissioned pathway

Dimethyl Fumarate For treatment of adults with active 8.2.4 Other Red Hospital / Specialist (Tecfidera®) relapsing-remitting multiple sclerosis immunomodulating only (RRMS) - as per NICE TA 320 drugs

Dinutuximab beta High-risk neuroblastoma in people 8.1.5 Other antineoplastic Red Hospital / Specialist aged 12 months and over - as per drugs only NICE TA538

Disulfiram Maintenance of abstinence in alcohol- 4.10.1 Drugs used in Red Hospital / Specialist dependent patients substance dependence only

Docetaxel Advanced breast cancer - as per NICE 8.1.5 Other antineoplastic Red Hospital / Specialist CG 80 drugs only

Docetaxel Non-small cell lung cancer - as per 8.1.5 Other antineoplastic Red Hospital / Specialist NHS England policy drugs only

Docetaxel Substitute for paclitaxel causing 8.1.5 Other antineoplastic Red Hospital / Specialist peripheral neuropathy in ovarian drugs only cancer - as per NHS England policy

Dolutegravir ▼ (in combination with other antiretroviral 5.3.1 HIV infection Red Hospital / Specialist drugs) Treatment of HIV-1 infection in only adults and adolescents - as per NHS England policy Donepezil Mild to moderate Alzheimer's 4.11 Drugs for dementia Amber Option for Shared dementia - as per NICE TA 217 Care Prescribing

Doravirine HIV infection in combination with other 5.3.1 HIV Infection - not a Double Red Not recommended for antiretroviral drugs licensed product routine use / Not commissioned

Dornase alfa Primary Ciliary Dyskinesia 3.7 Mucolytics Double Red Not recommended for routine use / Not commissioned

Printed: 14 September 2021 Page 25 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Dornase alfa Cystic fibrosis - as per NHS England 3.7 Mucolytics Red Hospital / Specialist policy only

Dosulepin hydrochloride Depression - as per NICE CG 90 - Do 4.3.1 Tricyclic and related Double Red Not recommended for Not Do antidepressant drugs routine use / Not commissioned

Doxazosin MR Hypertension; benign prostatic 2.5.4 Alpha-adrenoceptor Double Red Not recommended for hyperplasia - as per N&W DROP List blocking drugs routine use / Not commissioned

Doxepin Urticaria in dermatology Double Red Not recommended for routine use / Not commissioned

Doxepin Antidepressant Tricyclic Double Red Not recommended for antidepressants routine use / Not commissioned

Doxorubicin HCl (pegylated As monotherapy or with platinum for 8.1.5 Anthracycline Red Hospital / Specialist liposomal) (PLDH) treatment of advanced recurrent topoisomerase inhibitor only ovarian cancer - as per NICE TA 389 Doxycycline Anthrax exposure - as per Public 5.1.3 Tetracyclines Double-GreenSuitable for GPs to Health guidance initiate and prescribe

Doxylamine succinate + (with pyridoxine hydrochloride 10mg in 3.4.1 Antihistamine + Double Red Not recommended for Pyridoxine a delayed-release formulation) for the Vitamin B6 routine use / Not treatment of nausea and vomiting in commissioned pregnancy

Dried Prothrombin (complex) Licensed indications incl treatment 2.11 Antifibrinolytic drugs Red Hospital / Specialist and peri-operative prophylaxis of and haemostatics only haemorrhage in patients with congenital deficiency of factors II, VII, IX, or X if purified specific coagulation factors not available

Drisapersen Duchenne Muscular Dystrophy Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Dronedarone Non-permanent Atrial Fibrillation - for 2.3.2 Drugs for arrhythmias Amber Option for Shared use only where amiodarone is Care Prescribing contraindicated or has previously not been tolerated (except lung toxicity due to amiodarone)

Dulaglutide ▼ Type 2 diabetes mellitus - third line 6.1.2.3 Glucagon-Like Green GP prescribable at option Peptide-1 receptor request of agonists Consultant/Specialist

Duloxetine Moderate to Severe Stress Urinary 7.4.2 For urinary frequency, Green GP prescribable at Incontinence (SUI) - (but not first- line enuresis & request of as per NICE CG 171 - Do Not Do) incontinence Consultant/Specialist

Duloxetine Depression 4.3.3 Serotonin and Double-GreenSuitable for GPs to noradrenaline re- initiate and prescribe uptake inhibitors

Dupilumab treating chronic rhinosinusitis with 13.5.3 Drugs affecting the Double Red Not recommended for nasal polyps as per TA648 immune response routine use / Not (terminated) commissioned

Dupilumab ▼ For adults with severe atopic Human Monoclonal Red Hospital / Specialist dermatitis who have failed to respond, Antibody only or who are intolerant of or ineligible for all approved therapies - as per NICE TA 534 Durvalumab in combination for untreated extensive- 8.1.5 Other antineoplastic Double Red Not recommended for stage small-cell lung cancer as per drugs routine use / Not TA662 (terminated appraisal) commissioned

Dymista (fluticasone Moderate to severe seasonal and 12.2.1 Drugs used in nasal Double Red Not recommended for propionate /azelastine HCl) perennial rhinitis, if monotherapy with allergy routine use / Not antihistamine or corticosteroid is commissioned inadequate - as per N&W DROP List

Printed: 14 September 2021 Page 26 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Ear wax softening products Softening of excessive ear wax to aid 12.1.3 Removal of ear wax Double Red Not recommended for removal - selfcare & purchasing routine use / Not encouraged commissioned

Ecallantide Hereditary angiodema - acute 3.4.3 Allergic emergencies - Double Red Not recommended for treatment only not listed in BNF routine use / Not commissioned

Eculizumab Refractory myasthenia gravis as per 9.1.3 Hypoplastic, Double Red Not recommended for TA636 (June 2020 - terminated haemolytic and renal routine use / Not appraisal) anaemias commissioned

Eculizumab Treatment of refractory antibody 9.1.3 Drugs for hypoplastic, Double Red Not recommended for mediated rejection post kidney haemolytic & renal routine use / Not transplant - as per NHS England policy anaemias commissioned

Eculizumab C3 glomerulopathy (post transplant) - 9.1.3 Drugs for hypoplastic, Red Hospital / Specialist as per NHSE policy haemolytic & renal only anaemias

Eculizumab Atypical haemolytic uremic syndrome 9.1.3 Drugs for hypoplastic, Red Hospital / Specialist (aHUS) haemolytic & renal only anaemias

Eculizumab for treating relapsing neuromyelitis 9.1.3 Drugs for hypoplastic, Double Red Not recommended for optica as per TA647 (terminated) haemolytic & renal routine use / Not anaemias commissioned

Eculizumab Paroxysmal noctural haemoglobinuria 9.1.3 Drugs for hypoplastic, Red Hospital / Specialist haemolytic & renal only anaemias

Edoxaban ▼ Combined use with with dual 2.8.2 Oral anticoagulants Double Red Not recommended for antiplatelet therapy in people who routine use / Not otherwise need anticoagulation, who commissioned have had an MI - as per NICE CG 172 - Do Not Do

Edoxaban ▼ Treatment and secondary prevention 2.8.2 Oral anticoagulants - Green GP prescribable at of pulmonary embolism as per NICE Factor Xa inhibitor request of TA 354 (where warfarin is not Consultant/Specialist appropriate - see Full Guidance)

Edoxaban ▼ Treatment and prevention of proximal 2.8.2 Oral anticoagulants - Green GP prescribable at deep vein thrombosis in specified Factor Xa inhibitor request of patient groups (see Full Guidance) Consultant/Specialist Edoxaban ▼ Treatment of calf vein deep vein 2.8.2 Oral anticoagulants Red Hospital / Specialist thrombosis (as per NICE TA 354) only

Edoxaban ▼ For preventing stroke and systemic 2.8.2 Oral anticoagulants - Double-GreenSuitable for GPs to embolism in people with non valvular factor Xa inhibitor initiate and prescribe atrial fibrillation who have one or more risk factors (as per NICE TA 355) Edtratide Systemic lupus erythematosus (SLE) Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Efalex Dyslexia - as per N&W DROP List Not listed in the BNF Double red Not recommended for routine use / Not commissioned

Efavirenz HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Eflornithine 11.5% cream Hirsutism in women, transgender and 13.9 Preparations for hair Double-GreenSuitable for GPs to non-binary adults - restricted use conditions initiate and prescribe where alternative therapy is ineffective, contraindicated or inappropriate as per local guidance

Efraloctocog alfa Haemophilia A - as per NHS England Not listed in BNF Red Hospital / Specialist policy SSC1652 only

Eftrenonacog alfa Haemophilia B - as per NHS England Not listed in BNF Red Hospital / Specialist SSC1652 only

Elbasvir-grazoprevir ▼ Genotype 1 or 4 chronic hepatitis C in 5.3.3.2 Antiviral drugs Red Hospital / Specialist adults - as per NICE TA 413 only

Printed: 14 September 2021 Page 27 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Electronic cigarettes Tobacco dependence / smoking Not listed in the BNF Double Red Not recommended for reduction or cessation - as per Public routine use / Not Health guidance commissioned

Eliglustat ▼ Treatment of Type 1 Gaucher disease Glucosylceramide Red Hospital / Specialist synthase inhibitor only

Elosulfase alpha ▼ Treatment of Mucopolysaccharidosis Not listed in the BNF Double Red Not recommended for IV Type A (MPS IVA) (Morquio A routine use / Not syndrome) - as per NHS England commissioned policy

Elotuzumab ▼ Multiple myeloma - as per NICE TA 8.1.5 Other antineoplastic Double Red Not recommended for 434 drugs routine use / Not commissioned

Eltrombopag Severe aplastic anaemia refractory to 9.1.4 Drugs used in platelet Double Red Not recommended for immunosuppressive therapy - as per disorders routine use / Not NICE TA 382 commissioned

Eltrombopag Treatment of chronic immune 9.1.4 Drugs used in platelet Red Hospital / Specialist (idiopathic) thrombocytopenic disorders only purpura - as per NICE TA 293

Eltrombopag Thrombocytopenia which affects the 9.1.4 Drugs used in platelet Double Red Not recommended for initiation or maintenance of optimal disorders routine use / Not interferon therapy in adults with commissioned chronic Hepatitis C Eluxadoline ▼ 3rd line option in irritable bowel 1.2 Antispasmodics & Green GP prescribable at syndrome with diarrhoea in adults - as other drugs altering request of per NICE TA 471 and local treatment gut motility Consultant/Specialist pathway

Elvitegravir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs - as per NHS only England Policy 16043/P Elvitegravir/cobicistat/emtricita HIV infection - as per NHS England 5.3.1 Treatments for HIV Red Hospital / Specialist bine/tenofovir ▼ policy 16043/P infection only

Elvucitabine HIV infection in combination with other 5.3.1 HIV Infection - Not Double Red Not recommended for antiretroviral drugs listed in BNF routine use / Not commissioned

Empagliflozin ▼ As 4th line monotherapy option for 6.1.2.3 Other antidiabetic Green GP prescribable at treating type 2 diabetes - as per NICE drugs request of TA 390 Consultant/Specialist

Empagliflozin ▼ In combination therapy for treating 6.1.2.3 Other antidiabetic Green GP prescribable at type 2 diabetes - as per NICE TA 336 drugs request of (Prescriber's Rating - nothing new) Consultant/Specialist

Emricasan Non alcoholic steatohepatitis (NASH) Not listed in BNF Double Red Not recommended for fibrosis routine use / Not commissioned

Emtricitabine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Emtricitabine and tenofovir 5.3.1 HIV Infection Red Hospital / Specialist only

Emtricitabine and Tenofovir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist alafenamide fumarate antiretroviral drugs only

Emtricitabine, Rilpivirine, HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist tenofovir alafenamide antiretroviral drugs - as per NHSE only policy

Encorafenib (with binimetinib (Mektovi®)) for 8.1.5 Other antineoplastic Red Hospital / Specialist treating unresectable or metastatic drugs only BRAF V600 mutation-positive melanoma in adults - as per NICE TA 562

Encorafenib plus cetuximab for previously treated 8.1.5 Other antineoplastic Red Hospital / Specialist BRAF V600E mutation-positive drugs only metastatic colorectal cancer as per TA668

Printed: 14 September 2021 Page 28 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Enfuvirtide HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Entecavir Chronic hepatitis B - as per NHS 5.3.3 Viral hepatitis Red Hospital / Specialist England policy only

Enteral nutrition PEG and NG tube feeding 9.4.2 Enteral nutrition - Double-GreenSuitable for GPs to initiate and prescribe

Entrectinib treating NTRK fusion-positive solid 8.1.5 Protein kinase Red Hospital / Specialist tumours as per TA644 inhibitors only

Entrectinib treating ROS1-positive advanced non- 8.1.5 Protein kinase Red Hospital / Specialist small-cell lung cancer as per TA643 inhibitors only

Enzalutamide Metastatic hormone relapsed prostate 8.3.4.2 Anti-androgens Red Hospital / Specialist cancer previously treated with a only docetaxel-containing regimen - as per NICE TA 316 Enzalutamide Metastatic hormone-relapsed prostate 8.3.4.2 Anti-androgens Red Hospital / Specialist cancer before chemotherapy is only indicated - as per NICE TA 377

Epifix® Chronic wounds No BNF entry Double Red Not recommended for routine use / Not commissioned

Epinephrine (Adrenaline) Asthma - reliever therapy - as per 3.1.1 Adrenoceptor agonists Double Red Not recommended for inhaler (Primatene Mist®) N&W DROP List routine use / Not commissioned

Eplerenone Second-line therapy in patients with 2.2.3 Second-line Double-GreenSuitable for GPs to heart failure who are intolerant to aldosterone antagonist initiate and prescribe spironolactone due to hormonal side- effects

Epoprostenol Primary pulmonary hypertension - as 2.8.1 Parenteral Red Hospital / Specialist per NHS England policy - specialist anticoagulants only centres only

Epoprostenol Acute respiratory distress syndrome 2.8.1 Parenteral Double red Not recommended for (ARDS) anticoagulants routine use / Not commissioned

Epoprostenol (prostacyclin) ▼ Primary pulmonary hypertension - as 2.8.1 Parenteral Special Special contract - not per NHS England policy - specialist anticoagulants for GP prescribing centre only

Epratuzumab Systemic lupus erythematosus (SLE) CD22 antigen Double Red Not recommended for inhibitor - Not listed in routine use / Not BNF commissioned

Eprodisate Amyloidosis AA-amyloid Double Red Not recommended for fibrillogenesis routine use / Not inhibitor - not listed commissioned

Eptifibatide Prevention of MI in unstable angina - 2.9 Antiplatelet drugs Red Hospital / Specialist as per NICE TA 47 only

Eptotermin alfa Complex spinal surgery Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Erectile dysfunction drugs Erectile dysfunction - limited 7.4.5 Drugs for impotence Double-GreenSuitable for GPs to categories of patients under SLS for initiate and prescribe certain drugs Erectile dysfunction drugs Severe distress from erectile 7.4.5 Drugs for erectile Red Hospital / Specialist dysfunction seeking treatment on the dysfunction in SLS list only NHS

Erenumab preventing migraine as per TA682 4.7.4.2 Prophylaxis of migraine Double Red Not recommended for routine use / Not commissioned

Eribulin Treatment of locally advanced or 8.1.5 Other antineoplastic Red Hospital / Specialist metastatic breast cancer - as per drugs only NICE TA 423 and NHS England policy

Printed: 14 September 2021 Page 29 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Eribulin Locally advanced or metastatic breast 8.1.5 Other antineoplastic Double Red Not recommended for cancer after 1 chemotherapy drugs routine use / Not regimen - as per NICE TA 515 commissioned

Eribulin Locally advanced or metastatic breast 8.1.5 Other antineoplastic Red Hospital / Specialist cancer after 2 or more chemotherapy grugs only regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 423

Erlotinib Monotherapy for maintenance 8.1.5 Tyrosine kinase Double red Not recommended for treatment of non-small-cell lung inhibitor routine use / Not cancer - as per NICE TA 227 and commissioned NHS England policy

Erlotinib First-line treatment of locally advanced 8.1.5 Other antineoplastic Double Red Not recommended for or metastatic EGFR-TK mutation- drugs routine use / Not positive non-small-cell lung cancer - commissioned as per NICE TA 258 and NHS England policy

Erlotinib Treatment of non-small-cell lung 8.1.5 Other antineoplastic In progress Prescribing cancer (NSCLC) as per NICE TA 374 - drugs responsibility yet to be as per NHS England policy confirmed

Erlotinib Treating locally advanced or 8.1.5 Other antineoplastic Double Red Not recommended for metastatic NSCLC that doesn’t test drugs routine use / Not positive for the EGFR TK mutation (as commissioned per NICE TA 374)

Ertugliflozin With metformin and a depeptidyl 6.1.2.3 Other antidiabetic Double-GreenSuitable for GPs to peptidase-4 inhibitor for Type 2 drugs initiate and prescribe diabetes

Ertugliflozin As monotherapy or with metformin for 6.1.2.3 Other antidiabetic Green GP prescribable at treating type 2 diabetes - as per NICE drugs request of TA 572 Consultant/Specialist

Erythropoietin (epoetin / Treatment of anaemia in people with 9.1.3 Rx for hypoplastic, Red Hospital / Specialist darbepoetin) cancer having chemotherapy - as per haemolytic, & renal only NICE TA 323 and NHS England policy anaemias

Erythropoietin / Epoetin Dialysis-induced anaemia 9.1.3 Drugs in hypoplastic, Red Hospital / Specialist haemolytic & renal only anaemias

Erythropoietin / Epoetin Anaemia in renal failure pre-dialysis. 9.1.3 Drugs in hypoplastic, Double Red Not recommended for haemolytic & renal routine use / Not anaemias commissioned

Erythropoietin / Epoetin Treatment of transfusion-dependent 9.1.3 Drugs in hypoplastic, In progress Prescribing anaemia in myelodysplasia haemolytic & renal responsibility yet to be anaemias confirmed

Eslicarbazepine Epilepsy 4.8.1 CNS - Carbamazepine Double Red Not recommended for and Oxcarbazepine routine use / Not commissioned

Eslicarbazepine trigeminal neuralgia 4.8.1 CNS - Carbamazepine Double Red Not recommended for and Oxcarbazepine routine use / Not commissioned

Esomeprazole Limited use where other PPI options 1.3.5 Proton pump inhibitors Green GP prescribable at have been ineffective; Barrett's request of oesophagus - as per N&W DROP List Consultant/Specialist

Esomeprazole First line PPI option for licensed 1.3.5 Proton pump inhibitors Double Red Not recommended for indications - as per N&W DROP List routine use / Not commissioned

Estradiol / Dienogest Contraception - as per N&W DROP 7.3.1 Combined hormonal Double Red Not recommended for List contraceptives routine use / Not commissioned

Estramustine phosphate All indications 8.1.1 Alkylating drugs Red Hospital / Specialist only

Printed: 14 September 2021 Page 30 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Etamsylate Heavy menstrual bleeding - as per 2.11 Antifibrinolytic drugs Double Red Not recommended for NICE CG 44 and the BNF and haemostatics routine use / Not commissioned

Etanercept Rheumatoid arthritis - after other 10.1.3 Drugs which suppress Red Hospital / Specialist DMARDs including a TNF inhibitor - as the rheumatic process only per NICE TA 195 and local policy

Etanercept Idiopathic juvenile arthritis - 10.1.3 Drugs which suppress Red Hospital / Specialist polyarticular, psoriatic and enthesitis- the rheumatic process only related JIA as per NICE TA 373 and NHS England policy

Etanercept Ankylosing spondilitis - as per NICE 10.1.3 Drugs which suppress Red Hospital / Specialist TA 383 the rheumatic disease only process

Etanercept moderate rheumatoid arthritis after 10.1.3 Drugs that suppress Red Hospital / Specialist conventional DMARDs have failed as the rheumatic disease only per TA715 process

Etanercept Behcet's Disease 10.1.3 Drugs which suppress Double red Not recommended for the rheumatic disease routine use / Not process commissioned

Etanercept Plaque psoriasis in children and young 13.5.3 Drugs affecting the Red Hospital / Specialist people - as per NICE TA 455 immune response only

Etanercept Active and progressive psoriatic 13.5.3 Drugs affecting the Red Hospital / Specialist arthritis - as per NICE 199 and local immune response only policy

Etanercept Psoriasis - as per NICE TA 103 and 13.5.3 Cytokine modulators Red Hospital / Specialist the local treatment pathway only

Etanercept Axial spondyloarthritis (severe, non- 10.1.3 Drugs which suppress Red Hospital / Specialist radiographic) where NSAIDs not the rheumatoci only effective or not tolerated - as per NICE disease proces TA 383 and local policy

Etelcalcetide (aka Velcalcetide) Secondary hyperparathyroidism in 9.5.1.2 Bone resorption Red Hospital / Specialist patients with chronic kidney disease inhibitors only on haemodialysis

Etelcalcetide ▼ Secondary hyperparathyroidism in Calcimimetic - No BNF Red Hospital / Specialist adults with chronic kidney disease on entry only haemodialysis - as per NICE TA 448

Eteplirsen Duchenne Muscular Dystrophy Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Ethambutol Non-TB related Mycobacterium 5.1.9 Antituberculosis drugs Green GP prescribable at infections. request of Consultant/Specialist

Etilefrine Priapism in sickle cell crisis 7.4.5 Phosphodiesterase Double Red Not recommended for type 5 inhibitors routine use / Not commissioned

Etonogestrel / ethinylestradiol Medium acting reversible 7.3.1 Combined Green GP prescribable at contraception where oral and contraceptives request of transdermal options are not suitable Consultant/Specialist Etoposide All indications 8.1.4 Vinca alkaloids and Red Hospital / Specialist etoposide only

Etravirine HIV infection in combination with other 5.3.1 HIV Infection - Red Hospital / Specialist antiretroviral drugs only

Etrolizumab Paediatric indications (IBD) where Monoclonal antibody - Double Red Not recommended for adult TA available Not listed in BNF routine use / Not commissioned

Everolimus 2nd line for advanced renal cell 8.1.5 Other antineoplastic Red Hospital / Specialist carcinoma - as per NICE TA 432 drugs only

Everolimus Unresectable or metastatic 8.1.5 Other antineoplastic Red Hospital / Specialist neuroendocrine tumours in people drugs only with progressive disease in adults - as per NICE TA 449

Printed: 14 September 2021 Page 31 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Everolimus Renal angiomyolipoma associated 8.1.5 Protein Kinase Double Red Not recommended for with tubular sclerosis inhibitors routine use / Not commissioned

Everolimus (with exemestane) for advanced HER2- 8.1.5 Other antineoplastic Red Hospital / Specialist negative, hormone-receptor-positive drugs only breast cancer in postmenopausal women - as per NICE TA 421 and NHS England policy

Everolimus Subependymal giant cell astrocytoma 8.1.5 Protein Kinase Double Red Not recommended for (SEGA) associated with tubular inhibitors routine use / Not sclerosis commissioned

Everolimus Treatment for preventing organ 8.1.5 Antineoplastic drugs - Double Red Not recommended for rejection in liver transplantation - as protein kinase inhibitor routine use / Not per NICE TA 348 commissioned

Everolimus Initial treatment to prevent organ 8.1.5 Protein kinase Double Red Not recommended for rejection in adults, children and young inhibitors routine use / Not people having a kidney transplant - as commissioned per NICE TAs 481 & 482

Evolocumab ▼ For treating primary 2.12 Lipid-regulating Red Hospital / Specialist hypercholesterolaemia and mixed drugs - PSCK9 only dyslipidaemia - as per NICE TA 394 inhibitors

Exemestane Advanced breast cancer in 8.3.4 Hormone antagonists Green GP prescribable at postmenopausal women in whom anti- request of oestrogen therapy has failed - as per Consultant/Specialist NICE CG 81 Exemestane Adjuvant treatment of oestrogen- 8.3.4 Hormone antagnoists Green GP prescribable at receptor-positive early breast cancer - request of as per NICE TA 112 and CG80/81 Consultant/Specialist

Exenatide Co-use with insulin under specified 6.1.2 Antidiabetic drugs Green GP prescribable at criteria for T2DM - as per local policy request of Consultant/Specialist

Exenatide 3rd line use in Type 2 diabetes with 6.1.2.3 Other antidiabetics Green GP prescribable at metformin + sulphonylurea - as per request of NICE CG 28 Consultant/Specialist

Exenatide (prolonged-release) in combination with oral antidiabetic 6.1.2 Antidiabetic drugs Green GP prescribable at therapy for type-2 diabetes - as per request of NICE TA 248 Consultant/Specialist

Eye compress Eye conditions including dry-eye Not listed Double Red Not recommended for syndrome, meibomian cysts, styes routine use / Not and blepharitis commissioned

Eyelid care preparations Conditions affecting the eyelids - Not listed Double Red Not recommended for including blepharitis routine use / Not commissioned

Ezetimibe and combination Lowering cholesterol in at-risk 2.12 Lipid-regulating drugs Double-GreenSuitable for GPs to products patients - as per NICE TA 385 initiate and prescribe

Factor VIII and IX Deficiency states 2.11 Antifibrinolytic drugs Red Hospital / Specialist and haemostatics only

Fampridine Improvement of walking in adults with 10.2.1 Drugs that enhance Double red Not recommended for Multiple Sclerosis with walking neuromuscular routine use / Not disability (EDSS 4-7) - as per NHS transmission commissioned England policy

Farco-fill Protect indwelling urinary catheterisation 7.4.4 Maintenance of Double Red Not recommended for indwelling urinary routine use / Not catheters commissioned

Febuxostat Management of chronic 10.1.4 Gout and cytotoxic- Double-GreenSuitable for GPs to hyperuricaemia in patients with gout induced initiate and prescribe who are intolerant of allopurinol - as hyperuricaemia per NICE TA 164

Fenofibrate Prevention of CVD - as per NICE CG 2.12 Lipid-regulating Double Red Not recommended for 181 "Do Not Do" drugs - Fibrates routine use / Not commissioned

Printed: 14 September 2021 Page 32 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Fentanyl I-R - buccal tabs, loz, (Acute) breakthrough pain in cancer 4.7.2 Opioid analgesics Double red Not recommended for nasal sprays routine use / Not commissioned

Fentanyl I-R sublingual tabs 3rd line option for (Acute) 4.7.2 Opioid analgesics Red Hospital / Specialist (Abstral®) breakthrough pain in cancer as part of only an agreed pathway of care

Ferric maltol (Feraccru®) Treatment of iron-deficiency anaemia 9.1.1.1 Iron decficiency Double Red Not recommended for in adults (see separate Red entry anaemia routine use / Not regarding use in IBD) commissioned

Ferric maltol (Feraccru®) Treatment of iron-deficiency anaemia 9.1.1.1 Iron deficiency Red Hospital / Specialist in adults with Inflammatory Bowel anaemia in IBD only Disease that are intolerant of at least 2 other oral iron products

Fesoterodine M-R Increased urinary frequency and/or 7.4.2 For urinary frequency, Double-GreenSuitable for GPs to urgency and/or urgency incontinence) enuresis & initiate and prescribe in Overactive Bladder Syndrome incontinence

Fibrin sealants Haemostatic / tissue glue 2.11 Antifibrinolytic drugs Red Hospital / Specialist and haemostatics only

Fibrinogen, dried (Human) Treatment of haemorrhage in 2.11 Antifibrinolytic drugs Red Hospital / Specialist congenital hypofibrinogenaemia or and haemostatics only afibrinogenaemia - as per BCSH guidelines

Fibroblast growth factor 1 All indications 8.3.4.3 Somatostatin analogue Double Red Not recommended for (FGF1) gene therapy routine use / Not commissioned

Fidaxomicin Treatment of mild to moderate C. 5.1.7 Some other Green GP prescribable at difficile infection (CDI) in patients who antibacterials request of have had two previous episodes in the Consultant/Specialist last 3 months under consultant microbiologist recommendation - as per local policy

Filgotinib moderate to severe rheumatoid 10.1.3 Drugs that suppress Red Hospital / Specialist arthritis as per TA676 the rheumatic disease only process

Filgotinib Paediatric indications (where adult TA 10.1.3 Drugs that suppress Double Red Not recommended for available) - specialist centres only the rheumatic disease routine use / Not process commissioned

Filgrastim Reduction in the duration of 9.1.6 Drugs used in Red Hospital / Specialist neutropenia and the incidence of neutropenia only febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy

Filgrastim Barth Syndrome - specialist centres 9.1.6 Drugs used in Red Hospital / Specialist only neutropenia only

Filibuvir Viral Hepatitis (B&C) and Respiratory 5.3 Antiviral drugs - not Double Red Not recommended for Syncytial Virus listed in BNF routine use / Not commissioned

Fingolimod ▼ Highly active, or rapidly evolving 8.2.4 Other Red Hospital / Specialist severe, relapsing-remitting multiple immunomodulating only sclerosis outside NICE TA 254 drugs

Fingolimod ▼ Highly active relapsing remitting 8.2.4 Other Red Hospital / Specialist multiple sclerosis as per NICE TA 254 immunomodulating only drugs

Fish oils (omega-3 fatty acids) Prevention of CVD, alone or added to 2.12 Lipid-regulating Double Red Not recommended for a statin - as per NICE CG 181 - Do drugs - omega-3 fatty routine use / Not Not Do acids commissioned

Fish oils (omega-3 fatty acids) Treatment of attention deficit 2.12 Fish oils Double red Not recommended for hyperactivity disorder (ADHD) - as per routine use / Not N&W DROP List commissioned

Flavoxate hydrochloride Overactive bladder and unrinary 7.4.2 Drugs for urinary Double Red Not recommended for incontinence in women - as per NICE incontinence routine use / Not CG 171 - Do Not Do commissioned

Printed: 14 September 2021 Page 33 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Fluconazole (Oral) Vaginal candidiasis in pregnancy - as 5.2 Antifungal drugs Double Red Not recommended for per NICE CG 62 - Do Not Do routine use / Not commissioned

Fludarabine B-cell Chronic Lymphocytic 8.1.3 Antimetabolites Double red Not recommended for Leukaemia - 1st line treatment - as routine use / Not per NICE TA 119 commissioned

Fludarabine B-cell Chronic Lymphocytic 8.1.3 Antimetabolites Red Hospital / Specialist Leukaemia - 2nd line treatment - as only per NICE TA 29

Fluocinolone acetonide Chronic diabetic macular oedema 11.4.1 Intravitrel Double Red Not recommended for intravitreal implant insufficiently responsive to available corticosteroids routine use / Not therapies in an eye with a natural lens commissioned (phakic eye)

Fluocinolone acetonide Treatment of chronic diabetic macular 11.4.1 Intravitreal Red Hospital / Specialist intravitreal implant oedema after inadequate response to corticosteroids only prior therapy - as per NICE TA 301

Fluocinolone acetonide Recurrent non-infectious uveitis as per 11.4.1 Intravitreal Red Hospital / Specialist intravitreal implant TA590 corticosteroids only

Fluoride supplements - Prevention of dental caries in at-risk 9.5.3 Fluoride Red Hospital / Specialist Toothpaste; dental products patients (where the specialist is a only dentist) - as per N&W DROP List

Folic Acid For preventing hypertensive disorders 9.1.2 Drugs used in Double Red Not recommended for during pregnancy - as per NICE CG megaloblastic routine use / Not 107 - Do Not Do anaemias commissioned

Folic acid Secondary prevention of MI / reduce 9.1.2 Drugs used in Double Red Not recommended for cardiovsacular risk post MI - as per megalobalstic routine use / Not NICE CG 172 - Do Not Do anaemias commissioned

Fomepizole Methanol and ethylene glycol Poisoning,emergency Special Special contract - not poisoning (Poison Centre prescribing treatment for GP prescribing only)

Fondaparinux sodium Prophylaxis of venous 2.8.1 Parenteral Double red Not recommended for thromboembolism in those undergoing anticoagulants routine use / Not major orthopaedic surgery of the legs - commissioned as per NICE DoNotDo recommendation Fondaparinux sodium Treatment of unstable angina or non- 2.8.1 Parenteral Red Hospital / Specialist ST segment elevation myocardial anticoagulants only infarction (UA/NSTEMI) in adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per regional network policy

Forigerimod acetate Systemic lupus erythematosus (SLE) 10.1.3 Cytokine modulators - Double Red Not recommended for No BNF entry routine use / Not commissioned

Fosamprenavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs- with low-dose only ritonavir

Foscarnet CMV infection 5.3.2.2 Cytomegalovirus Red Hospital / Specialist infection only

Fosphenytoin sodium Status epilepticus, seizures with head 4.8.2 Drugs used in status Double red Not recommended for injury,etc. epilepticus routine use / Not commissioned

Fostemsavir HIV infection in combination with other 5.3.1 HIV infection - not Double Red Not recommended for antiretroviral drugs listed in BNF routine use / Not commissioned

FreeStyle Libre BGS device Blood Glucose Monitoring in Flash (Blood) Glucose Red Hospital / Specialist (sensors are "Green") diabetes - as per NHSE criteria March Monitoring DEVICE only

FreeStyle Libre BGS sensors Blood Glucose Monitoring in Flash (Blood) Glucose Green GP prescribable at (BGS device is "Red") diabetes - as per NHSE criteria March Monitoring SENSORS request of Consultant/Specialist

Printed: 14 September 2021 Page 34 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Fremanezumab Preventing migraine as per TA631 4.7.4.2 Prophylaxis of migraine Red Hospital / Specialist (June 2020) only

Fulvestrant Treatment of locally advanced or 8.3.4 Hormone antagonists Double red Not recommended for metastatic breast cancer - as per routine use / Not NICE TA 239 commissioned

Fumaric acid ester Severe psoriasis - specialist use only Not listed in the BNF Red Hospital / Specialist only

Gabapentin Neuropathic pain 4.8.1 Control of epilepsy Double-GreenSuitable for GPs to initiate and prescribe

Galantamine Mild to moderate Alzheimer's 4.11 Drugs for dementia Amber Option for Shared dementia - as per NICE TA 217 Care Prescribing

Galaxy UNYCO for temporary stabilisation of lower Not listed in the BNF Double Red Not recommended for limb fractures routine use / Not commissioned

Galcanezumab preventing migraine as per TA659 4.7.4.2 Prophylaxis of migraine Red Hospital / Specialist only

Galsufase Mucopolysaccharidosis VI - specialist 9.8.1 Drugs used in Red Hospital / Specialist centre only metabolic disorders only

Gamolenic Acid (Evening All - not for NHS prescribing Not listed Double red Not recommended for Primrose Oil) routine use / Not commissioned

Ganciclovir sodium Cytomegalovirus infection 5.3.2.2 Cytomegalovirus Red Hospital / Specialist infection only

Ganetespib Cancer 8.1.5 Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Gefitinib Treatment of locally advanced or 8.1.5 Other antineoplastic Red Hospital / Specialist metastatic non-small-cell lung cancer drugs only (NSCLC) that has progressed after prior non-targeted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status (as per NICE TA 374)

Gefitinib First-line treatment of locally advanced 8.1.5 Other antineoplastic Red Hospital / Specialist or metastatic non-small-cell lung drugs only cancer

Gefitinib Treating NSCLC that has progressed 8.1.5 Other antineoplastic Double Red Not recommended for after chemotherapy (as per NICE TA drugs routine use / Not 374) commissioned

Gemcitabine Treatment of the first recurrence of 8.1.3 Antimetabolites Double Red Not recommended for platinum sensitive ovarian cancer routine use / Not commissioned

Gemcitabine Pancreatic cancer 8.1.3 Antimetabolites Red Hospital / Specialist only

Gemcitabine Non-small cell lung carcinoma 8.1.3 Antimetabolites Red Hospital / Specialist only

Gemfibrozil Prevention CVD - as per NICE CG 2.12 Lipid-regulating Double Red Not recommended for 181 "Do Not Do" drugs - Fibrates routine use / Not commissioned Gemtuzumab ozogamicin Untreated de novo CD33-positive 8.1.5 Other antineoplastic Red Hospital / Specialist acute myeloid leukaemia in people drugs - monoclonal only aged ≥15 years - as per NICE TA 545 antibodies

Gentamicin (nebulised) Ps. aeurginosa infection in non-Cystic 5.1.4 Aminoglycosides Red Hospital / Specialist Fibrosis bronchiectasis only

Gevokizumab Uveitis 8.2.3 Monoclonal antibody - Double Red Not recommended for Not listed in BNF routine use / Not commissioned

Gilteritinib treating relapsed or refractory acute 8.1.5 Protein kinase Red Hospital / Specialist myeloid leukaemia as per TA642 inhibitors only

Printed: 14 September 2021 Page 35 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Glasdegib with chemotherapy for untreated acute 8.1.4 Vinca alkaloids and Double Red Not recommended for myeloid leukaemia as per TA646 etoposide routine use / Not (terminated) commissioned

Glatiramer Multiple Sclerosis - as per NICE TA 8.2.4 Other Red Hospital / Specialist 527 immunomodulating only drugs

Glecaprevir Chronic hepatitis C - as per NICE TA 5.3.3.2 Antiviral drugs Red Hospital / Specialist 499 only

Glecaprevir-pibrentasvir ▼ Chronic hepatitis C 5.3.3.2 Chronic hepatitis C Red Hospital / Specialist only

Glibenclamide Type 2 diabetes mellitus 6.1.2 Oral antidiabetic drugs Double red Not recommended for routine use / Not commissioned

Gliclazide modified release Type 2 diabetes mellitus 6.1.2.1 Antidiabetic drugs - Double Red Not recommended for sulfonylureas routine use / Not commissioned

GLP-1 agonist Semaglutide Adults with insufficiently controlled 6.1.2.3 Antidiabetic drugs Green GP prescribable at type 2 diabetes mellitus request of Consultant/Specialist

Glucarpidase Urgent treatment of methotrexate- Not listed Red Hospital / Specialist induced renal dysfunction in patients only receiving high-dose MTX chemotherapy - as per NHSE policy Glucocorticoids (inc Chronic fatigue syndrome/myalgic 6.3.2 Glucocorticoids Double Red Not recommended for hydrocortisone, prednisolone) encephalomyelitis (or routine use / Not encephalopathy) - as per NICE CG commissioned 53 - Do Not Do

Glucosamine Osteoarthritis - as per NICE CG 177 - 10.1.5 Other drugs for Double Red Not recommended for Do Not Do rheumatic diseases routine use / Not commissioned Glucosamine, Glucosamine & Osteoarthritis 10.1.5 Other drugs for Double red Not recommended for Chondroitin rheumatic diseases routine use / Not commissioned

Gluten-free bread or flour Gluten-sensitive enteropathies in 7.6.1 Not listed in the BNF Double-GreenSuitable for GPs to children up to 18 years of age (West initiate and prescribe Norfolk CCG area only)

Gluten-free foods Gluten sensitive enteropathies in 7.6.1 Not listed Double red Not recommended for adults (all CCGs) routine use / Not commissioned

Glycerol phenylbutyrate Urea cycle disorders (specialist use 9.8.1 Drugs used in Double Red Not recommended for only) metabolic disorders routine use / Not commissioned

GlycoPEGylated Factor IX Haemophilia B 2.11 Antifibrinolytic drugs Double Red Not recommended for and haemostatics routine use / Not commissioned

Glycopyrronium bromide Inhaled treatment for Chronic 3.1.2 Antimuscarinic Double-GreenSuitable for GPs to Obstructive Pulmonary Disease bronchodilators initiate and prescribe (COPD)

Glycopyrronium bromide Hyperhidrosis 13.12 Antiperspirants Green GP prescribable at (prescribe as Glycobromag) request of Consultant/Specialist

Golimumab Severe non-radiographic axial 10.1.3 Drugs that suppress Double Red Not recommended for spondyloarthritis in adults whose the rheumatic disease routine use / Not disease has responded inadequately process commissioned to, or who cannot tolerate, nonsteroidal anti-inflammatory drugs - as per NICE TA 497

Golimumab Treatment of rheumatoid arthritis after 10.1.3 Drugs that suppress Red Hospital / Specialist the failure of previous disease- the rheumatic disease only modifying anti-rheumatic drugs - as process per NICE TA 225

Printed: 14 September 2021 Page 36 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Golimumab Treatment of methotrexate-naïve 10.1.3 Drugs that suppress Double red Not recommended for rheumatoid arthritis - as per NICE TA the rheumatic disease routine use / Not 224 process commissioned

Golimumab For induction of remission, with or 10.1.3 Drugs that suppress Double Red Not recommended for without steroids, in patients with the rheumatic disease routine use / Not Crohn’s disease colitis with moderate- process commissioned severe disease as a third-line anti-TNF after failure of or adverse reaction to two previous agents

Golimumab Ankylosing spondilitis - as per NICE 10.1.3 Drugs that suppress Red Hospital / Specialist TA 233 the rheumatic disease only process

Golimumab Treatment of psoriatic arthritis 10.1.3 Drugs that suppress Red Hospital / Specialist (including switching between the rheumatic disease only treatments) - as per NICE TA 220 and process local treatment pathway

Golimumab For rheumatoid arthritis not previously 10.1.3 Drugs that suppress Red Hospital / Specialist treated with DMARDs or after the rheumatic disease only conventional DMARDs only have process failed - as per NICE TA 375 Golimumab 2nd line (Biologic) treatment option for 1.5.3 Drugs that suppress Red Hospital / Specialist moderately to severely active the rheumatic disease only ulcerative colitis after the failure of process conventional therapy - as per NICE TA 329 and the local treatment pathway

GORD - treatments (various) Treatment of GORD in children and 1.3 Antisecretory drugs Double-GreenSuitable for GPs to young people - as per NICE NG1 and mucosal initiate and prescribe protectants

Goserelin Management of endometriosis; pre- 6.7.2 Drugs affecting Amber Option for Shared operative management of uterine gonadotrophins Care Prescribing fibroids - as per NICE NG 73

Goserelin Prostate cancer 8.3.4 Hormone antagonists Green GP prescribable at request of Consultant/Specialist Grass pollen allergen extract Seasonal allergic hay fever due to 3.4.2 Allergen Double red Not recommended for grass pollen immunotherapy routine use / Not commissioned

Guanfacine Prolonged- For children aged 6-17yr with ADHD 4.4 CNS stimulants and Red Hospital / Specialist Release ▼ for whom stimulants are not suitable, drugs used for ADHD only not tolerated or have been shown to be ineffective Guselkumab Moderate to severe plaque psoriasis in 10.1.3 Drugs that suppress Red Hospital / Specialist adults - as per NICE TA 521 the rheumatic disease only process

Haem Arginate Hepatic porphyria Acute porphyrias Red Hospital / Specialist only

Haem iron tablets (GlobiFer) Anaemia Haem-iron supplement Double Red Not recommended for (bovine origin) routine use / Not commissioned

Head lice devices and Head lice 13.10.4 Parasiticidal Double Red Not recommended for products - including combs preparations routine use / Not commissioned Heparin - Low Molecular For patients requiring long term 2.8.1 Parenteral Amber Option for Shared Weight (LMWH) anticoagulation in whom warfarin is anticoagulant Care Prescribing contraindicated or inappropriate

Heparin - Low Molecular Use in obstetrics for management of 2.8.1 Parenteral Red Hospital / Specialist Weight (LMWH) VTE in high risk patients (e.g. anticoagulants only overweight, multiparous, or who smoke) and require LMWH post partum Heparin - Low Molecular DVT (if suspected out of hours - first 2.8.1 Parenteral Double-GreenSuitable for GPs to Weight (LMWH) dose only) anticoagulants initiate and prescribe

Printed: 14 September 2021 Page 37 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Heparin - Low Molecular Unstable angina/coronary artery 2.8.1 Parenteral Red Hospital / Specialist Weight (LMWH) disease/NSTEMI anticoagulants only

Heparin - Low molecular Prevention of DVT during flights 2.8.1 Parenteral Double red Not recommended for weight (LMWH) anticoagulants routine use / Not commissioned

Heparinised saline Central venous catheter lock in No BNF entry Double Red Not recommended for adults - as per RMOC guidance (Feb routine use / Not 2019) commissioned

Heparinoid 0.3% Cream / Gel Improving circulation in bruising, 13.13 Topical circulatory Double Red Not recommended for superficial thrombophlebitis, chilblains, preparations routine use / Not varicose veins commissioned

Herbal medicines / All uses Not listed in BNF Double Red Not recommended for supplements incl St John's routine use / Not Wort commissioned

HGH - Saizen®, Zomacton®, Growth hormone deficiency (GHD) - 6.5.1 Hypothalamic & Double Red Not recommended for Nordiflex®, Nutropin® Aq as per East of England PAC policy anterior pituitary routine use / Not hormones commissioned

HIV vaccine HIV infection prophylaxis 14.4 Vaccines and antisera Double Red Not recommended for routine use / Not commissioned

HIV/AIDS treatments HIV infection / post exposure 5.3 Antiviral drugs Red Hospital / Specialist prophylaxis (PEP) only

Homeopathy Various Not listed in BNF Double red Not recommended for routine use / Not commissioned

Hormone Replacement Treatment of urinary incontinence - as 6.4.1.1 Oestrogens and HRT Double Red Not recommended for Therapy (HRT) - systemic per NICE CG 171 - NICE Do Not Do routine use / Not commissioned

HRT implants Hormone replacement therapy 6.4.1.1 Oestrogens and HRT Double-GreenSuitable for GPs to initiate and prescribe

Human heterologous liver Urea cycle disorders No BNF entry Double Red Not recommended for cells (HHLivC) routine use / Not commissioned

Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin (Aragam®) Plan - NHSE policy only

Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin Plan only (Flebogamma®)

Human normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist immunoglobulin Plan - NHSE policy only (Gammagard®)

Human normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist immunoglobulin Plan - NHSE policy only (Gammanorm®)

Human normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist immunoglobulin Plan - NHSE policy only (Gammaplex®)

Human normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist immunoglobulin (Gamunex®) Plan - NHSE policy only

Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin (Hizentra) Plan - NHSE policy only Plan - NHSE policy

Human normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist immunoglobulin (Intratect®) Plan - NHSE policy only

Human normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist immunoglobulin (IVIg) Plan only

Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin (Kiovig) Plan - NHSE policy only

Printed: 14 September 2021 Page 38 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin (Octagam) Plan - NHSE policy only

Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin (Subcuvia®) Plan - NHSE Policy only

Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin (Subgam®) Plan - NHSE policy only

Human Normal As per National Demand Management 14.5 mmunoglobulins Red Hospital / Specialist Immunoglobulin (Vigam®) Plan - NHSE policy only

Human Normal As per National Demand Management 14.5 Immunoglobulins Red Hospital / Specialist Immunoglobulin (Vivaglobin®)) Plan - NHSE policy only

Human parathyroid hormone- Male and juvenile osteoporosis 6.6.1 Calcitonin and Double Red Not recommended for related protein analogue parathyroid hormone routine use / Not Calcitonin and commissioned

Hyaluronate Intra-articular injection in osteoarthritis 10.1 Drugs used in Double red Not recommended for rheumatic diseases routine use / Not and gout commissioned

Hydrocortisone To prevent prescribing in primary care 6.3.2 Glucocorticoid therapy Red Hospital / Specialist as a treatment for covid-19 only

Hydrocortisone granules in Cortisol replacement therapy for 6.3.2 Glucocorticoid therapy Green GP prescribable at capsules children (0-6 years) with adrenal request of insufficiency Consultant/Specialist

Hydrocortisone MR Treatment of adrenal insufficiency in 6.3.2 Glucocorticoid therapy Double Red Not recommended for adults routine use / Not commissioned

Hydroxycarbamide Sickle Cell disease 9.1.3 Drugs for hypoplastic, Red Hospital / Specialist (hydroxyurea) - generic haemolytic & renal only anaemias

Hydroxycarbamide CML / Myeloproliferative disorders 8.1.5 Other antineoplastic Amber Option for Shared (Hydroxyurea) 500mg capsules requiring cytoreduction drugs Care Prescribing

Hydroxycarbamide Sickle-cell disease 9.1.3 Drugs for hypoplastic, Double red Not recommended for (hydroxyurea) as Siklos® ▼ haemolytic & renal routine use / Not anaemias commissioned

Hylan G-F 20 Intra-articular injection in osteoarthritis 10.1 Drugs used in Double red Not recommended for rheumatic disease and routine use / Not gout commissioned

HyQvia (HN Immunoglobulin & As per national Demand Management Not listed in BNF Double Red Not recommended for Hyalurnidase) Plan routine use / Not commissioned

Ibalizumab HIV in combination with other anti- 5.3.1 HIV infection Double Red Not recommended for retroviral drugs routine use / Not commissioned

Ibandronate / Ibandronic acid Daily use for two years to improve 6.6.2 Bisphosphonates Green GP prescribable at survival in post-menopausal women request of with breast cancer receiving Consultant/Specialist chemotherapy

Ibandronic acid Treatment of osteoporosis in 6.6.2 Bisphosphonates & Red Hospital / Specialist postmenopausal women drugs affecting bone only metabolism

Ibandronic Acid, Ibandronate Reduction of bone damage in bone 6.6.2 Bisphosphonates & Green GP prescribable at metastases in breast cancer drugs affecting bone request of metabolism Consultant/Specialist

Ibrutinib (with obinutuzumab) untreated chronic lymphocytic 8.1.5 Other antineoplastic Double Red Not recommended for leukaemia and small lymphocytic drugs routine use / Not lymphoma (TA702 - terminated commissioned appraisal) Ibrutinib (with rituximab) untreated chronic lymphocytic 8.1.5 Other antineoplastic Double Red Not recommended for leukaemia (TA703 - terminated drugs routine use / Not appraisal) commissioned

Printed: 14 September 2021 Page 39 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Ibrutinib ▼ Untreated chronic lymphocytic 8.1.5 Other antineoplastic Double Red Not recommended for leukaemia without a 17p deletion or drugs routine use / Not TP53 mutation - as per NICE TA 452 commissioned

Ibrutinib ▼ Previously treated adults with chronic 8.1.5 Other antineoplastic Red Hospital / Specialist lymphocytic leukaemia and untreated drugs only chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - as per NICE TA 429

Ibrutinib ▼ Relapsed or refractory mantle cell 8.1.5 Other antineoplastic Red Hospital / Specialist lymphoma drugs only

Ibrutinib ▼ Waldenstrom's macroglubulinaemia 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Ibrutinib ▼ (with Relapsed or refractory chronic 8.1.5 Other antineoplastic Double Red Not recommended for bendamustine and rituximab) lymphocytic leukaemia after systemic drugs routine use / Not therapy commissioned

Ibrutinib with rituximab Waldenstrom's macroglobulinaemia 8.1.5 Other antineoplastic Double Red Not recommended for drugs routine use / Not commissioned

Ibuprofen Pain relief No BNF entry Double Red Not recommended for routine use / Not commissioned

Icatibant Hereditary angiodema - prophylactic 3.4.3 Allergic emergencies Red Hospital / Specialist treatment - as per NHSE policy only

Icatibant Hereditary angioedema - acute 3.4.3 Allergic emergencies Red Hospital / Specialist treatment only

Idarubicin HCl All indications 8.1.2 Anthracyclines and Red Hospital / Specialist other cytotoxic drugs only

Idebenone Duchenne muscular dystrophy Benzoquinone Double Red Not recommended for antioxidant routine use / Not commissioned

Idelalisib Refractory follicular lymphoma that 8.1.5 Other antineoplastic Double Red Not recommended for has not responded to 2 prior lines of drugs routine use / Not treatment in adults commissioned

Idelalisib ▼ Chronic lymphocytic leukaemia for 8.1.5 Other antineoplastic Red Hospital / Specialist adults (in combination with rituximab) drugs only

Idelalisib ▼ Treatment of follicular lymphoma that 8.1.5 Other antineoplastic Double Red Not recommended for is refractory to two prior treatments drugs routine use / Not commissioned

Idelalisib ▼ Chronic lymphocytic leukaemia (with 8.1.5 Other antineoplastic Double Red Not recommended for ofatumumab (Arzerra®)) - as per drugs routine use / Not NICE TA 469 commissioned

Idursulfase Mucopolysaccharidosis - highly Enzyme replacement Red Hospital / Specialist specialised criteria therapy only

Iloprost Pulmonary arterial hypertension 2.5.1 Vasodilator Special Special contract - not antihypertensive drugs for GP prescribing

Iloprost Primary pulmonary arterial 2.5.1 Vasodilator Red Hospital / Specialist hypertension antihypertensive drugs only

Imatinib ▼ Kit-positive unresectable and /or 8.1.5 Other antineoplastic Red Hospital / Specialist metastatic GIST drugs only

Imatinib ▼ Adjuvant treatment of gastrointestinal 8.1.5 Other antineoplastic Red Hospital / Specialist stromal tumours (GIST) after surgery drugs only

Imatinib mesylate (high dose) Imatinib-resistant or intolerant chronic 8.1.5 Other antineoplastic Double Red Not recommended for ▼ myeloid leukaemia drugs routine use / Not commissioned

Imatinib mesylate ▼ Untreated chronic-phase Philadelphia- 8.1.5 Other antineoplastic Red Hospital / Specialist chromosome-positive chronic myeloid drugs only leukaemia in adults

Imatinib mesylate ▼(high Imatinib-resistant Chronic Myeloid 8.1.5 Other antineoplastic Double red Not recommended for dose) Leukaemia drugs routine use / Not commissioned

Printed: 14 September 2021 Page 40 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Imatinib mesylate ▼(standard Chronic myeloid leukaemia (CML) 8.1.5 Other antineoplastic Red Hospital / Specialist dose) drugs only

Imiglucerase Gaucher's disease 9.8.1 Drugs used in Special Special contract - not metabolic disorders for GP prescribing

Imiglucerase Gaucher's disease 9.8.1 Drugs used in Red Hospital / Specialist metabolic disorders only

Imipramine Overactive bladder and urinary 7.4.2 Drugs for urinary Double Red Not recommended for incontinence in women - as per NICE frequency and routine use / Not CG 171 - NICE Do Not Do incontinence commissioned

Imiquimod Cream Non-hypertrophic actinic keratosis 13.8.1 Photodamage Green GP prescribable at request of Consultant/Specialist

Immunoglobulin ▼ Various 14.5 Immunoglobulins Red Hospital / Specialist only

Immunoglobulin ▼ Congenital agammaglobulinaemia 14.5 Immunoglobulins Special Special contract - not for GP prescribing

Indacaterol Maintenance treatment of obstructive 3.1.1 Adrenoceptor agonistsDouble-GreenSuitable for GPs to pulmonary disease (COPD) initiate and prescribe

Indacaterol / Glycopyrronium Chronic Obstructive Pulmonary 3.1.4 Compound Double-GreenSuitable for GPs to inhaler▼ Disease (COPD) bronchodilator initiate and prescribe preparations

Indapamide (immediate- Hypertension 2.2.1 Thiazides and related Double-GreenSuitable for GPs to release) diuretics initiate and prescribe

Indapamide MR tablets Essential hypertension 2.2.1 Thiazides and related Double-GreenSuitable for GPs to diuretics initiate and prescribe

Independence wound Haemodialysis patients - protection of Not listed Double Red Not recommended for protection pouch - all sizes line when washing routine use / Not commissioned

Indinavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Infertility drugs Infertility treatment 6.5.1 Hypothalamic and Red Hospital / Specialist anterior pituitary only hormones etc.

Infliximab Treatment of Juvenile Idiopathic 10.1.3 Drugs that suppress Red Hospital / Specialist Arthritis (JIA) - in patients with uveitis the rheumatic disease only only if etanercept or adalimumab not process appropriate or are ineffective Infliximab Connective tissue disease - interstitial 10.1.3 Drugs which suppress Double Red Not recommended for lung disease the rheumatic disease routine use / Not process commissioned

Infliximab moderate rheumatoid arthritis after 10.1.3 Drugs that suppress Red Hospital / Specialist conventional DMARDs have failed as the rheumatic disease only per TA715 process

Infliximab Acute exacerbations of ulcerative 1.5.3 Drugs used in chronic Red Hospital / Specialist colitis - use in children, aligning with bowel disorders only NICE TA 163 (NHSE responsibility)

Infliximab Crohn's disease - use in children, 1.5.3 Drugs used in chronic Red Hospital / Specialist aligning with NICE TA 187 (NHSE bowel disorders only responsibility) Infliximab Moderately to severely active 1.5.3 Drugs used in chronic Red Hospital / Specialist ulcerative colitis after the failure of bowel disorders only conventional therapy - use in children, aligning with NICE TA 329 (NHSE responsibility)

Infliximab Renal indications 10.1.3 Drugs which suppress Double Red Not recommended for the rheumatic disease routine use / Not process commissioned

Infliximab Sarcoidosis 10.1.3 Drug which suppress Double Red Not recommended for the rheumatic disease routine use / Not process commissioned

Printed: 14 September 2021 Page 41 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Infliximab Ankylosing spondylitis - use in 10.1.3 Drugs which suppress Red Hospital / Specialist children, aligning with NICE TA 143 the rheumatic disease only (NHSE responsibility) process

Infliximab Hidradenitis Suppurativa 10.1.3 Drugs which suppress Double Red Not recommended for the rheumatic disease routine use / Not process commissioned Infliximab Psoriasis - use in children, aligning 10.1.3 Drugs which suppress Red Hospital / Specialist with NICE TA 134 (NHSE the rheumatic disease only responsibility) process

Infliximab Rheumatoid arthritis - use in children, 10.1.3 Drugs which suppress Red Hospital / Specialist aligning with NICE TA 130 (NHSE the rheumatic disease only responsibility) process

Infliximab Anti-TNF Alpha treatment option for 10.1.3 Drugs that suppress Double Red Not recommended for paediatric patients with severe the rheumatic disease routine use / Not refractory uveitis - NHSE policy process commissioned

Infliximab Anti-TNF treatment option for adult 10.1.3 Drugs that suppress Double Red Not recommended for patients with severe refractory uveitis - the rheumatic disease routine use / Not as per NHSE policy process commissioned

Infliximab Behcet's Disease 10.1.3 Drugs which suppress Red Hospital / Specialist the rheumatic disease only process

Infliximab Graft versus host disease 10.1.3 Drug which suppress Red Hospital / Specialist the rheumatic disease only process

Infliximab Treatment of psoriatic arthritis - use in 10.1.3 Drugs which suppress Red Hospital / Specialist children, aligning with NICE TA 199 the rheumatic disease only (NHSE responsibility) process

Infliximab (Biosimilar to be Rheumatoid arthritis - after other 10.1.3 Drugs which suppress Red Hospital / Specialist used 1st line) DMARDs including a TNF inhibitor - as the rheumatic process only per NICE TA 195

Infliximab (biosimilar) Crohn's disease which has not 1.5.3 Drugs affecting the Red Hospital / Specialist responded to conventional therapy - immune response only as per NICE TA 187

Infliximab (biosimilar) Subacute manifestations of 1.5.3 Drugs used in Chronic Red Hospital / Specialist moderately to severely active Bowel Disorders only ulcerative colitis - as per NICE TA 329 and the local treatment pathway Infliximab (biosimilar) Acute exacerbations of ulcerative 1.5 Drugs used in chronic Red Hospital / Specialist colitis - as per the local treatment bowel disorders only pathway

Infliximab (biosimilar) Psoriatic arthritis (switching between 10.1.3 Drugs that suppress Red Hospital / Specialist treatments) the rheumatic disease only process

Infliximab (biosimilar) Axial spondyloarthritis (non- 10.1.3 Drugs which suppress Red Hospital / Specialist radiographic) - as per NICE TA 383 the rheumatic disease only and NNUH application process

Infliximab (biosimilar) Treatment of psoriasis in adults - as 13.5.3 Drugs which suppress Red Hospital / Specialist per NICE TA 134 and local treatment the rheumatic disease only pathway process

Infliximab (biosimilar) Immunotherapy toxicity (causing 1.5.3 Drugs used in Chronic Red Hospital / Specialist colitis) Bowel Disorders only

Infliximab (biosimilar) Ankylosing spondilitis - severe active, 10.1.3 Drugs which suppress Red Hospital / Specialist where NSAIDs are not effective or not the rheumatic disease only tolerated - as per NICE TA 383 process

Infliximab (biosimilar) Active and progressive psoriatic 13.5.3 Drugs affecting the Red Hospital / Specialist arthritis - as per NICE TA 199 immune response only

Infliximab (biosimilar) Rheumatoid arthritis not previously 10.1.3 Drugs that suppress Red Hospital / Specialist treated with DMARDs or after the rheumatic disease only conventional DMARDs only have process failed - as per NICE TA 375 and local treatment pathway

Printed: 14 September 2021 Page 42 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Infliximab (Remicade®) Anti-TNF Alpha treatment option for 10.1.3 Drugs that suppress Double Red Not recommended for paediatric patients with severe the rheumatic disease routine use / Not refractory uveitis process commissioned

Influenza vaccination Vaccination of non-target patients on 14.4 Vaccines and antisera Double red Not recommended for the NHS routine use / Not commissioned Influenza vaccine - intradermal Influenza vaccination 14.4 Vacines and antisera Double red Not recommended for routine use / Not commissioned Ingenol mebutate topical gel Non-hypertrophic actinic keratosis 13.8.1 Photodamage Double Red Not recommended for routine use / Not commissioned

Inhaled corticosteroids Children who wheeze with a cold (viral 3.2 Corticosteroids Double red Not recommended for wheeze / bronchiolitis) routine use / Not commissioned

Inositol nicotinate Treatment of intermittent claudication 2.6.4 Peripheral Double red Not recommended for in people with peripheral arterial vasodilators and routine use / Not disease related drugs commissioned

Inotuzumab ozogamicin Relapsed or refractory B-cell acute 8.1 Cytotoxics - Red Hospital / Specialist lymphoblastic leukaemia - as per monoclonal antibodies only NICE TA 541

Insert for female stress Female stress urinary incontinence - Not listed Double Red Not recommended for incontinence (Contiform) as per NICE CG 171 - Do Not Do routine use / Not commissioned

Inspiratory muscle training Inspiratory muscle training in COPD, Not listed Double Red Not recommended for devices non-CF bronchiectasis, upper spinal routine use / Not cord injuries, Cystic fibrosis, asthma commissioned Insulin - Non-basal-bolus Newly diagnosed Type 1 diabetes - 6.1.1.2 Intermediate and long- Double Red Not recommended for regimens NICE Do Not Do acting insulins routine use / Not commissioned

Insulin analogues (rapid Routine use after meals in T1 6.1.1.1 Rapid-acting insulins Double Red Not recommended for acting) Diabetes - NICE Do Not Do routine use / Not commissioned

Insulin Aspart (Fiasp®) ▼ Diabetes mellitus 6.1.1.1 Short-acting insulins Green GP prescribable at request of Consultant/Specialist

Insulin degludec ROUTINE use in Type 1 and Type 2 6.1.1.2 Intermediate and long- Double Red Not recommended for diabetes mellitus - see separate entry acting insulins routine use / Not regarding RESTRICTED USE commissioned

Insulin degludec RESTRICTED use in Type 1 and Type 6.1.1.2 Intermediate and long- Green GP prescribable at 2 Diabetes mellitus - consultant acting insulins request of initiation only Consultant/Specialist

Insulin degludec / liraglutide Diabetes mellitus 6.1.1.2 Intermediate and long- Double Red Not recommended for combi (Xultophy®) acting insulins routine use / Not commissioned

Insulin detemir Diabetes in adults & children >1 yrs 6.1.1.2 Intermediate & long- Green GP prescribable at acting insulins request of Consultant/Specialist Insulin glargine Diabetes mellitus 6.1.1.2 Long-acting insulin Green GP prescribable at request of Consultant/Specialist

Insulin glargine 300 units/ml Restricted use in adults aged ≥18 6.1.1.2 Long-acting insulin Green GP prescribable at (Toujeo®) years with diabetes mellitus under request of specified criteria - see full guidance Consultant/Specialist

Insulin Glargine and Diabetes mellitus 6.1.1.2 Long-acting insulin Double Red Not recommended for Lixisenatide solution routine use / Not commissioned

Insulin glargine biosimilar Diabetes mellitus 6.1.1.2 Long-acting insulin Green GP prescribable at 100iu/ml (Abasaglar®) request of Consultant/Specialist

Printed: 14 September 2021 Page 43 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Insulin glulisine Diabetes mellitus 6.1.1.1 Insulins: short-acting Green GP prescribable at request of Consultant/Specialist

Insulin Lispro ▼ 200units/ml A specific group of adults with 6.1.1.1 Insulins: Short-acting Green GP prescribable at (Humalog KwikPen®) diabetes mellitus who require more request of than 20 units of quick-acting insulin Consultant/Specialist per day

Insulin pump therapy Type 1 Diabetes under specified 6.1.1 Insulins Red Hospital / Specialist circumstances only

Insulin safety needles Insulin administration Not listed - devices Double Red Not recommended for routine use / Not commissioned

Interferon alfa Metastatic renal cell carcinoma 8.2.4 Other Red Hospital / Specialist immunomodulating only drugs

Interferon alfa Chronic myelogenous leukaemia 8.2.4 Other Red Hospital / Specialist immunomodulating only drugs

Interferon alfa In combination with ribavirin for 8.2.4 Other Red Hospital / Specialist Hepatitis C, and for Hepatitis B - as immunomodulating only per NICE 75 and CG 165 drugs

Interferon alfa Adjunct to surgery in malignant 8.2.4 Other Double red Not recommended for melanoma immunomodulating routine use / Not drugs commissioned

Interferon beta 1a Multiple Sclerosis - as per NICE TA 8.2.4 Other Red Hospital / Specialist 527 immunomodulating only drugs

Interferon beta 1b (Betaferon®) Multiple sclerosis - as per NICE TA 8.2.4 Other Double Red Not recommended for 527 immunomodulating routine use / Not drugs commissioned

Interferon beta 1b (Extavia®) Multiple Sclerosis - as per NICE TA 8.2.4 Other Red Hospital / Specialist 527 immunomodulating only drugs

Intrathecal drug delivery Treatment of severe cancer pain Not listed in the BNF - Red Hospital / Specialist procedure only

Intrathecal pumps Treatment of severe chronic (non- Not listed - device Double Red Not recommended for cancer) pain routine use / Not commissioned

Intra-uterine progestogen-only Contraception, primary menorrhagia 7.3.2.3 Intra-uterine Double-GreenSuitable for GPs to system progestogen-only initiate and prescribe device

Intravenous nutrition Total Parenteral Nutrition in premature 9.3 Intravenous nutrition Red Hospital / Specialist infants with intestinal failure only

Ipilimumab Previously untreated advanced 8.1.5 Other antineoplastic Red Hospital / Specialist (unresectable or metastatic) melanoma drugs only

Ipilimumab Previously treated advanced 8.1.5 Other antineoplastic Red Hospital / Specialist (unresectable or metastatic) drugs only melanoma (stage III or IV) in previously treated people

i-Port Advance Blood glucose monitoring as per PAC 6.1.6 Blood glucose Double Red Not recommended for guidance - March 2020 monitoring routine use / Not commissioned

Iqoro Stroke-related dysphagia No BNF entry Double Red Not recommended for routine use / Not commissioned

IQoro neuromuscular training Stroke-related dysphagia No BNF entry - device Double Red Not recommended for device routine use / Not commissioned

IQoro neuromuscular training Stroke-related dysphagia No BNF entry Double Red Not recommended for device routine use / Not commissioned

Printed: 14 September 2021 Page 44 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Irinotecan Colorectal cancer 2nd line 8.1.5 Topoisomerase I Red Hospital / Specialist inhibitors only

Isatuximab with pomalidomide and 8.1.5 Other antineoplastic Red Hospital / Specialist dexamethasone for treating relapsed drugs only and refractory multiple myeloma as per TA658 Isavuconazole Systemic fungal infections 5.2 Antifungal drugs Red Hospital / Specialist only

Isoniazid Non-TB related Mycobacterium 5.1.9 Antituberculosis drugs Green GP prescribable at infections request of Consultant/Specialist

Isotretinoin All indications 13.6.2 Oral retinoid for acne Red Hospital / Specialist only

Isotretinoin Acne 13.6.2 Oral preparations for Red Hospital / Specialist acne only

Ivabradine ▼ Treatment of chronic heart failure 2.6.3 Other antianginal drugs Green GP prescribable at request of Consultant/Specialist

Ivabradine ▼ Chronic stable angina when beta- 2.6.3 Other antianginal drugsDouble-GreenSuitable for GPs to blockers are contra-indicated or not initiate and prescribe tolerated Ivacaftor ▼ Cystic Fibrosis 3.7 Mucolytics Red Hospital / Specialist only

Ivermectin Cream 10mg/g (1%) Papulopustular Rosacea (PPR) 13.6.3 Topical preparations Double-GreenSuitable for GPs to for rosacea initiate and prescribe

Ixazomib Amyloidosis 8.1.5 Other antineoplastic Double Red Not recommended for drugs routine use / Not commissioned

Ixazomib ▼ (with lenalidomide Relapsed or refractory multiple 8.1.5 Other antineoplastic Red Hospital / Specialist and dexamethasone) myeloma - as per NICE TA 505 - CDF drugs only list

Ixekizumab Active psoriatic arthritis after 13.5.3 Drugs affecting the Red Hospital / Specialist inadequate response to DMARDs, immune response only used alone or with methotrexate - as per NICE TA 537

Ixekizumab ▼ 3rd line biologic option in moderate to 13.5.3 Drugs affecting the Red Hospital / Specialist severe plaque psoriasis under certain immune response only conditions - as per NICE TA 442 and local treatment pathway Jaw rehabilitation devices Following head and neck radiotherapy No BNF entry Red Hospital / Specialist or head and neck surgery when only recommended by an appropriate Secondary Care Specialist

Ketoprofen/omeprazole Patients requiring ketoprofen for OA, 10.1.1 Non-steroidal anti- Double Red Not recommended for RA and ankylosing spondylitis who are inflammatory drugs routine use / Not at risk of NSAID-associated DU or GU commissioned

Lacosamide Adjunctive therapy in the treatment of 4.8.1 Control of epilepsy Green GP prescribable at partial-onset seizures with or without request of secondary generalisation in patients Consultant/Specialist with epilepsy aged 16 years and older

Lamivudine Chronic hepatitis B 5.3.1 HIV infection Red Hospital / Specialist only

Lamotrigine Augmentation of an antidepressant - 4.8.1 Control of epilepsies Double Red Not recommended for as per NICE CG 90 - Do Not Do routine use / Not commissioned

Lamotrigine (Relapse of) Bipolar Depression (as 4.8.1 Control of epilepsy Green GP prescribable at alternative to, or in addition to lithium) request of Consultant/Specialist

Lanadelumab Prevention of recurrent attacks of Humanised Red Hospital / Specialist hereditary angioedema monoclonal antibody only

Printed: 14 September 2021 Page 45 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Lancet (single use, safety) Single use safety lancet Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Lanreotide Reducing vomiting in terminal bowel 8.3.4.3 Somatostatin Green GP prescribable at obstruction analogues request of Consultant/Specialist

Lanreotide Carcinoid and other neuroendocrine 8.3.4.3 Somatostatin Red Hospital / Specialist tumours - for new patients analogues only

Lanreotide Acromegaly 8.3.4.3 Somatostatin Red Hospital / Specialist analogues only

Lanreotide Congenital hyperinsulinism 8.3.4.3 Somatostatin Red Hospital / Specialist only

Lanthanum carbonate Hyperphosphataemia in end-stage 9.5.2.2 Phosphate-binding Green GP prescribable at chronic renal failure - if on treatment agents request of before 1st April 2013 Consultant/Specialist

Lanthanum carbonate hydrate Hyperphosphataemia in end-stage 9.5.2.2 Phosphate-binding Green GP prescribable at chronic renal failure in patients on agents request of renal dialysis Consultant/Specialist

Lapatinib 1st-line treatment of metastatic 8.1.5 Other antineoplastic Double red Not recommended for hormone-receptor-positive breast drugs routine use / Not cancer that overexpresses HER2 commissioned Laquinimod Multiple sclerosis Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Laronidase Treatment of non-neurological Enzyme replacement Red Hospital / Specialist manifestations of therapy only mucopolysaccharidosis I - as per NHSE policy

Larotrectinib treating NTRK fusion-positive solid 8.1.5 Protein kinase Red Hospital / Specialist tumours as per TA630 (May 2020) inhibitors only

Ledipasvir-sofosbuvir ▼ For treating chronic hepatitis C as per 5.3.3.2 Chronic hepatitis C in Red Hospital / Specialist NICE TA 363 adults only

Leflunomide Rheumatoid arthritis and psoriatic 10.1.3 Drugs which suppress Amber Option for Shared arthritis the rheumatic disease Care Prescribing process

Lenalidomide With bortezomib and dexamethasone 8.2.4 Other Double Red Not recommended for for untreated multiple myeloma immunomodulating routine use / Not drugs commissioned

Lenalidomide Cancer - as per NHSE policy / Cancer 8.2.4 Other Red Hospital / Specialist Drugs Fund immunomodulating only drugs

Lenalidomide maintenance treatment after an 8.2.4 Other Red Hospital / Specialist autologous stem cell transplant for immunomodulating only newly diagnosed multiple myeloma as drugs per TA680 Lenalidomide POEMS syndrome - as per NHSE 8.2.4 Other Red Hospital / Specialist policy immunomodulating only drugs

Lenalidomide (with rituximab) for previously treated 8.2.4 Other Red Hospital / Specialist follicular lymphoma as per NICE immunomodulating only TA627 April 2020 drugs

Lenalidomide ▼ Treatment of multiple myeloma in 8.2.4 Other Red Hospital / Specialist people who have received at least two immunomodulating only prior therapies - as per NICE TA 171 drugs

Lenalidomide ▼ Treatment of myelodysplastic 8.2.4 Other Red Hospital / Specialist syndromes associated with an isolated immunomodulating only deletion 5q cytogenetic abnormality - drugs as per NICE TA 322

Lenalidomide plus Previously untreated multiple myeloma 8.2.4 Other Red Hospital / Specialist dexamethasone immunomodulating only drugs

Printed: 14 September 2021 Page 46 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Lenalidomide plus Multiple myeloma after 1 treatment 8.2.4 Other Red Hospital / Specialist dexamethasone with bortezomib immunomodulating only drugs

Lenograstim Barth Syndrome - Highly specialised 9.1.6 Drugs used in Red Hospital / Specialist criteria by Specialist centres only neutropenia only

Lenograstim Reduction in the duration of 9.1.6 Drugs used in Red Hospital / Specialist neutropenia and the incidence of neutropenia only febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy

Lenvatinib Untreated advanced, unresectable 8.1.5 Other antineoplastic Red Hospital / Specialist hepatocellular carcinoma in adults - as drugs only per NICE TA 551

Lenvatinib (with sorafenib) Progressive, locally advanced or 8.1.5 Other antineoplastic Red Hospital / Specialist metastatic differentiated thyroid drugs only cancer - as per NICE TA 535 Lenvatinib ▼ (with everolimus) Previously treated advanced renal cell 8.1.5 Other antineoplastic Red Hospital / Specialist carcinoma in adults who have had 1 drugs only previous vascular endothelial growth factor (VEGF)-targeted therapy - as per NICE TA 498

Lesinurad ▼ (with a xanthine Chronic hyperuricaemia in people with No BNF entry Double Red Not recommended for oxidase inhibitor gout whose serum uric acid is above routine use / Not the target level despite an adequate commissioned dose of a xanthine oxidase inhibitor alone

Letermovir Prophylaxis of cytomegalovirus (CMV) Red Hospital / Specialist reactivation and disease in adult CMV- only seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT) - NHSE responsibility

Letrozole Adjuvant treatment of early oestrogen- 8.3.4 Hormone antagonists Green GP prescribable at receptor-positive breast cancer in request of postmenopausal women Consultant/Specialist

Leuprorelin acetate Management of endometriosis; pre- 6.7.2 Drugs affecting Amber Option for Shared operative management of uterine gonadotrophins Care Prescribing fibroids

Leuprorelin acetate Prostate cancer 6.7.2 Drugs affecting Green GP prescribable at gonadotrophins request of Consultant/Specialist

Levocetirizine Symptomatic relief of allergy such as 3.4.1 Antihistamines Double Red Not recommended for hay fever, urticaria routine use / Not commissioned Levodopa Management of dystonia in adults with 4.9.1 Dopaminergic drugs Double Red Not recommended for cerebral palsy - as per NG 119 - NICE used in parkinsonism routine use / Not Do Not Do commissioned

Levonorgestrel 1500 Post-coital contraception 7.3.1 Emergency Double-GreenSuitable for GPs to micrograms contraception initiate and prescribe

Lidocaine / Prilocaine Spray Primary premature ejaculation in adult 15.2 Local anaesthesia Double Red Not recommended for men routine use / Not commissioned Lidocaine 5% medicated Localised neuropathic pain when first 15.2 Local anaesthesia Green GP prescribable at plasters line systemic therapies are ineffective request of or not tolerated as per the local Consultant/Specialist Neuropathic Pain Pathway

Linaclotide Symptomatic treatment of moderate to 1.6.7 Other drugs used in Double-GreenSuitable for GPs to severe Irritable Bowel Syndrome with constipation initiate and prescribe Constipation (IBS-C) in adults - as per local treatment algorithms for IBS-C and Refractory Symptomatic Chronic Constipation in adults

Printed: 14 September 2021 Page 47 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Linezolid Pneumonia, complicated skin and soft 5.1.7 Some other Red Hospital / Specialist tissue infections caused by G+ve antibacterials only bacteria

Liothyronine / L-tri- Liothyronine for NON-ROUTINE use in 6.2.2 Thyroid hormones Green GP prescribable at iodothyronine sodium (T3) people with hypothyroidism who request of continue to suffer with symptoms Consultant/Specialist despite adequate biochemical correction, who have not previously taken or who are currently prescribed Liothyronine by their NHS GP

Liothyronine / L-tri- RESTRICTED use for long term 6.2.2 Anti-thyroid drugs Green GP prescribable at iodothyronine sodium (T3) treatment in rare cases of request of levothyroxine-induced liver injury, and Consultant/Specialist are assessed by an NHS consultant as requiring treatment - as per RMOC guidance Liothyronine / L-tri- Niche, short-term use for up to three 6.2.2 Thyroid replacement Red Hospital / Specialist iodothyronine sodium (T3) months in patients awaiting surgery drugs only pre-cancer therapy

Liothyronine / L- ROUTINE use of liothyronine as 6.2.1 Thyroid Hormones Double Red Not recommended for triiodothyronine monotherapy or in combination with routine use / Not sodium (T3) levothyroxine for treatment of commissioned hypothyroidism Liothyronine/L-tri- Patients with thyroid cancer following 6.2.2 Thyroid replacement Red Hospital / Specialist iodothyronine sodium (T3) thyroid surgery, pre- and post radio drugs only iodine ablation

Liothyronine/L-tri- Resistant depression - as per RMOC 6.2.2 Thyroid hormones Double Red Not recommended for iodothyronine sodium (T3) guidance routine use / Not commissioned

Liposomal cytarabine- Untreated therapy-related acute 8.1.3 Antimetabolites Red Hospital / Specialist daunorubicin myeloid leukaemia or acute myeloid only leukaemia with myelodysplasia-related changes in adults - as per NICE TA 552

Liraglutide 1.8 mg dose for Type 2 diabetes 6.1.2.3 Antidiabetic drugs Double red Not recommended for mellitus - currently under review routine use / Not commissioned

Liraglutide Adjunctive use in Type 2 diabetes 6.1.2.3 Antidiabetic drugs Green GP prescribable at request of Consultant/Specialist

Liraglutide (marketed as Treatment of obesity as per TA664 4.5 Obesity Double Red Not recommended for Saxenda®)▼ routine use / Not commissioned Lisdexamfetamine Mesilate ▼ ADHD in children aged 6 years and 4.4 CNS stimulants and Amber Option for Shared over, up to 17 years when response to drugs used for ADHD Care Prescribing previous methylphenidate treatment is considered clinically inadequate

Lisdexamfetamine Mesilate ▼ Attention Deficit Hyperactivity Disorder 4.4 CNS stimulants and Amber Option for Shared in adults (if continued from childhhood) drugs used in ADHD Care Prescribing

Lithium Treatment and prophylaxis of mania, 4.2.3 Antimanic drugs Green GP prescribable at bipolar disorder, and recurrent request of depression; aggressive or self- Consultant/Specialist mutilating behaviour Lixisenatide Treatment of Type 2 diabetes, HbA1c 6.1.2 Antidiabetic drugs Green GP prescribable at ≥ 58mmol/mol (7.5%), BMI ≥35 kg/m2 request of Consultant/Specialist

Lixivaptan (Unlicensed drug) Hyponatraemia and other endocrine Vasopressin receptor Double Red Not recommended for uses - NHSE responsibility V2 antagonist routine use / Not commissioned

Lomitapide Homozygous familial 2.12 Lipid-regulating drugs Double Red Not recommended for hypercholesterolemia routine use / Not commissioned

Lomustine All indications 8.1.1 Alkylating drugs Red Hospital / Specialist only

Printed: 14 September 2021 Page 48 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Lonafarnib Hepatitis D infection (with ritonavir) 5.3 Farnesyl transferase Double Red Not recommended for inhibitor - Not listed in routine use / Not BNF commissioned

Lopinavir (with ritonavir) HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Lorlatinib previously treated ALK-positive 8.1.5 Protein kinase Red Hospital / Specialist advanced non-small-cell lung cancer inhibitors only as per TA628 (May 2020)

Loxapine inhalation Acute agitation and disturbed 4.2.1 Antipsychotic drugs Double red Not recommended for behaviours associated with routine use / Not schizophrenia and bipolar disorder commissioned

Lubiprostone ▼ Treatment of chronic idiopathic 1.6.7 Other drugs used in Double-GreenSuitable for GPs to constipation - as per local treatment constipation initiate and prescribe algorithm for Refractory Symptomatic Chronic Constipation in Adults

Lumacaftor-ivacaftor ▼ For treating cystic fibrosis in people 12 3.7 Mucolytics Double Red Not recommended for years and older who are homozygous routine use / Not for the F508del mutation in the cystic commissioned fibrosis transmembrane conductance regulator (CFTR) gene

Lurasidone • Off-label use of lurasidone to manage 4.2.1 Second generation Double Red Not recommended for hallucinations/aggression relating to antipsychotic drugs routine use / Not dementia commissioned

Lurasidone ▼ Treatment of schizophrenia in adults 4.2.1 Antipsychotic drugs Green GP prescribable at aged 18 years and over - third-line request of option under the Early Intervention Consultant/Specialist Treatment Pathway

Lurasidone ▼ Third antipsychotic option for 4.2.1 Antipsychotic drugs Green GP prescribable at schizophrenia in adults aged 18 years request of and over Consultant/Specialist

Lusutrombopag thrombocytopenia in people with 9.1.4 Drugs used in platelet Double Red Not recommended for chronic liver disease needing a disorders routine use / Not planned invasive procedure as per commissioned TA617 Jan 2020

Lutetium(177Lu) oxodotreotide Unresectable or metastatic, Not listed in the BNF Red Hospital / Specialist progressive, well-differentiated (grade only 1 or grade 2), somatostatin receptor- positive gastroenteropancreatic neuroendocrine tumours in adults - as per NICE TA 539 Lymphoedema garments Compression in management of Not listed Red Hospital / Specialist lymphoedema assessed by the only specialist service

Lymphoedema garments Uses other than compression in Not listed Double Red Not recommended for management of lymphoedema routine use / Not assessed by the specialist service commissioned

Macimorelin Growth hormone deficiency in adults Not listed in the BNF Double Red Not recommended for (diagnostic test) routine use / Not commissioned

Macitentan Pulmonary Arterial Hypertension 2.5.1 Vasodilator Double Red Not recommended for antihypertensive drugs routine use / Not commissioned

Malaria prophylaxis Malaria chemoprophylaxis 5.4.1 Antimalarials Double Red Not recommended for routine use / Not commissioned Mannitol (dry powder for (Adjunctive) treatment of cystic 3.7 Mucolytics Red Hospital / Specialist inhalation) fibrosis (CF) only

Maraviroc HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Masitinib Pancreatic cancer / GIST Tyrosine kinase Double Red Not recommended for inhibitor - not listed in routine use / Not BNF commissioned

Printed: 14 September 2021 Page 49 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Melanorm-HC® Melasma / Chloasma Not listed Double Red Not recommended for routine use / Not commissioned

Melatonin Jet lag 4.1.1 Hypnotics Double Red Not recommended for routine use / Not commissioned

Melatonin Management of sleep disorders 4.1.1 Hypnotics Double Red Not recommended for routine use / Not commissioned

Melatonin (immediate-release Management of sleep disorders in 4.1.1 Hypnotics Red Hospital / Specialist formulations) children with ADHD and behavioural only disorders

Melatonin Prolonged Release Monotherapy in short term 4.1.1 Hypnotics Red Hospital / Specialist (Circadin) management of primary insomnia only characterised by poor quality of sleep in patients aged 55 years or over whilst at the Julian Hospital, Norwich

Melatonin prolonged release Management of sleep disorders in 4.1.1 Hypnotics Double Red Not recommended for tablets (CIRCADIN) adults aged 18-55 routine use / Not commissioned

Melatonin prolonged-release Management of sleep disorders in 4.1.1 Hypnotics Amber Option for Shared tablets (Circadin) ▼ children Care Prescribing

Melatonin prolonged-release Short term treatment of primary 4.1.1 Hypnotics Double red Not recommended for tablets ▼ (Circadin) ▼ insomnia in adults aged 55 years and routine use / Not over commissioned

Meloxicam Osteoarthritis - short-term 10.1.1 Non-steroidal anti- Double-GreenSuitable for GPs to inflammatory drugs initiate and prescribe

Melphalan All indications 8.1.1 Alkylating drugs Red Hospital / Specialist only

Memantine Moderate to severe dementia in 4.11 Drugs for dementia Amber Option for Shared Alzheimer's Disease - as per NICE TA Care Prescribing 217

Mepolizumab severe eosinophilic asthma as per 3.4.2 Allergen Red Hospital / Specialist TA671 immunotherapy only

Mepolizumab ▼ Severe refractory eosinophilic asthma 3.4.2 Allergen Red Hospital / Specialist in adults - as per NICE TA 431 immunotherapy only

Mercaptopurine Acute leukaemias and chronic myeloid 8.1.3 Antimetabolites Red Hospital / Specialist leukaemia only

Mercaptopurine 50mg tablets Steroid-sparing effect in ulcerative 8.1.3 Antimetabolites Amber Option for Shared colitis and Crohn's disease Care Prescribing

Mesenchymal stem cells Acute Graft vs Host Disease (GVHD) Not listed in BNF - Double Red Not recommended for (Prochymal®) & other indications Stem cell therapy routine use / Not commissioned

Methadone Substance dependence (only if the 4.10 Drugs used in Double-GreenSuitable for GPs to practitioner is suitably trained and substance dependence initiate and prescribe accredited to prescribe)

Methotrexate (Oral and High doses used in malignant disease 8.1.3 Drugs affecting the Red Hospital / Specialist injectable)) immune response only

Methotrexate (oral) Use in severe psoriasis; inflammatory 10.1.3 Drug affecting the Amber Option for Shared bowel disease; rheumatoid arthritis; immune response Care Prescribing connective tissue disease

Methotrexate (Parenteral) Subcutaneous use in inflammatory 10.1.3 Drugs affecting the Amber Option for Shared bowel disease, psoriasis; rheumatoid immune response Care Prescribing arthritis; connective tissue disease

Methoxy polyethylene glycol- Symptomatic anaemia associated with 9.1.3 Used in hypoplastic, Red Hospital / Specialist epotein beta ▼ Chronic Kidney Disease (dialysis haemolytic & renal only patients only) anaemias

Methylnaltrexone bromide ▼ Opioid-induced bowel dysfunction in 1.6.6 Peripheral opioid- Double red Not recommended for palliative care - as per NICE TA 468 receptor antagonists routine use / Not commissioned

Printed: 14 September 2021 Page 50 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Methylphenidate HCl Attention Deficit Hyperactivity Disorder 4.4 CNS stimulants and Amber Option for Shared in Children and Adolescents drugs used for ADHD Care Prescribing

Methylphenidate HCl ADHD in adults who had previously 4.4 CNS stimulants and Amber Option for Shared been treated, or who had symptoms drugs used for ADHD Care Prescribing identified, in childhood or adolescence

Methylphenidate Hydrochloride Chronic fatigue syndrome/myalgic 4.4 CNS Stimulants Double Red Not recommended for encephalomyelitis (or routine use / Not encephalopathy) - as per NICE CG commissioned 53 - Do Not Do

Metreleptin Dyslipidaemia - Generalised Not listed in BNF - Double Red Not recommended for lipodystrophy and partial lipodystrophy synthetic leptin routine use / Not analogue commissioned Metyrapone Cushing's syndrome 6.7.3 Red Hospital / Specialist only

Mexiletine (imported generic) Ventricular tachycardia only Red Hospital / Specialist unlicensed in the UK only

Mexiletine (imported generic) NOT recommended for any indication Double Red Not recommended for unlicensed in the UK (EXCEPT ventricular tachycardia - routine use / Not Hospital / Specialist use only) commissioned

Mexiletine (Namuscla®) Treatment of myotonia in adults with Red Hospital / Specialist non-dystrophic myotonic disorders only (NDMD) - as per NHSE policy - specialist use only

Mexiletine (Namuscla®) NOT recommended for any indication Double Red Not recommended for (EXCEPT myotonia in adults with non- routine use / Not dystrophic myotonic disorders - as per commissioned NHSE commissioning policy - Hospital / Specialist use only)

Micafungin Systemic fungal infections 5.2.4 Echinocandin Double red Not recommended for antifungals routine use / Not commissioned

Midodrine Treatment of severe orthostatic 2.7.2 Vasoconstrictor Green GP prescribable at hypotension due to autonomic sympathomimetic request of dysfunction - second line use after Consultant/Specialist fludrocortisone Midostaurin Untreated FLT3-mutation-positive 8.1.5 Protein kinase Red Hospital / Specialist acute myeloid leukaemia in adults - as inhibitors only per NICE TA 523

Mifamurtide Treatment of osteosarcoma 8.2.4 Other Red Hospital / Specialist immunomodulating only drugs

Migalastat ▼ Fabry disease in people over 16 years No BNF entry Double Red Not recommended for of age with an amenable mutation, routine use / Not and only if enzyme replacement commissioned therapy (ERT) (with agalsidase alfa or agalsidase beta) would otherwise be offered - as per NICE HST4 Miglustat ▼ Mild to moderate type I Gaucher's Glucosylceramide Red Hospital / Specialist disease for whom enzyme synthase inhibitors only replacement therapy is unsuitable / Niemann-Pick

Mineralocorticoids (such as Chronic fatigue syndrome/myalgic 6.3.1 Mineralocorticoids Double Red Not recommended for fludrocortisone) encephalomyelitis (or (such as routine use / Not encephalopathy) - as per NICE CG fludrocortisone) commissioned 53 - Do Not Do Minocycline Acne vulgaris 13.6.2 Oral antibacterials for Double Red Not recommended for acne routine use / Not commissioned

Minoxidil (Regaine®) Androgenetic alopecia Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Printed: 14 September 2021 Page 51 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Mirabegron 3rd line option for overactive bladder 7.4.2 Drugs for urninary Double-GreenSuitable for GPs to (OAB) symptoms where frequency and initiate and prescribe antimuscarinics are contraindicated or incontinence not tolerated Mitotane Adrenocortical carcinoma 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Modafinil All unlicensed indications, including 4.4 CNS Stimulants and Double red Not recommended for excess sleepiness in MS, Parkinson’s drugs used for ADHD routine use / Not Disease, obstructive sleep apnoea, or commissioned chronic shift work sleep disorder.

Modafinil Narcolepsy 4.4 Central nervous Green GP prescribable at system stimulants request of Consultant/Specialist

Molgramostim (rhGM-CSF) Autoimmune (acquired) pulmonary Granulocyte- Double Red Not recommended for alveolar proteinosis macrophage colony- routine use / Not stimulating factor commissioned

Molludab / Molutrex Molluscum contagiosum Not listed Double Red Not recommended for routine use / Not commissioned

Momelotinib Cancer Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Monoamine oxidase inhibitors Chronic fatigue syndrome/myalgic 4.3.2 Monoamine-oxidase Double Red Not recommended for (MAOIs) encephalomyelitis (or inhibitors routine use / Not encephalopathy) - as per NICE CG commissioned 53 - Do Not Do Montelukast Prophylaxis of asthma - use in children 3.3.2 Leukotriene receptor Green GP prescribable at antagonists request of Consultant/Specialist

Montelukast Adults - Steps 3 and 4 of BTS 3.3.2 Leukotriene receptor Double-GreenSuitable for GPs to guidelines antagonists initiate and prescribe

MooGoo Skincare emollients Emollients for dry skin conditions Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Motavizumab Respiratory syncytial virus (RSV) Not listed in BNF - Double Red Not recommended for prophylaxis humanized routine use / Not monoclonal antibody commissioned

Moxifloxacin Respiratory infection, including 5.1.12 Quinolones Red Hospital / Specialist resistant TB only

Mycophenolate Mofetil For use as an immunosuppressive 8.2.1 Antiprolifertive Amber Option for Shared agent in the treatment of connective immunosuppressants Care Prescribing tissue disease and other autoimmune conditions managed by Rheumatology, Gastroenterology, Dermatology, Neurology and Nephrology

Mycophenolate mofetil / Immunosuppression in adult renal 8.2.1 Antiproliferative Amber Option for Shared Mycophenolic acid transplant patients - as per NICE TA immunosuppressants Care Prescribing 481

Mycophenolate sodium Initial treatment to prevent organ 8.2.2 Corticosteroids and Double Red Not recommended for rejection in adults, children and young immunosuppressants routine use / Not people having a kidney transplant - as commissioned per NICE TAs 481 & 482

Nabilone Pain and spasticity in Multiple 4.6 Drugs used in nausea Double red Not recommended for Sclerosis and vertigo routine use / Not commissioned N-acetylcysteine Idiopathic pulmonary fibrosis 3.7 Mucolytics Double Red Not recommended for routine use / Not commissioned

Naftidrofuryl oxalate Treatment of intermittent claudication 2.6.4 Peripheral Green GP prescribable at in people with peripheral arterial vasodilators and request of disease related drugs Consultant/Specialist

Printed: 14 September 2021 Page 52 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Nail lacquer- Amorolfine & Fungal nail infections 13.10.2 Antifungal preparations Double Red Not recommended for Ticonazole routine use / Not commissioned

Naldemedine treating opioid-induced constipation as 1.6.6 Peripheral opioid- Double Red Not recommended for per TA651 receptor antagonist routine use / Not commissioned

Nalmefene Reduction of alcohol consumption in 4.10.1 Drugs used in alcohol Double red Not recommended for those aged ≥18 years with alcohol dependence routine use / Not dependence that have a high drinking commissioned risk level, without physical withdrawal symptoms and who do not require immediate detoxification.

Naloxegol ▼ Treatment of opioid-induced 1.6.6 Peripheral opioid- Double-GreenSuitable for GPs to constipation in adults who have not receptor antagonists initiate and prescribe adequately responded to standard laxatives in line with NICE TA345 and as per the local treatment pathway

Naltrexone Alcohol Use Disorder - maintenance of 4.10 Drugs used in Amber Option for Shared abstinence only (under an approved substance dependence Care Prescribing shared care agreement)

Naltrexone Management of opioid dependence 4.10 Drugs used in Red Hospital / Specialist substance dependence only

Naltrexone Alcohol misuse disorder - controlled 4.10.1 Drugs used in Red Hospital / Specialist drinking substance dependence only

Naltrexone - low dose Use of a Low Dose in Multiple 4.10 Drugs used in Double red Not recommended for Sclerosis substance dependence routine use / Not commissioned

Naltrexone and Bupropion Treatment of obesity 4.5 Obesity Double Red Not recommended for (Mysimba®)▼ routine use / Not commissioned

Natalizumab ▼ Highly active relapsing-remitting 8.2.4 Other Red Hospital / Specialist multiple sclerosis in adults - as per immunomodulating only NHS England policy and NICE TA 127 drugs

Necitumumab ▼ Adults with locally advanced or Not listed Double Red Not recommended for metastatic epidermal growth factor routine use / Not receptor (EGFR)-expressing commissioned squamous non-small-cell lung cancer that has not been treated with chemotherapy - as per NICE TA 411

Needle free injection devices Insulin needle free injection device Not listed - device Double Red Not recommended for routine use / Not commissioned

Nelarabine Cancer - lymphoblastic leukaemia - as 8.1.3 Antimetabolites Red Hospital / Specialist per Cancer Drug Fund policy only

Nelfinavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Neratinib Extended adjuvant treatment of 8.1.5 Other antineoplastic Red Hospital / Specialist hormone receptor-positive, HER2- drugs only positive early stage breast cancer after adjuvant trastuzumab

Nevirapine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Nicotinamide Mild to moderate acne 13.6 Acne and Rosacea Double Red Not recommended for routine use / Not commissioned

Nicotinamide Various indications 9.6.2 Vitamin B group Double Red Not recommended for routine use / Not commissioned

Nicotine Replacement Therapy Smoking cessation 4.10 Drugs used in Double-GreenSuitable for GPs to substance dependence initiate and prescribe

Printed: 14 September 2021 Page 53 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Nicotine Replacement Therapy Harm reduction in smoking 4.10 Drugs used in In progress Prescribing (NRT) substance dependence responsibility yet to be confirmed

Nicotinic acid (niacin) and All indications including prevention in 2.12 Lipid-regulating Double Red Not recommended for derivatives CVD, alone or added to a statin - as drugs - nicotinic acid routine use / Not per NICE CG 181 - Do Not Do group commissioned

Nilotinib Untreated chronic-phase Philadelphia- 8.1.5 Other antineoplastic Red Hospital / Specialist chromosome-positive chronic myeloid drugs only leukaemia in adults - as per NICE TA 426

Nilotinib ▼ Chronic myeloid leukaemia in adults 8.1.5 Antineoplastic agents - Red Hospital / Specialist resistant or intolerant to imatinib as protein kinase only per NICE TA 425 inhibitors

Nintedanib Ovarian cancer 8.1.5 Neoplastic drugs Double Red Not recommended for Tyrosine protein routine use / Not kinase inhibitor commissioned

Nintedanib ▼ Idiopathic pulmonary fibrosis - as per 8.1.5 Other antineoplastic Red Hospital / Specialist NICE TA 379 drugs only

Nintedanib ▼ Previously treated locally advanced, 8.1.5 Other Antineoplastic Red Hospital / Specialist metastatic, or locally recurrent non drugs only small cell lung cancer - as per NICE TA 347

Niraparib Maintenance treatment of relapsed, 8.1.5 Other antineoplastic Red Hospital / Specialist platinum-sensitive ovarian, fallopian drugs only tube and peritoneal cancer - as per NICE TA 528 Niraparib maintenance treatment of advanced 8.1.5 Other antineoplastic Red Hospital / Specialist ovarian, fallopian tube and peritoneal drugs only cancer after response to first-line platinum-based chemo as per TA673

Nitazoxanide Viral Hepatitis C Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Nitisinone Alkaptonuria Alimentary tract and Red Hospital / Specialist metabolism products only

Nitisinone Hereditary tyrosinemia type 1 (HT-1) Alimentary tract and Red Hospital / Specialist in combination with dietary restriction metabolism products only of tyrosine and phenylalanine

Nitric oxide Pulmonary Arterial Hypertension No BNF entry Red Hospital / Specialist only

Nivolumab advanced squamous non-small-cell 8.1.5 Other antineoplastic Red Hospital / Specialist lung cancer after chemotherapy as per drugs only TA655

Nivolumab Locally advanced unresectable or 8.1.5 Other antineoplastic Double Red Not recommended for metastatic urothelial cancer after drugs routine use / Not platinum-containing chemotherapy - commissioned as per NICE TA 530

Nivolumab adjuvant treatment of completely 8.1.5 Other antineoplastic Red Hospital / Specialist resected melanoma with lymph node drugs only involvement or metastatic disease as per TA684

Nivolumab Adjuvant treatment of completely 8.1.5 Other antineoplastic Red Hospital / Specialist resected melanoma in adults with drugs only lymph node involvement or metstatic disease - as per NICE TA 558

Nivolumab ▼ For previously treated locally 8.1.5 Other antineoplastic Red Hospital / Specialist advanced or metastatic non- drugs only squamous non-small-cell lung cancer in adults after chemotherapy, only if their tumours are PD L1 positive and nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression - as per NICE TA 484

Printed: 14 September 2021 Page 54 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Nivolumab ▼ Relapsed or refractory classical 8.1.5 Other antineoplastic Red Hospital / Specialist Hodgkin lymphoma in adults after drugs only autologous stem cell transplant and treatment with brentuximab vedotin - as per NICE TA 462 Nivolumab ▼ Advanced (unresectable or metastatic) 8.1.5 Other antineoplastic Red Hospital / Specialist melanoma - as per NICE TA 384 drugs only

Nivolumab ▼ Previously treated advanced renal cell 8.1.5 Other antineoplastic Red Hospital / Specialist carcinoma in adults - as per NICE TA drugs only 417

Nivolumab ▼ For previously treated local advanced 8.1.5 Other antineoplastic Red Hospital / Specialist or metastatic squamous non-small-cell drugs only lung cancer in adults after chemotherapy only if nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression - as per NICE TA 483 Nivolumab ▼ Squamous cell carcinoma of the head 8.1.5 Other antineoplastic Red Hospital / Specialist and neck after platinum-based drugs only chemotherapy

Nivolumab ▼ in combination Advanced (unresectable or metastatic) 8.1.5 Other antineoplastic Red Hospital / Specialist with Ipilimumab melanoma in adults, only when the drugs only company provides ipilimumab with discount agreed under PAS - as per NICE TA 400

Nonacog alpha Haemophilia - as per BCSH Guidelines Not listed in BNF Red Hospital / Specialist only

Nonacog beta pegol Haemophilia B (congenital factor IX Not listed in BNF Double Red Not recommended for deficiency). routine use / Not commissioned

Nusinersen Spinal muscular Red Hospital / Specialist atrophy only

Obeticholic acid ▼ Primary biliary cholangitis - as per 1.9.2 Bile acid preparations Red Hospital / Specialist NICE TA 443 only

Obinutuzumab Untreated advanced follicular 8.2.3 Anti-lymphocyte Red Hospital / Specialist lymphoma - as per NICE TA 513 monoclonal antibodies only

Obinutuzumab ▼ For untreated chronic lymphocytic 8.2.3 Anti-lymphocyte Red Hospital / Specialist leukaemia for adults who have monoclonal antibodies only comorbidities that make full-dose fludarabine based therapy unsuitable for them - as per NICE TA 343

Obinutuzumab ▼ (with bendamustine, then as 8.2.3 Anti-lymphocyte Red Hospital / Specialist maintenance) for follicular lymphoma monoclonal antibodies only in adults that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen - as per NICE TA 472 - updated to TA629 (May 2020)

Occlusive dressings and dry Treatment of infected atopic eczema Appendix 5 Wound Double Red Not recommended for bandages in children - asper NICE CG 57 - Do management products routine use / Not Not Do commissioned Ocrelizumab ▼ Relapsing-remitting multiple sclerosis 8.2.3 Anti-lymphocyte Red Hospital / Specialist in adults in line with NICE TA 533 monoclonal antibodies only

Ocrelizumab ▼ Multiple sclerosis in adults - as per 8.2.3 Anti-lymphocyte Double Red Not recommended for NHS England policy (under review monoclonal antibodies routine use / Not post NICE 533) commissioned

Ocriplasmin intravitreal Treatment of vitreomacular traction in 11.8.2 Ocular peripoperative Red Hospital / Specialist injection ▼ adults - as per NICE TA 297 preparations only

Octocog alfa Haemophilia A (congenital factor VIII Antihaemorrhagics, Double Red Not recommended for deficiency) blood coagulation routine use / Not factor VIII commissioned

Printed: 14 September 2021 Page 55 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Octreotide Reducing vomiting in terminal bowel 8.3.4.3 Somatostatin Green GP prescribable at obstruction analogues request of Consultant/Specialist

Octreotide Congenital hyperinsulinism 8.3.4.3 Somatostatin Red Hospital / Specialist analogues only

Octreotide Carcinoid and other neuroendocrine 8.3.4.3 Somatostatin Red Hospital / Specialist tumours analogues only

Octreotide Acromegaly 8.3.4.3 Somatostatin Red Hospital / Specialist analogues only

Octreotide (Oral) Octreolin® Acromegaly Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Ofatumumab For untreated chronic lymphocytic 8.2.3 Anti-lymphocyte Red Hospital / Specialist leukaemia in combination with monoclonal antibodies only chlorambucil or bendamustine - as per NICE TA 344

Ofatumumab relapsing multiple sclerosis as per 8.2.3 Anti-lymphocyte Red Hospital / Specialist TA699 monoclonal antibodies only

Ofatumumab Chronic lymphocytic leukaemia (with 8.2.3 Anti-lymphocyte Double Red Not recommended for chemotherapy) - as per NICE TA 470 monoclonal antibodies routine use / Not commissioned

Ofatumumab ▼ Treatment of chronic lymphocytic 8.2.3 Anti-lymphocyte Red Hospital / Specialist leukaemia refractory to fludarabine monoclonal antibodies only and alemtuzumab

Olanzapine Schizophrenia - 1st line 4.2.1 Atypical antipsychotic Green GP prescribable at drugs request of Consultant/Specialist

Olanzapine Maintenance in Bipolar Mania 4.2.1 Antipsychotic drugs Green GP prescribable at request of Consultant/Specialist

Olanzapine For hallucinations and delusions in 4.2.1 Atypical antipyschotic Double Red Not recommended for Parkinson’s disease, where no drugs routine use / Not cognitive impairment commissioned

Olaparib plus bevacizumab for maintenance 8.1 Cytotoxic drugs Red Hospital / Specialist treatment of advanced ovarian, only fallopian tube or primary peritoneal cancer as per TA693

Olaparib for maintenance treatment of relapsed 8.1.5 Other antineoplastic Red Hospital / Specialist platinum-sensitive ovarian, fallopian drugs only tube or peritoneal cancer as per NICE TA620 - Jan 2020

Olaparib Maintenance treatment of BRCA 8.1 Cytotoxic drugs Red Hospital / Specialist mutation-positive advanced ovarian, only fallopian tube or peritoneal cancer after response to first-line platinum- based chemotherapy

Olaparib ▼ Maintenance treatment of relapsed, 8.1 Cytotoxic drugs Red Hospital / Specialist platinum-sensitive, BRCA mutation- only positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum- based chemotherapy Olaratumab ▼ (in combination with duxorubicin) for 8.1.5 Other antineoplastic Red Hospital / Specialist treating advanced soft tissue sarcoma drugs only in adults - as per NICE TA 465

Olesoxime Spinal muscular atrophy Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Omalizumab For previously treated severe chronic 3.4.2 Allergen Red Hospital / Specialist spontaneous urticaria in adults and immunotherapy only young people aged 12 years and over

Printed: 14 September 2021 Page 56 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Omalizumab Treatment of severe persistent allergic 3.4.2 Allergen Red Hospital / Specialist asthma in children aged 6 to under 12 immunotherapy only years

Omalizumab chronic rhinosinusitis with nasal 3.4.2 Allergen Double Red Not recommended for polyps (terminated appraisal) as per immunotherapy routine use / Not TA678 commissioned

Omalizumab Severe persistent allergic asthma in 3.4.2 Allergen Red Hospital / Specialist patients aged 12 years and over Immunotherapy only

Ombitasvir-paritaprevir- Genotype 1 or 4 chronic hepatitis C in 5.3.3.2 Chronic hepatitis C Red Hospital / Specialist ritonavir ▼ adults (with or without dasabuvir only (Exviera®) as per NICE TA 365

Omega-3-acid ethyl esters Adjunct in lowering triglycerides in 2.12 Lipid-regulating drugs Double red Not recommended for secondary prevention of coronary (Fish oils) routine use / Not heart disease / ADHD commissioned

Ondansetron (generic plain Drug-induced nausea and vomiting in 4.6 Drugs used in nausea Green GP prescribable at tablets) palliative care and vertigo request of Consultant/Specialist

Ondansetron (generic plain Second line option in hyperemesis 4.6 Drugs used in nausea Green GP prescribable at tablets) gravidarum and vertigo request of Consultant/Specialist

Ondansetron + other 5HT3 Nausea & vomiting associated with 4.6 Drugs used in nausea Red Hospital / Specialist antagonists chemotherapy and other hospital-led and vertigo only treatments

Opicapone ▼ Adjunctive therapy to preparations of 4.9.1 Catechol-O- Green GP prescribable at levodopa/ DOPA decarboxylase methyltransferase request of inhibitors (DDCI) in adult patients with inhibitors Consultant/Specialist Parkinson’s disease (PD) and end-of- dose motor fluctuations who cannot be stabilised on those combinations Organic and natural eczema All dermatology conditions including Not listed in the BNF Double Red Not recommended for skincare products eczema and psoriasis routine use / Not commissioned

Orlistat Identification, assessment and 4.5.1 Anti-obesity drugs Red Hospital / Specialist management of overweight and acting on the GI tract only obesity in children

Orlistat Obesity - in adults only 4.5.1 Anti-obesity drugs Double-GreenSuitable for GPs to acting on the GI tract initiate and prescribe

Orphenadrine NICE Do Not Do - Dyskinesia and/or 4.9.2 Antimuscarinic drugs Double Red Not recommended for motor fluctuations in Parkinson's used in parkinsonism routine use / Not disease - as per NG 71 commissioned

Oscillating Positive Expiratory Mucus clearance in Chronic Not listed in the BNF - Double Red Not recommended for Pressure devices Bronchitis, Bronchiectasis, device routine use / Not Emphysema, Asthma, Cystic commissioned Fibrosis - as per N&W DROP List

Oseltamivir Treatment of influenza in at-risk people 5.3.4 Antiviral drugs Double-GreenSuitable for GPs to initiate and prescribe

Oseltamivir Prophylaxis of influenza in at-risk 5.3.4 Antiviral drugs Double-GreenSuitable for GPs to people initiate and prescribe

Osilodrostat Cushing's Disease Not listed in BNF - 11β- Double Red Not recommended for hydroxylase inhibitor routine use / Not commissioned

Osimertinib for untreated EGFR mutation-positive 8.1.5 Protein kinase Red Hospital / Specialist nonsmall-cell lung cancer as per inhibitors only TA654

Osimertinib treating EGFR T790M mutation- 8.1.5 Protein kinase inibitors Red Hospital / Specialist positive advanced non-small-cell lung only cancer as per TA653

Printed: 14 September 2021 Page 57 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Osimertinib ▼ Locally advanced or metastatic EGFR Not listed in the BNF Red Hospital / Specialist T790M mutation-positive non-small- only cell lung cancer in adults whose disease has progressed only after first- line treatment with an EGFR tyrosine kinase inhibitor Ospemifene Moderate to Severe Symptomatic 6.4.1.1 Oestrogens and HRT Double Red Not recommended for Vulvar And Vaginal Atrophy (VVA) In routine use / Not Post-Menopausal Women Who Are commissioned Not Candidates For Local Vaginal Oestrogen Therapy

Ostomy underwear Any use other than for parastomal Not listed Double Red Not recommended for hernia assessed by a specialist routine use / Not commissioned

Ostomy underwear Support following stoma surgery for Not listed Green GP prescribable at parastomal hernia request of Consultant/Specialist

Oxaliplatin Colorectal cancer 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Oxcarbazepine Epilepsy 4.8.1 Control of epilepsy Green GP prescribable at request of Consultant/Specialist

Oxybutynin (immediate Use in frail elderly women - as per 7.4.2 Drugs for urinary Double Red Not recommended for release) NICE CG 171 - Do Not Do frequency and routine use / Not incontinence commissioned

Oxycodone / Naloxone Pain / opioid-induced constipation 4.7.2 Opioid analgesics Double red Not recommended for (Targinact®) ▼ routine use / Not commissioned

Oxygen therapy Approved indications outside of usual 3.6 Oxygen Special Special contract - not Long Term Oxygen Therapy (LTOT) for GP prescribing

Ozanimod Relapsing-remitting multiple sclerosis 8.2.4 Other Double Red Not recommended for (RRMS) immunomodulating routine use / Not drugs commissioned

Paclitaxel Lymph node positive breast cancer 8.1.5 Other antineoplastic Double red Not recommended for drugs routine use / Not commissioned

Paclitaxel In combination with platinum or as 8.1.5 Other antineoplastic Red Hospital / Specialist monotherapy for treatment of drugs only advanced recurrent ovarian cancer

Paclitaxel For untreated non-small-cell lung 8.1.5 Other antineoplastic Double Red Not recommended for cancer (as albumin-bound drugs routine use / Not nanoparticles with carboplatin) commissioned

Paclitaxel Non-small cell lung cancer 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Paclitaxel As albumin-bound nanoparticles in 8.1.5 Protein kinase Red Hospital / Specialist combination with gemcitabine inhibitors only (Gemzar®) for previously untreated metastatic adenocarcinoma of the pancreas in adults - as per NICE TA 476

Paclitaxel albumin As monotherapy for metastatic breast 8.1.5 Other antineoplastic Red Hospital / Specialist cancer in patients who have not or are drugs only unlikely to tolerate first-line treatment with standard taxanes Pacritinib Myelofibrosis Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Padeliporfin Untreated localised (unilateral, low- No BNF entry Double Red Not recommended for risk) prostate cancer - as per NICE TA routine use / Not 546 commissioned

Printed: 14 September 2021 Page 58 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Palbociclib with fulvestrant for treating hormone 8.1.5 Protein kinase Red Hospital / Specialist receptor-positive, HER2-negative, inhibitors only advanced breast cancer as per NICE TA619 - Jan 2020 Palbociclib ▼ (with an Previously untreated, hormone 8.1.5 Protein kinase inhibitor Red Hospital / Specialist aromatase inhibitor) receptor-positive, HER2-negative, only locally advanced or metastatic breast cancer

Palivizumab Prevention of Respiratory Syncytial 5.3 Antiviral drugs Red Hospital / Specialist Virus (RSV) in infants only

Panitumumab Treatment of metastatic colorectal 8.1.5 Other antineoplastic Double red Not recommended for cancer after first-line chemotherapy drugs routine use / Not commissioned

Panitumumab Previously untreated metastatic 8.1.5 Other antineoplastic Red Hospital / Specialist colorectal cancer (with chemo) drugs only

Panobinostat ▼ Treatment of multiple myeloma (in Not listed in the BNF Red Hospital / Specialist combination with bortezomib and only dexamethasone) after at least 2 previous treatments, including bortezomib and an immunomodulatory agent.

Parathyroid hormone Specialist endocrinology conditions 6.6.1 Calcitonin and Red Hospital / Specialist parathyroid hormone only

Parathyroid Hormone hypoparathyroidism as per NICE 6.6.1 Calcitonin and Double Red Not recommended for (recombinant) TA625 March 2020 (terminated Parathyroid Hormone routine use / Not appraisal) commissioned Paritaprevir-ombitasvir- Genotype 1 or 4 chronic hepatitis C in 5.3.3.2 Chronic hepatitis C Red Hospital / Specialist ritonavir ▼ adults (with or without dasabuvir only (Exviera®) as per NICE TA 365

Paroxetine Depression in children and young 4.3.3 Selective Serotonin Double Red Not recommended for people - as per NICE CG 28 "Do Not RE-uptake Inhibitors routine use / Not Do" commissioned

Pasireotide Acromegaly 8.3.4.3 Somatostatin Double Red Not recommended for analogues routine use / Not commissioned

Pasireotide Cushing's Disease - as per NHS 8.3.4.3 Somatostatin Red Hospital / Specialist England Policy 16052/P analogues only

Path Finder laser shoe Walking aid for freezing of gait in No BNF entry - device Double Red Not recommended for attachment Parkinson's disease routine use / Not commissioned

Patiromer hyperkalaemia as per TA623 - Feb 9.5.2.2 Phosphate-binding Double Red Not recommended for 2020 agents routine use / Not commissioned

Pazopanib First-line treatment of advanced renal 8.1.5 Other antineoplastic Red Hospital / Specialist cell carcinoma drugs only

Pegaptanib sodium Neovascular (wet) age-related 11.8.2 Ocular peri-operative Double red Not recommended for macular degeneration routine use / Not commissioned Pegaspargase ▼ Acute lymphoblastic leukaemia in 8.1.5 Other antineoplastic Red Hospital / Specialist children, young people and adults only drugs only when they have untreated newly diagnosed disease

Pegfilgrastim Reduction in the duration of 9.1.6 Drugs used in Double Red Not recommended for neutropenia and the incidence of neutropenia routine use / Not febrile neutropenia in patients treated commissioned with established cytotoxic chemotherapy for malignancy

Peginterferon alfa Treatment of chronic hepatitis C (with 8.2.4 Other Red Hospital / Specialist ribavirin) immunomodulating only drugs

Printed: 14 September 2021 Page 59 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Peginterferon alfa Treatment of mild chronic hepatitis C 8.2.4 Other Red Hospital / Specialist (with ribavirin) immunomodulating only drugs

Peginterferon alfa Treating children and young people 8.2.4 Other Red Hospital / Specialist with chronic hepatitis C (with ribavirin) immunomodulating only drugs Peginterferon alfa-2a Chronic Hepatitis B 8.2.4 Other Red Hospital / Specialist immunomodulating only drugs

Peginterferon Beta-1a Multiple sclerosis - as per NHS 8.2.4 Other Red Hospital / Specialist England policy SSC1534 immunomodulating only drugs

Peginterferon beta-1a for treating relapsing–remitting 8.2.4 Other Red Hospital / Specialist multiple sclerosis as per TA624 - Feb immunomodulating only 2020 drugs

Peginterferon Lambda-1a Hepatitis C Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Pegloticase Severe debilitating chronic 10.1.4 Gout and cytotoxic- Double red Not recommended for tophaceous gout induced routine use / Not hyperuricaemia commissioned

Pegvisomant Acromegaly (where other treatments Anterior pituitary lobe Red Hospital / Specialist failed / not tolerated) - as per NHS hormones and only England Policy 16050/P analogues Pegylated liposomal Cancer - as per NHS England / 8.1.5 Other antineoplastic Red Hospital / Specialist doxorubicin Cancer Drug Fund policy drugs only

Pegylated liposomal irinotecan For treating metastatic 8.1.5 Other antineoplastic Double Red Not recommended for adenocarcinoma of the pancreas in agents routine use / Not adults whose disease has progressed commissioned after gemcitabine-based therapy

Pelvic floor muscle toning Pelvic floor muscle training Not listed Double Red Not recommended for devices routine use / Not commissioned

Pembrolizumab Relapsed or refractory classical 8.1 Cytotoxics - Double Red Not recommended for Hodgkin lymphoma in adults who have monoclonal antibodies routine use / Not had autologous stem cell transplant commissioned and brentuximab vedotin - as per NICE TA 540 Pembrolizumab Locally advanced or metastatic 8.1 Cytotoxics - Red Hospital / Specialist urothelial carcinoma after platinum- monoclonal antibodies only containing chemotherapy - as per NICE TA 519

Pembrolizumab Untreated, metastatic, non-squamous 8.1 Cytotoxics - Red Hospital / Specialist non-small-cell lung cancer (NSCLC) in monoclonal antibodies only adults whose tumours have no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-positive mutations - as per NICE TA 557

Pembrolizumab with axitinib for untreated advanced 8.1 Cytotoxics - Double Red Not recommended for renal cell carcinoma as per TA650 monoclonal antibodies routine use / Not commissioned

Pembrolizumab pemetrexed and platinum 8.1 Cytotoxic monoclonal Red Hospital / Specialist chemotherapy for untreated, antibiotics only metastatic, non-squamous non-small- cell lung cancer as per TA683

Pembrolizumab untreated PD-L1-positive, locally 8.1 Cytotoxics - Double Red Not recommended for advanced or metastatic urothelial monoclonal antibodies routine use / Not cancer when cisplatin is unsuitable commissioned (terminated appraisal) as per TA674

Printed: 14 September 2021 Page 60 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Pembrolizumab Adjuvant treatment of resected 8.1 Cytotoxics - Red Hospital / Specialist melanoma with high risk of Monoclonal antibodies only recurrence - stage III melanoma with lymph node involvement in adults who have had complete resection - as per NICE TA 553 Pembrolizumab untreated metastatic or unresectable 8.1.5 Other antineoplastic Red Hospital / Specialist recurrent head and neck squamous drugs only cell carcinoma as per TA661

Pembrolizumab With carboplatin and paclitaxel for 8.1 Cytotoxics - Red Hospital / Specialist untreated metastatic squamous non- Monoclonal antibodies only small-cell lung cancer

Pembrolizumab Untreated locally advanced or 8.1 Cytotoxics - Red Hospital / Specialist metastatic urothelial cancer when monoclonal antibodies only cisplatin is unsuitable - as per NICE TA 522

Pembrolizumab locally advanced or metastatic 8.1 Cytotoxics - Double Red Not recommended for urothelial carcinoma after platinum- monoclonal antibodies routine use / Not containing chemotherapy as per TA692 commissioned

Pembrolizumab For treating recurrent or metastatic 8.1 Cytotoxics - Double Red Not recommended for squamous cell carcinoma of the head monoclonal antibiotics routine use / Not and neck after platinum-based commissioned chemotherapy - as per NICE TA 570 (terminated appraisal)

Pembrolizumab Relapsed or refractory classical 8.1 Cytotoxics - Red Hospital / Specialist Hodgkin lymphoma in adults who have monoclonal antibodies only had brentuximab vedotin and cannot have autologous stem cell transplant - as per NICE TA 540

Pembrolizumab ▼ untreated PD-L1-positive metastatic 8.1 Cytotoxics - Red Hospital / Specialist non-small-cell lung cancer (NSCLC) in monoclonal antibodies only adults whose tumours express PD L1 (with at least a 50% tumour proportion score) and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations - as per NICE TA 531

Pembrolizumab ▼ Advanced melanoma after disease 8.1 Cytotoxics - Red Hospital / Specialist progression with ipilimumab in adults - monoclonal antibodies only as per NICE TA 357

Pembrolizumab ▼ Untreated PD-L1-positive metastatic 8.1 Cytotoxics - Red Hospital / Specialist non-small-cell lung cancer - as per monoclonal antibodies only NICE TA 447

Pembrolizumab ▼ Locally advanced or metastatic PD-L1- 8.1 Cytotoxics - Red Hospital / Specialist positive non-small-cell lung cancer monoclonal antibodies only after chemotherapy - as per NICE TA 428 Pembrolizumab ▼ Advanced (unresectable or metastatic) 8.1 Cytotoxics - Red Hospital / Specialist melanoma in adults not previously Monoclonal antibodies only treated with ipilimumab as per NICE TA 366

Pemetrexed Maintenance treatment of locally 8.1.3 Antimetabolites Red Hospital / Specialist advanced or metastatic non- only squamous non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin Pemetrexed Maintenance treatment of non-small- 8.1.3 Antimetabolites Red Hospital / Specialist cell lung cancer only

Pemetrexed Treatment of malignant pleural 8.1.3 Antimetabolites Red Hospital / Specialist mesothelioma only

Pemetrexed Non-small-cell lung cancer - patients 8.1.3 Antimetabolites Red Hospital / Specialist who have had prior chemotherapy only

Pemetrexed First-line treatment of non-small-cell 8.1.3 Antimetabolites Red Hospital / Specialist lung cancer only

Printed: 14 September 2021 Page 61 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Pen needle and remover Insulin administration Not listed in the BNF - Double Red Not recommended for (Unifine Pentips Plus) device routine use / Not commissioned

Penicillamine Wilson’s disease (as recommended 10.1.3 Drugs which suppress Red Hospital / Specialist by a specialist centre - Cambs the rheumatic disease only Universty Hospitals /Addenbrooke's process Hospital)

Pentosan polysulfate sodium Bladder pain syndrome / Interstitial Heparinoids Red Hospital / Specialist 100mg capsules Cystitis characterised by either only glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition

Pentoxifylline (Oxpentifylline) Treatment of intermittent claudication 2.6.4 Peripheral Double red Not recommended for in people with peripheral arterial vasodilators and routine use / Not disease related drugs commissioned

Peptide receptor Cancer Not listed in the BNF Double Red Not recommended for radionucleotide therapy routine use / Not commissioned

Perampanel Second line adjunctive treatment of 4.8.1 Control of the Green GP prescribable at patients over the age of 12 years with epilepsies request of partial seizures with or without Consultant/Specialist secondary generalisation

Pergolide Pharmacological neuroprotective 4.9.1 Dopamine-receptor Double Red Not recommended for therapy in Parkinson's disease agonists routine use / Not commissioned Pergolide First-line use in Parkinson's disease 6.7.1 Ergot-derived Double Red Not recommended for dopamine agonists routine use / Not commissioned

Perindopril arginine All indications 2.5.5 Drygs affecting the Double Red Not recommended for renin-angiotensin routine use / Not system commissioned

Pertuzumab In combination with trastuzumab and 8.1.5 Other antineoplastic Red Hospital / Specialist chemotherapy for the neoadjuvant drugs only treatment of adults with HER2- positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence Pertuzumab For adjuvant treatment of HER2- 8.1.5 Other antineoplastic Red Hospital / Specialist positive early stage breast cancer in drugs only adults, only if they have lymph node- positive disease - as per NICE TA 569 (NHSE commissioning responsibility)

Pertuzumab (with trastuzumab and docetaxel) for 8.1.5 Other antineoplastic Red Hospital / Specialist treating HER2-positive breast cancer - drugs only as per NICE TA 509

Phenothiazines (see list of NICE Do Not Do - Use in Parkinson's 4.2.1 First-generation Double Red Not recommended for drugs in TAG Guidance) disease - as per NG 71 antipsychotic drugs routine use / Not commissioned

Phenylketonuria (PKU) Foods Guidance on the recommended 9.4.1 Foods for psecial diets Double-GreenSuitable for GPs to quantities of specialist PKU foods for initiate and prescribe patients diagnosed with phenylketonuria Pibrentasvir Chronic hepatitis C - as per NICE TA 5.3.3.2 Antiviral drugs Red Hospital / Specialist 499 only

Pigmanorm® Pigmanorm® Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Pimecrolimus 1% Cream Option for 2nd line treatment of 13.5.3 Drug affecting the Green GP prescribable at moderate atopic eczema on the face immune response request of and neck in children aged 2 to 16 Consultant/Specialist years not controlled by topical steroids or where there is serious risk of important ADRs from further use of topical steroids - as per NICE CG 57

Printed: 14 September 2021 Page 62 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Pindolol Augmentation of an antidepressant - 2.4 Beta-adrenoceptor Double Red Not recommended for as per NICE CG 90 - Do Not Do blocking drugs routine use / Not commissioned

Pioglitazone In combination for type 2 diabetes 6.1.2.3 Other antidiabetics Double-GreenSuitable for GPs to initiate and prescribe

Pirfenidone Idiopathic Pulmonary Fibrosis 3.11 Collagen inhibitor Red Hospital / Specialist only

Pixantrone ▼ Monotherapy treatment of multiply 8.1.2 Anthracyclines and Red Hospital / Specialist relapsed or refractory aggressive non- other cytotoxic only Hodgkin's B-cell lymphoma antibiotics

Plantar pressure offloading Prevention and management of Not listed Green GP prescribable at devices diabetic foot problems request of Consultant/Specialist

Plerixafor Mobilisation of stem cells in Bone 9.1.7 Drugs used to Red Hospital / Specialist Marrow Transplant mobilise stems cells only

Plerixafor Stem cell mobilisation 9.1.7 Drugs used to Red Hospital / Specialist mobilise stem cells only

Polatuzumab vedotin with rituximab and bendamustine - 8.1.1 Alkylating drugs Red Hospital / Specialist relapsed or refractory diffuse large B- only cell lymphoma as per TA649

Pomalidomide With bortezomib and dexamethasone 8.2.4 Other Double Red Not recommended for for treating relapsed or refractory immunomodulating routine use / Not multiple myeloma drugs commissioned

Pomalidomide ▼ Myelofibrosis 8.2.4 Other Double Red Not recommended for immunomodulating routine use / Not drugs commissioned

Pomalidomide ▼ In combination with dexamethasone - 8.2.4 Other Red Hospital / Specialist treatment of relapsed and refractory immunomodulating only multiple myeloma previously treated drugs with lenalidomide and bortezomib as per NICE TA 427

Ponatinib ▼ Chronic myeloid leukaemia and acute 8.1.5 Other antineoplastic Red Hospital / Specialist lymphoblastic leukaemia in adults - as drugs only per NICE TA 451

Ponesimod Multiple sclerosis Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Poractant alfa Respiratory distress syndrome Pulmonary surfactants Red Hospital / Specialist only

Posaconazole Systemic fungal infections - as per 5.2.1 Triazole antifungals Red Hospital / Specialist Trust Guidelines & NHSE policy only

Potassium aminobenzoate Peyronie's disease, Scleroderma 6 Vitamins and trace Double Red Not recommended for (capsules and powder) elements - B group routine use / Not commissioned

Pramipexole Pharmacological neuroprotective 4.9.1 Dopamine-receptor Double Red Not recommended for therapy in Parkinson's disease agonists routine use / Not commissioned

Pramipexole - Immediate Idiopathic Parkinson's disease, alone 4.9.1 Dopaminergic drugs Green GP prescribable at Release (without levodopa) or in combination used in Parkinson's request of with levodopa disease Consultant/Specialist

Pramipexole - Prolonged Idiopathic Parkinson's disease - alone 4.9.1 Dopaminergic drugs Green GP prescribable at Release or with levodopa, for patients initiated used in Parkinson's request of on treatment prior to mid March 2011 disease Consultant/Specialist only - no new patients to be started on Pramipexole PR after this date.

Pramipexole - Prolonged Idiopathic Parkinson's disease, alone 4.9.1 Dopaminergic drugs Double red Not recommended for Release (without levodopa) or in combination used in Parkinson's routine use / Not with levodopa - Not commissioned disease commissioned from mid March 2011 onwards

Printed: 14 September 2021 Page 63 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Prasterone Vulvar and vaginal atrophy (in post- 7.2.1 Preparations for Double Red Not recommended for menopausal women with moderate to vaginal and vulval routine use / Not severe symptoms) changes commissioned

Prasugrel Targeted use in diabetics: In 2.9 Antiplatelet drugs Double red Not recommended for combination with aspirin, prevention of routine use / Not atherothrombotic events in patients commissioned with acute coronary syndrome (ACS) undergoing primary or delayed percutaneous coronary intervention (PCI) Prasugrel In combination with aspirin: Prevention 2.9 Antiplatelet drugs Green GP prescribable at of atherothrombotic events in patients request of with acute coronary syndrome (ACS) Consultant/Specialist undergoing percutaneous coronary intervention (PCI) with known intolerance to clopidogrel or who have restenosed whilst on clopidogrel.

PredictSure-IBD - prognostic Prediction of prognosis in No BNF entry - Double Red Not recommended for tool Inflammatory bowel disease prognostic tool routine use / Not commissioned

Prednisone MR Moderate to severe RA 6.3.2 Glucocorticoid therapy Double Red Not recommended for routine use / Not commissioned

Pregabalin Control of epilepsy 4.8.1 Control of epilepsy Green GP prescribable at request of Consultant/Specialist

Pregabalin Peripheral neuropathic pain in adults 4.7.3 Neuropathic Pain Double-GreenSuitable for GPs to only where other options have failed to initiate and prescribe provide adequate benefit

Pregabalin Generalised anxiety disorder (GAD) - 4.8.1 Control of epilepsy Green GP prescribable at for use only where all other options request of have failed. Consultant/Specialist

Pretomanid Multi drug resistant tuberculosis (TB) 5.1.9 Not listed in the BNF - Double Red Not recommended for Antituberculosis drugs routine use / Not commissioned

Probiotics Any indication Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Procarbazine All indications 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Procyclidine NICE Do Not Do - Dyskinesia and/or 4.9.2 Antimuscarinic drugs Double Red Not recommended for motor fluctuations in Parkinson's used in parkinsonism routine use / Not disease - as per NG 71 commissioned

Progest cream Hormone replacement therapy Not listed in the BNF Double red Not recommended for routine use / Not commissioned

Progestogens (oral) (given during the luteal phase only) for 6.4.1.2 Progestogens and Double Red Not recommended for treatment of Heavy Menstrual progesterone receptor routine use / Not Bleeding - as per NICE CG 44 - Do modulators commissioned Not Do Prolonged release oxycodone Analgesia 4.7.2 Opioid analgesics Double Red Not recommended for (Onexila XL) routine use / Not commissioned

Prontoderm bacterial Topical decolonisation of MRSA 12.2.3 Topical decolonisation Double Red Not recommended for decolonisation foam/nasal gel carriers of MRSA carriers routine use / Not commissioned

Propantheline Overactive bladder and urinary 7.4.2 Drugs for urinary Double Red Not recommended for incontinence in women - as per NICE frequency and routine use / Not CG 171 - NICE Do Not Do incontinence commissioned

Prosource Jelly protein-containing food supplement for Not listed Double Red Not recommended for use in patients with protein energy routine use / Not malnutrition commissioned

Printed: 14 September 2021 Page 64 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Protein C concentrate Congenital protein C deficiency - as 2.11 Coagulation proteins Red Hospital / Specialist per B(C)SH Guidelines only

Protein Kinase Inhibitors Endocrinology non-malignant 8.1.5 Anti-neoplastic drugs - Double Red Not recommended for conditions Protein Kinase routine use / Not Inhibitors commissioned

Prothrombin Complex As per B(C)SH Guidelines 2.11 Antifibrinolytic drugs Red Hospital / Specialist and haemostatics only

Proton pump inhibitors Dyspepsia 1.3.5 Proton pump inhibitorsDouble-GreenSuitable for GPs to initiate and prescribe

Prucalopride Chronic constipation in adults - as per 1.6.7 5HT4 receptor agonistsDouble-GreenSuitable for GPs to local treatment algorithm for initiate and prescribe Refractory Symptomatic Chronic Constipation in Adults

Pyridostigmine Myasthenia gravis 10.2.1 Anticholinesterases Green GP prescribable at request of Consultant/Specialist

Quetiapine Schizophrenia - 1st line 4.2.1 Atypical antipsychotic Green GP prescribable at drugs request of Consultant/Specialist

Quetiapine Generalised anxiety disorder 4.2.1 2nd generation Double red Not recommended for antipsychotic drugs routine use / Not commissioned

Rabbit anti-human thymocyte INITIAL treatments to prevent organ Immunoglobulins Double Red Not recommended for immunoglobulin rejection in adults, children and young routine use / Not people having a kidney transplant - as commissioned per NICE TAs 481 and 482 Radium-223 dichloride ▼ Hormone-relapsed prostate cancer Not listed in the BNF Red Hospital / Specialist with bone metastases. only

Raloxifene Chemoprophylaxis for no more than 5 6.4.1 Female sex hormones Green GP prescribable at years for pre- or post-menopausal and their modulators request of women at either high or moderate risk Consultant/Specialist of developing breast cancer

Raloxifene Primary prevention of osteoporotic 6.4.1 Female sex hormones Double red Not recommended for fragility fractures in postmenopausal routine use / Not women commissioned

Raloxifene HCl Secondary prevention of osteoporotic 6.4.1 Female sex hormones Double-GreenSuitable for GPs to fragility fractures in postmenopausal initiate and prescribe women Raltegravir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs - as per BHIVA only Guidelines

Raltitrexed Advanced colorectal cancer 8.1.3 Antimetabolites Double red Not recommended for routine use / Not commissioned

Ramucirumab Unresectable hepatocellular 8.1 Cytotoxics - Double Red Not recommended for carcinoma after sorafenib monoclonal antibodies routine use / Not commissioned

Ramucirumab (with erlotinib) untreated EGFR-positive metastatic 8.1 Cytotxics - Monoclonal Double Red Not recommended for non-small-cell lung cancer as per antibodies routine use / Not TA635 (June 2020 - terminated commissioned appraisal)

Ramucirumab ▼ Advanced gastric cancer or gastro- 8.1 Cytotxics - Monoclonal Double Red Not recommended for oesophageal junction adenocarcinoma antibodies routine use / Not previously treated with chemotherapy. commissioned

Ramucirumab ▼ in Locally advanced or metastatic non- 8.1 Cytotoxics - Double Red Not recommended for combination with doxetaxel small-cell lung cancer in adults whose Monoclonal antibodies routine use / Not disease has progressed after platinum- commissioned based chemotherapy

Ranibizumab Choroidal neovascularisation 11.8.2 Ocular diagnostic and Red Hospital / Specialist associated with pathological myopia peri-operative only preparations

Printed: 14 September 2021 Page 65 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Ranibizumab Treatment of visual impairment 11.8.2 Ocular peri-operative Red Hospital / Specialist caused by macular oedema preparations only secondary to retinal vein occlusion (RVO) Ranibizumab Visual impairment due to diabetic 11.8.2 Ocular peri-operative Red Hospital / Specialist macular oedema preparations only

Ranibizumab Treatment of Wet Age-related Macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist Degeneration (AMD) as part of a treat peri-operative only and extend regimen in line with the preparations locally commissioned treatment pathway

Ranibizumab Treatment of Diabetic Macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist Oedema (DMO) as part of a treat and peri-operative only extend regimen in line with the locally preparations commissioned treatment pathway Ranibizumab treating diabetic retinopathy as per 11.8.2 Ocular peri-operative Double Red Not recommended for TA637 (June 2020 - terminated preparations routine use / Not appraisal) commissioned

Ranibizumab Neovascular (wet) age-related 11.8.2 Ocular peri-operative Red Hospital / Specialist macular degeneration preparations only

Ranolazine Adjunctive use in stable angina 2.6.3 Other antianginal drugs Green GP prescribable at unresponsive to other treatments request of Consultant/Specialist

Rasagiline Idiopathic Parkinson’s Disease 4.9.1 Dopaminergic drugs Green GP prescribable at used in Parkinsonism request of Consultant/Specialist Rasagiline NICE Do Not Do - Pharmacological 4.9.1 Monamine oxidase-B Double Red Not recommended for neuroprotective therapy in Parkinson's inhibitors routine use / Not disease - as per NG 71 commissioned

Rasburicase Prophylaxis & treatment of acute 10.1.4 Gout and cytotoxic- Red Hospital / Specialist hyperuricaemia to prevent renal failure induced only in patients with high tumour burden hyperuricaemia who are at risk of tumour lysis syndrome Ravulizumab paroxysmal nocturnal haemoglobinuria 8.1.5 Other antineoplastic Red Hospital / Specialist as per TA698 drugs only

Reagent Pad (Neuropad) Diagnostic test for peripheral Not listed in the BNF - Double Red Not recommended for neuropathy diagnostic tool routine use / Not commissioned

Regorafenib Previously treated advanced 8.1.5 Other antineoplastic Double Red Not recommended for hepatocellular carcinoma - as per drugs routine use / Not NICE TA 514 commissioned

Regorafenib Advanced unresectable hepatocellular 8.1.5 Other antineoplastic Red Hospital / Specialist carcinoma in adults who have had drugs only sorafenib - as per NICE TA 555

Regorafenib ▼ Previously treated unresectable or 8.1.5 Other antineoplastic Red Hospital / Specialist metastatic gastrointestinal stromal drugs only tumours

Regorafenib ▼ Metastatic colorectal cancer after 8.1.5 Other antineoplastic Double Red Not recommended for treatment for metastatic disease drugs routine use / Not commissioned

Repaglinide to treat CF patients who have 6.1.2.3 Other antidiabetic Green GP prescribable at diabetes, as an alternative to insulin drugs request of Consultant/Specialist

Reslizumab ▼ Treatment of severe eosinophilic Humanised Red Hospital / Specialist asthma inadequately controlled in monoclonal antibody only adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug - as per NICE TA 479

RESPeRATE® Device used to lower BP by changing Not listed in the BNF - Double Red Not recommended for breathing rates device routine use / Not commissioned

Printed: 14 September 2021 Page 66 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Retigabine ▼ (discontinued Adjunctive treatment for partial onset 4.8.1 Control of the Double Red Not recommended for June 2017) seizures +/- secondary generalization epilepsies routine use / Not commissioned

Reveglucosidase alfa Pompe Disease Not listed in the BNF - Double Red Not recommended for Enzyme replacement routine use / Not therapy commissioned

Ribavirin Chronic hepatitis C 5.3 Antiviral drugs Red Hospital / Specialist only

Ribociclib with fulvestrant for treating hormone 8.1.5 Protein kinase inhibitor Red Hospital / Specialist receptor-positive, HER2-negative only advanced breast cancer after endocrine therapy as per TA687

Ribociclib with fulvestrant Hormone receptor-positive, HER2- 8.1.5 Other antineoplastic Red Hospital / Specialist negative, advanced breast cancer drugs only

Ribociclib▼(with an Previously untreated, hormone 8.1.5 Protein kinase inhibitor Red Hospital / Specialist aromatase inhibitor) receptor-positive, HER2-negative, only locally advanced or metastatic breast cancer

Riboflavin Various indications 9.6.2 Vitamin B Group Double Red Not recommended for routine use / Not commissioned

Riboflavin (vitamin B2) Migraine prophylaxis 9.6.2 Vitamin B group Double Red Not recommended for routine use / Not commissioned

Rifampicin Non-TB related Mycobacterium 5.1.9 Antituberculosis drugs Green GP prescribable at infections request of Consultant/Specialist

Rifaximin Chronic diarrhoea in G-I disorders 5.1.7 Some other Double Red Not recommended for (including Crohn’s disease, Ulcerative antibacterials routine use / Not Colitis, Diverticular disease, IBS, commissioned recurrent C. diff infection, small intestinal bacterial ovegrowth, and in UC with pouchitis)

Rifaximin Treatment and prophylaxis of 5.1.7 Some other Red Hospital / Specialist secondary hepatic encephalopathy antibacterials only

Rifaximin For treatment of traveller's diarrhoea 5.1.7 Some other Double Red Not recommended for antibacterials routine use / Not commissioned

Rigosertib Refractory myelodysplastic syndromes Not listed in the BNF Double Red Not recommended for (MDS), high-risk / Pancreatic cancer routine use / Not commissioned

Rilpivirine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Riluzole Amyotrophic Lateral Sclerosis (Motor 4.9.3 Drugs used in Amber Option for Shared Neurone Disease) essential tremor, Care Prescribing chorea, tics etc.

Riociguat ▼ Treatment chronic thromboembolic 2.5.1 Vasodilator Red Hospital / Specialist Pulmonary Hypertension in adults antihypertensive only

Risankizumab Moderte to severe plaque psoriasis as 13.5.3 Drugs affecting the Red Hospital / Specialist per NICE TA596 immune response only

Risankizumab Psoriasis as per NICE TA596 10.1.3 Drugs that suppress Red Hospital / Specialist the rheumatic disease only process

Risedronate sodium Primary prevention of osteoporotic 6.6.2 Bisphosphonates Double-GreenSuitable for GPs to fragility fractures in postmenopausal (drugs affecting bone initiate and prescribe women metabolism)

Risedronate sodium Secondary prevention of osteoporotic 6.6.2 Bisphosphonates Double-GreenSuitable for GPs to fragility fractures in postmenopausal (drugs affecting bone initiate and prescribe women metabolism)

Risperidone Unresponsive conduct disorder in 4.2.1 Antipsychotic drugs Red Hospital / Specialist ADHD only

Printed: 14 September 2021 Page 67 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Risperidone (Depot injection) Schizophrenia and other psychoses in 4.2.2 Antipsychotic depot Red Hospital / Specialist ▼ patients tolerant to risperidone by injections only mouth.

Ritonavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs - as per BHIVA only Guidelines

Ritonavir-paritaprevir- Genotype 1 or 4 chronic hepatitis C in 5.3.3.2 Chronic hepatitis C Red Hospital / Specialist ombitasvir ▼ adults (with or without dasabuvir only (Exviera®) as per NICE TA 365

Rituximab Treatment for relapsing Steroid 8.2.3 Anti-lymphocyte Red Hospital / Specialist Sensitive Nephrotic Syndrome (SSNS) monoclonal antibodies only in children

Rituximab Option for first-line treatment of 8.2.3 Anti-lymphocyte Red Hospital / Specialist chronic lymphocytic leukaemia monoclonal antibodies only

Rituximab Treatment of Steroid Resistant 8.2.3 Anti-lymphocyte Red Hospital / Specialist Nephrotic Syndrome (SRNS) in monoclonal antibodies only paediatric patients

Rituximab Connective tissue disease 8.2.3 Anti-lymphocyte Red Hospital / Specialist monoclonal antibodies only

Rituximab 1st-line treatment of stage III-IV 8.2.3 Anti-lymphocyte Red Hospital / Specialist follicular lymphoma monoclonal antibodies only

Rituximab 1st-line maintenance treatment of 8.2.3 Anti-lymphocyte Red Hospital / Specialist follicular non-Hodgkin’s lymphoma monoclonal antibodies only

Rituximab Relapsed or refractory stage III or IV 8.2.3 Anti-lymphocyte Red Hospital / Specialist follicular non-Hodgkin's lymphoma monoclonal antibodies only

Rituximab Option for treatment of Immune 8.2.3 Antilymphocyte Red Hospital / Specialist (Idiopathic) Thromboctyopenic monoclonal antibodies only Purpura (ITP)

Rituximab Steroid sensitive nephrotic syndrome - 8.2.3 Anti-lymphocyte Red Hospital / Specialist as per NHS England policy E03/P/c monoclonal antibodies only and b

Rituximab Treatment of relapsed or refractory 8.2.3 Anti-lymphocyte Red Hospital / Specialist chronic lymphocytic leukaemia monoclonal antibodies only

Rituximab Splenic marginal zone (B cell non 8.2.3 Anti-lymphocyte Red Hospital / Specialist Hodgkin) lymphoma monoclonal antibodies only

Rituximab Splenic B cell non Hodgkin's 8.2.3 Anti-lymphocyte Red Hospital / Specialist lymphoma monoclonal antibodies only

Rituximab Aggressive non-Hodgkin's lymphoma 8.2.3 Anti-lymphocyte Red Hospital / Specialist monoclonal antibodies only

Rituximab - subcutaneous Follicular Lymphoma maintenance - 8.2.3 Anti-lymphocyte Red Hospital / Specialist injection NHS England policy Lymphoma monoclonal antibodies only maintenance Rituximab (biosimilar) RhF +ve Poly-Articular Juvenile 8.2.3 Anti-lymphocyte Red Hospital / Specialist Idiopathic Arthritis monoclonal antibodies only

Rituximab (biosimilar) Eradication of inhibitors in patients 8.2.3 Anti-lymphocyte Red Hospital / Specialist with Acquired Haemophilia (2nd line monoclonal antibodies only option)

Rituximab (biosimilar) ANCA associated vasculitis - as per 8.2.3 Anti-lymphocyte Red Hospital / Specialist NICE TA 308 and NHS England policy monoclonal antibodies only A13/P/a

Rituximab (biosimilar) Nephritis 8.2.3 Anti-lymphocyte Double Red Not recommended for monoclonal antibodies routine use / Not commissioned Rituximab (biosimilar) Primary Sjogren's syndrome (PSS) 8.2.3 Anti-lymphocyte Double Red Not recommended for monoclonal antibodies routine use / Not commissioned

Rituximab (biosimilar) Rheumatoid arthritis - with MTX after 8.2.3 Anti-lymphocyte Red Hospital / Specialist DMARDs including a TNF inhibitor monoclonal antibodies only

Printed: 14 September 2021 Page 68 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Rituximab (biosimilar) Anti-neutrophil cytoplasmic antibody- 8.2.3 Anti-lymphocyte Red Hospital / Specialist associated (ANCA) vasculitis monoclonal antibodies only

Rituximab (biosimilar) Connective tissue disease - interstitial 8.2.3 Anti-lymphocyte Double Red Not recommended for lung disease monoclonal antibodies routine use / Not commissioned

Rituximab (biosimilar) Cytopenia complicating primary 8.2.3 Anti-lymphocyte Red Hospital / Specialist immunodeficiency - as per NHS monoclonal antibodies only England policy 16044/P

Rituximab (biosimilar) Chronic inflammatory demyelinating 8.2.3 Anti-lymphocyte Double Red Not recommended for polyneuropathy monoclonal antibodies routine use / Not commissioned

Rituximab (biosimilar) Pemphigus Vulgaris - as per NHS 8.2.3 Anti-lymphocyte Red Hospital / Specialist England policy 16035/P monoclonal antibodies only

Rituximab (biosimilar) Immunoglobin G4 related disease - as 8.2.3 Anti-lymphocyte Red Hospital / Specialist per NHS England policy monoclonal antibodies only

Rituximab (biosimilar) ABO-incompatible kidney transplants - 8.2.3 Anti-lymphocyte Red Hospital / Specialist as per specification - Specialist monoclonal antibodies only centres only Rituximab (biosimilar) Graft versus host disease -as per 8.2.3 Anti-lymphocyte Red Hospital / Specialist Policy NHS England Policy 16069/P monoclonal antibodies only

Rituximab (biosimilar) Myositis - as per NHS England Policy 8.2.3 Anti-lymphocyte Red Hospital / Specialist 16035/P monoclonal antibodies only

Rituximab (biosimilar) Neuromyelitis optica 8.2.3 Anti-lymphocyte Red Hospital / Specialist monoclonal antibodies only

Rituximab (biosimilar) Systemic Lupus Erythematosus 8.2.3 Anti-lymphocyte Red Hospital / Specialist (SLE) - as per NHS England Policy monoclonal antibodies only A13/PS/a

Rituximab (biosimilar) treatment of autoimmune haemolytic 8.2.3 Anti-lymphocyte Red Hospital / Specialist anaemia (AIHA) in adults monoclonal antibodies only

Rivaroxaban Combined use with dual antiplatelet 2.8.2 Oral anticoagulants Double Red Not recommended for therapy in people who otherwise need routine use / Not anticoagulation, who have had an MI - commissioned as per NICE CG 172 - Do Not Do Rivaroxaban Anticoagulation in DC Cardioversion of 2.8.2 Oral anticoagulants In progress Prescribing Atrial Fibrillation / Atrial Flutter responsibility yet to be confirmed

Rivaroxaban Prevention of adverse outcomes after 2.8.2 Oral anticoagulants Red Hospital / Specialist acute management of acute coronary only syndrome in people with elevated cardiac biomarkers (as per NICE TA 335) Rivaroxaban For preventing atherothrombotic 2.8.2 Oral anticoagulants Green GP prescribable at events in people with coronary or request of peripheral artery disease as per Consultant/Specialist TA607 for a specific group of patients as per pathway

Rivaroxaban ▼ Prevention of venous 2.8.2 Oral anticoagulants Red Hospital / Specialist thromboembolism in adults after total only hip or total knee replacement (as per NICE TA 170)

Rivaroxaban ▼ Treatment and prevention of 2.8.2 Oral anticoagulants Green GP prescribable at pulmonary embolism as per NICE TA request of 261 (where warfarin is not Consultant/Specialist appropriate - see Full Guidance)

Rivaroxaban ▼ Treatment of deep vein thrombosis 2.8.2 Oral anticoagulants Green GP prescribable at (except calf vein DVT) and prevention request of of recurrent DVT in specified patient Consultant/Specialist groups Rivaroxaban ▼ Prevention of stroke in patients with 2.8.2 Oral anticoagulants Double-GreenSuitable for GPs to atrial fibrillation as per NICE TA 256 initiate and prescribe and local treatment pathway

Printed: 14 September 2021 Page 69 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Rivaroxaban ▼ Treatment of calf vein deep vein 2.8.2 Oral anticoagulants Red Hospital / Specialist thrombosis (as per NICE TA 261) only

Rivastigmine Mild to moderate dementia in 4.11 Drugs for dementia Green GP prescribable at Parkinson’s disease request of Consultant/Specialist

Rivastigmine Mild to moderate dementia in 4.11 Drugs for dementia Amber Option for Shared Alzheimer's Disease - as per NICE TA Care Prescribing 217

Roflumilast ▼ Adjunct to bronchodilators for 3.3.3 Phosphodiesterase Green GP prescribable at maintenance in chronic obstructive type-4 inhibitors request of pulmonary disease in adults with Consultant/Specialist chronic bronchitis and a history of frequent exacerbations - as per NICE 461

Romiplostim Chronic immune (idiopathic) 9.1.4 Drugs used in platelet Red Hospital / Specialist thrombocytopenic purpura disorders only

ronine / L-tri-iodothyronine ROUTINE use for long term for 6.2.2 Thyroid replacement Double Red Not recommended for sodium (T3) treatment of Hypothyroidism drugs routine use / Not commissioned

Ropeginterferon alfa 2b Hepatitis C 8.2.4 Other Double Red Not recommended for immunomodulating routine use / Not drugs commissioned

Ropinirole Parkinson's Disease 4.9.1 Dopaminergic drugs Green GP prescribable at used in parkinsonism request of Consultant/Specialist

Ropinirole Pharmacological neuroprotective 4.9.1 Dopamine-receptor Double Red Not recommended for therapy in Parkinson's disease agonists routine use / Not commissioned

Rotigotine Monotherapy for early and adjunct to 4.9.1 Dopaminergic drugs Green GP prescribable at levodopa in advanced stage used in parkinsonism request of Parkinson's disease Consultant/Specialist

Rotigotine Pharmacological neuroprotective 4.9.91 Dopamine-receptor Double Red Not recommended for therapy in Parkinson's disease agonists routine use / Not commissioned

Roxadustat Dialysis induced anaemia Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

RT300 (functional electrical Spinal cord injury rehabilitation - as No BNF entry Double Red Not recommended for stimulation system) per MIB 169 routine use / Not commissioned

Rubefacients Osteoarthritis - as per NICE CG 59 - 10.3.2 Rubefacients - Double Red Not recommended for Do Not Do routine use / Not commissioned

Rucaparib Maintenance of relapsed platinum- 8.1.5 Other antineoplastic Red Hospital / Specialist sensitive ovarian, fallopian tube or drugs only peritoneal cancer

Rupatadine Symptomatic relief of allergic rhinitis 3.4.1 Antihistamines Double Red Not recommended for and urticaria routine use / Not commissioned

Ruxolitinib Polycythaemia vera 8.1.5 Protein kinase Double Red Not recommended for inhibitors routine use / Not commissioned

Ruxolitinib Disease-related splenomegaly or 8.1.5 Protein kinase Red Hospital / Specialist symptoms in adults with inhibitors only myelofibrosis - as per NICE TA 386

Sacubitril / Valsartan ▼ Symptomatic chronic heart failure with 2.5 Heart failure Amber Option for Shared reduced ejection fraction in adults treatments Care Prescribing

Safety needles (insulin) Insulin administration Not listed - device Double Red Not recommended for routine use / Not commissioned

Printed: 14 September 2021 Page 70 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Safinamide Idiopathic Parkinson's disease where 4.9.1 Monoamine oxidase-B Green GP prescribable at existing oral agents are contra- inhibitors request of indicated or have failed to improve Consultant/Specialist motor fluctuations/dyskinesia Safinamide ▼ NICE Do Not Do - Pharmacological 4.9.1 Monoamine oxidase-B Double Red Not recommended for neuroprotective therapy in Parkinson's inhibitors routine use / Not disease - as per NG 71 commissioned

Sapropterin Management of Phenylkentonuria 9.4.1 Foods for special diets Red Hospital / Specialist (Tetrahydrobiopterin (BH4, (PKU) only during pregnancy only THB))

Sapropterin Treatment of children with 9.4.1 Foods for special diets Double Red Not recommended for (Tetrahydrobiopterin (BH4, phenylketonuria (PKU) routine use / Not THB)) commissioned

Saquinavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only

Sargramostim (GM-CSF) Antibody-positive pulmonary alveolar Granulocyte- Double Red Not recommended for proteinosis macrophage colony- routine use / Not stimulating factor commissioned

Sarilumab adult patients (aged 18 years and 10.1.3 Drugs affecting the Red Hospital / Specialist older) hospitalised with COVID-19 in immune response only accordance with the criteria set out in the NHS England document.as per ES34

Sarilumab ▼ Treatment of moderate to severe Not listed in the BNF Red Hospital / Specialist active rheumatoid arthritis in adults only (with and without methotrexate) - as per NICE 485

Sebelipase alfa Lysosomal acid lipase deficiency 10.3.1 Enzyme replacement Double Red Not recommended for therapy routine use / Not commissioned

Second-line drugs (DMARDs) Rheumatoid arthritis 10.1.3 Drugs which suppress Amber Option for Shared the rheumatic disease Care Prescribing process

Secukinumab Paediatric indications (where adult TA 10.1.3 Drugs that suppress Double Red Not recommended for available) the rheumatic disease routine use / Not process commissioned Secukinumab ▼ Treatment of moderate to severe 10.1.3 Drugs that suppress Red Hospital / Specialist plaque psoriasis - as per NICE TA 350 the rheumatic disease only and the local treatment pathway process

Secukinumab ▼ Active ankylosing spondylitis after 10.1.3 Drugs that suppress Red Hospital / Specialist treatment with non-steroidal anti- the rheumatic disease only inflammatory drugs or TNF-alpha process inhibitors - as per NICE TA 407 and local treatment pathway

Secukinumab ▼ (with or Active psoriatic arthritis after 10.1.3 Drugs that suppress Red Hospital / Specialist without MTX) inadequate response to DMARDs - as the rheumatic disease only per NICE TA 445 and local treatment process pathway Selective internal radiation hepatocellular carcinoma as per TA688 Not listed - Devices Red Hospital / Specialist therapies only

Selegiline NICE Do Not Do - Pharmacological 4.9.1 Monoamine oxidase-B Double Red Not recommended for neuroprotective therapy in Parkinson's inhibitors routine use / Not disease - as per NG 71 commissioned Selexipag Pulmonary arterial hypertension - as 2.5.1 Selective prostacyclin Double Red Not recommended for per NHSE policy (IP) receptor agonist routine use / Not commissioned

Selinexor with low-dose dexamethasone for 8.1.5 Other antineoplastic Double Red Not recommended for treating refractory multiple myeloma drugs routine use / Not (TA700 - terminated appraisal) commissioned

Printed: 14 September 2021 Page 71 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Semaglutide For adults with insufficiently controlled 6.1.2.3 Glucagon-Like Green GP prescribable at type 2 diabetes mellitus as adjunct to Peptide-1 receptor request of diet and exercise - monotherapy (if Agonists Consultant/Specialist metformin inappropriate) or in combination with other antidiabetic drugs as per local Diabetes Formulary guidance - 3rd line option Semaglutide oral preparations Diabetic patients where GLP1 6.1.2.3 Other antidiabetic Green GP prescribable at analogue is indicated but oral drugs request of preparation is more suitable Consultant/Specialist

Setrobuvir Viral Hepatitis C - as per NHSE policy 5.3.3 Not listed in the BNF - Double Red Not recommended for Antiviral drug routine use / Not commissioned

Sevelamer Hyperphosphataemia in chronic renal 9.5.2.2 Phosphate-binding Green GP prescribable at failure in patients on haemodialysis agents request of and on treatment Consultant/Specialist

Sialic acid Myopathy - as per NHSE policy Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Sildenafil Connective tissue diseases 2.5.1 Vasodilator Red Hospital / Specialist antihypertensive drug only

Sildenafil Use of regular, daily doses for penile 7.4.5 Drugs for erectile Double Red Not recommended for rehabilitation in prostate cancer/post dysfunction routine use / Not radical prostatectomy commissioned

Sildenafil (as Viagra®) Erectile dysfunction - limited 7.4.5 Drugs for impotence Double-GreenSuitable for GPs to categories under SLS initiate and prescribe

Sildenafil (generic plain Digital ulceration in severe secondary 2.5.1 Vasodilator Green GP prescribable at tablets only) Raynaud’s phenomenon associated antihypertensive drug request of with systemic sclerosis Consultant/Specialist Sildenafil (generic) Erectile dysfunction (any cause) 7.4.5 Drugs for impotence Double-GreenSuitable for GPs to initiate and prescribe

Sildenafil (Revatio®) Pulmonary Arterial Hypertension 2.5.1 Vasodilator Red Hospital / Specialist antihypertensive drug only

Silicone gel sheet dressing Reduce and prevent hypertrophic and Not listed - Double red Not recommended for keloid scarring Hydrocolloid dressing routine use / Not commissioned

Silk garments Dermatology Not listed Double Red Not recommended for routine use / Not commissioned

Simeprevir For treating genotype 1 or 4 chronic 5.3.3.2 Antiviral drugs Double Red Not recommended for hepatitis C in combination with routine use / Not sofosbuvir (Sovaldi®) commissioned

Simeprevir Treatment of genotypes 1 and 4 5.3.3.2 Antiviral drugs Red Hospital / Specialist chronic hepatitis C only

Simeprevir / Peginterferon + Hepatitis C - as per NHSE policy 8.2.4 Other Red Hospital / Specialist Ribavirin immunomodulating only drugs

Siponimod secondary progressive multiple 8.2.4 Other Red Hospital / Specialist sclerosis as per TA656 immunomodulating only drugs

Sipuleucel-T Treatment of adults with Not listed in the BNF Double Red Not recommended for asymptomatic or minimally routine use / Not symptomatic metastatic hormone commissioned relapsed prostate cancer

Sirolimus Initial treatment to prevent organ 8.2.2 Corticosteroids and Double Red Not recommended for rejection in adults, children and young other routine use / Not people having a kidney transplant - as immunosuppressants commissioned per NICE TAs 481 & 482

Sirolimus Immunosuppression in adult renal 8.2.2 Corticosteroids and Amber Option for Shared transplantation - as per NICE TA 481 other Care Prescribing immunosuppressants

Printed: 14 September 2021 Page 72 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Sirukumab Paediatric indications (where adult TA 10.1.3 Drugs which suppress Double Red Not recommended for available) - as per NHSE policy the rheumatic disease routine use / Not process commissioned

Sitagliptin Type 2 diabetes - restricted use as per 6.1.2 Antidiabetic drugs Double-GreenSuitable for GPs to agreed criteria initiate and prescribe

Smart One (portable Measuring lung function Not listed Double Red Not recommended for spirometer) routine use / Not commissioned

Smartinhaler Asthma Not listed Double Red Not recommended for routine use / Not commissioned

Sodium Chloride (Hypertonic 3- Prevent exacerbations in people with 3.7 Mucolytics Double Red Not recommended for 7%) as a mucolytic stable chronic obstructive pulmonary routine use / Not disease (COPD) - as per NICE CG commissioned 101 - Do Not Do

Sodium Chloride (Hypertonic 3- Clearance of mucosal secretions in 3.7 Mucolytics Red Hospital / Specialist 7%) for inhalation Cystic Fibrosis and Bronchiectasis only

Sodium chloride nasal Nasal congestion and sinusitis Not listed in the BNF Double Red Not recommended for appliance routine use / Not commissioned

Sodium Clodronate Bone pain associated with bony 6.6.2 Drugs affecting Bone Green GP prescribable at metastases Metabolism request of Consultant/Specialist

Sodium oxybate Cataplexy associated with narcolepsy 4.1.1 Hypnotics Red Hospital / Specialist in adults aged ≥19 years (under only specialist supervision)

Sodium oxybate Management of narcolepsy with 4.1.1 Hypnotics Red Hospital / Specialist cataplexy in children aged <19 years only (specialist centre use only - commisioned by NHS England) Sodium Phenylbutyrate Acute hyperammonaemia due to urea 9.8.1 Drugs used in Red Hospital / Specialist cycle disorders (specialist use only) metabolic disorders only

Sodium valproate ▼/ Augmentation of an antidepressant - 4.8.1 Control of the Double Red Not recommended for semisodium ▼ as per NICE CG 90 - Do Not Do epilepsies routine use / Not commissioned

Sodium zirconium cyclosilicate Hyperkalaemia in adults - emergency 9.2.1.1 Nutrition and Blood Red Hospital / Specialist care only

Sodium zirconium cyclosilicate Hyperkalaemia in adults - continued 9.2.1.1 Nutrition and Blood Double Red Not recommended for use routine use / Not commissioned

Sofosbuvir ▼ Treatment of chronic hepatitis C in 5.3.3.2 Antiviral drugs Red Hospital / Specialist adults - as per NICE TA 330 and only NHSE policy

Sofosbuvir-velpatasvir ▼ Chronic hepatitis C in adults - as pert 5.3.3.2 Antiviral drugs Red Hospital / Specialist NICE TA 430 and NHSE policy only

Sofosbuvir-velpatasvir- Chronic hepatitis C in adults 5.3.3.2 Antiviral drugs Red Hospital / Specialist voxilaprevir ▼ only

Solifenacin Urge incontinence - only where all 7.4.2 Urinary frequency, Double-GreenSuitable for GPs to other appropriate drug therapies have enuresis & initiate and prescribe been tried incontinence drugs

Somatropin (Growth hormone) Children with growth failure with 6.5.1 Hypothalamic & Red Hospital / Specialist growth hormone deficiency, Turner anterior pituitary only syndrome, Prader-Willi syndrome and hormones etc. chronic renal insufficiency - as per NICE TA 188 and East of England PAC policy

Somatropin (Growth Hormone) Growth disturbance in children born 6.5.1 Hypothalamic & Red Hospital / Specialist small for gestational age - as per anterior pituitary only NICE TA 188 and East of England hormones etc PAC policy

Printed: 14 September 2021 Page 73 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Somatropin (Growth hormone) Adults: Profound growth hormone 6.5.1 Hypothalamic & Red Hospital / Specialist deficiency anterior pituitary only hormones etc.

Sorafenib Treatment of advanced hepatocellular 8.1.5 Other antineoplastic Red Hospital / Specialist carcinoma as per NICE TA 474 / drugs only treatment of papillary or follicular thyroid cancer

Sorafenib (with lenvatinib) ▼ Treatment of progressive, locally 8.1.5 Other antineoplastic Red Hospital / Specialist advanced or metastatic differentiated drugs only thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine - as per NICE TA 535

Sotagliflozin type 1 diabetes as per NICE TA622 - 6.1.2.3 Other antidiabetic Double Red Not recommended for Feb 2020 drugs routine use / Not commissioned

Spatone Iron supplement Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

SSRI antidepressants Use for depression in children and 4.3.3 Selective serotonin re- Green GP prescribable at young people (only with talking uptake inhibitors request of therapies) - as per NICE CG 28 Consultant/Specialist

St Mark's solution (ready Oral rehydration solution (ORS) which Not listed in the BNF - Double Red Not recommended for made) is used in the management of Short unlicensed special routine use / Not Bowel Syndrome commissioned Statins Prevention of coronary events in 2.12 Lipid-regulating drugs Double-GreenSuitable for GPs to patients with Type II diabetes initiate and prescribe

Stavudine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs when no suitable only alternative available and when prescribed for shortest period possible

Stiripentol For SCN1A related and Severe 4.8.1 Control of epilepsy Double Red Not recommended for Myoclonic Epilepsies in Infancy routine use / Not commissioned

Strimvelis Adenosine deaminase deficiency - Not listed Double Red Not recommended for severe combined immunodeficiency routine use / Not (ADA-SCID) - as per NICE HST 7 commissioned

Strontium ranelate ▼ Secondary prevention of osteoporotic 6.6.2 Bisphosphonates Double Red Not recommended for fragility fractures in postmenopausal (drugs affecting bone routine use / Not women (last line option) metabolism) commissioned

Strontium ranelate ▼ Primary prevention of osteoporotic 6.6.2 Bisphosphonates Double Red Not recommended for (discontinued August 2017) fragility fractures in postmenopausal (drugs affecting bone routine use / Not women (last line option) metabolism) commissioned

Sucroferric oxyhydroxide Control serum phosphorus in dialysis 9.5.2.2 Phosphate-binding Red Hospital / Specialist agents only

Sulfasalazine Inflammatory Arthritis and 10.1.3 Drugs that suppress Amber Option for Shared Inflammatory Bowel Disease the rheumatic disease Care Prescribing process

Sumatriptan (as Imigran Acute migraine; cluster headaches 4.7.4.1 Treatment of acute Double Red Not recommended for RADIS®) migraine routine use / Not commissioned

Sunitinib Second-line treatment of advanced 8.1.5 Antineoplastic drugs - Double red Not recommended for and/or metastatic renal cell carcinoma protein kinase routine use / Not inhibitors commissioned

Sunitinib Unresectable or metastatic 8.1.5 Other antineoplastic Red Hospital / Specialist neuroendocrine tumours in people drugs only with progressive disease in adults - as per NICE TA 449

Sunitinib Treatment of gastrointestinal stromal 8.1.5 Other antineoplastic Red Hospital / Specialist tumours drugs only

Printed: 14 September 2021 Page 74 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Sunitinib First-line for advanced and/or 8.1.5 Antineoplastics - Red Hospital / Specialist metastatic renal cell carcinoma protein kinase only inhibitors

Susoctocog alfa Antihaemorrhagics, blood coagulation 2.11 Haemophilia A Double Red Not recommended for factor VIII (congenital factor VIII routine use / Not deficiency) commissioned Tabalumab Systemic Lupus Erythematosus (SLE) Anti-B-cell activating Double Red Not recommended for factor h. monoclonal routine use / Not AB commissioned

Tacrolimus (oral) Induction of remission, in combination 8.2.2 Immunosuppressants Amber Option for Shared with steroids, in patients with mild- Care Prescribing moderate Ulcerative Colitis which is unresponsive to steroids and 5-ASA preparations

Tacrolimus (oral) Immunosuppressive therapy to 8.2.2 Corticosteroids and Amber Option for Shared prevent organ rejection in renal other Care Prescribing transplant in adults - as per NICE TA immunosuppressants 481 Tacrolimus (oral) - immediate Immunosuppressive therapy to 8.2.2 Corticosteroids and Red Hospital / Specialist release prevent organ rejection in kidney immunosuppressants only transplant in children and young people - as per NICE TA 482

Tacrolimus (oral) - prolonged Initial treatments to prevent organ 8.2.2 Corticosteroids and Double Red Not recommended for release rejection in adults, children and young immunosuppressants routine use / Not people having a kidney transplant - as commissioned per NICE Tas 481 and 482

Tacrolimus 0.03% Ointment ▼ Option for 2nd line treatment of 13.5.3 Affecting immune Green GP prescribable at moderate to severe atopic eczema in response for eczema request of adults and children over 2 years not & psoriasis Consultant/Specialist controlled by topical steroids where there is serious risk of important ADRs further topical steroid use - as per NICE CG 57

Tadalafil (Adcirca) Pulmonary Arterial Hypertension 2.5.1 Vasodilator Red Hospital / Specialist antihypertensive drugs only

Tadalafil (Adcirca) Pulmonary Arterial Hypertension 2.5.1 Vasodilator Special Special contract - not antihypertenisive drugs for GP prescribing

Tadalafil (Adcirca) Raynaud’s disease or connective 2.5.1 Vasodilator Red Hospital / Specialist tissue diseases antihypertensive drug only

Tadalafil (Cialis) Treatment of symptoms associated 7.4.5 Phosphodiesterase Double red Not recommended for with benign prostatic hyperplasia type-5 inhibitors routine use / Not commissioned

Tadalafil (Cialis) Use of regular, daily doses for penile 7.4.5 Drugs for erectile Double Red Not recommended for rehabilitation in prostate cancer/post dysfunction routine use / Not radical prostatectomy commissioned

Tadalafil 10mg & 20mg Erectile dysfunction - as required use 7.4.5 Drugs for erectile Double-GreenSuitable for GPs to strength tablets for prn use as per SLS criteria - max 4 doses per dysfunction initiate and prescribe month (NOT regular daily use)

Tadalafil taken once every day Erectile dysfunction/penile 7.4.5 Drugs for erectile Double Red Not recommended for rehabilitation dysfunction routine use / Not commissioned

Tafamidis Amylodosis - Treatment of Neuroprotective drugs Double Red Not recommended for transthyretin familial amyloid routine use / Not polyneuropathy commissioned

Tafamidis transthyretin amyloidosis with 2.14 Cardiovascular Double Red Not recommended for cardiomyopathy as per TA696 system - miscellaneous routine use / Not commissioned

Taliglucerase alfa Gaucher's Disease 9.8.1 Drugs used in Red Hospital / Specialist metabolic disorders only

Printed: 14 September 2021 Page 75 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Talimogene laherparepvec ▼ Unresectable, regionally or distantly Not listed Red Hospital / Specialist metastatic (Stage IIIB, IIIC or IVM1a) only melanoma that has not spread to bone, brain, lung or other internal organs, only if treatment with systemically administered immunotherapies is not suitable Tamoxifen Chemoprophylaxis for no more than 5 8.3.4 Hormone antagonists Green GP prescribable at years for pre- or post-menopausal request of women at either high or moderate risk Consultant/Specialist of developing breast cancer

Tapentadol (immediate- Management of moderate to severe 4.7.2 Opioid analgesics Double red Not recommended for pain in adults, where opioid analgesia routine use / Not is necessary commissioned

Tapentadol (modified-release) Severe chronic pain in adults with 4.7.2 Opioid analgesics Green GP prescribable at intolerance to m-r morphine, which request of can be adequately managed only with Consultant/Specialist opioid analgesics

Taribavirin (viramidine) Viral Hepatitis C 5.3 Antiviral drugs Double Red Not recommended for routine use / Not commissioned

Teduglutide Short bowel syndrome Glucagon-like peptide- Double Red Not recommended for 2 (GLP-2) analogue routine use / Not commissioned

Teduglutide short bowel syndrome as per TA690 1.4.2 Antimotility drugs Double Red Not recommended for (terminated) routine use / Not commissioned

Tegafur with uracil All indications 8.1.3 Antimetabolites Red Hospital / Specialist only

Teicoplanin Intravenous treatment at home 5.1.7 Some other Red Hospital / Specialist antibacterials only

Teicoplanin Intramuscular treatment at home 5.1.7 Some other Green GP prescribable at antibacterials request of Consultant/Specialist

Telaprevir Treatment of genotype 1 chronic 5.3.3 Viral hepatitis Red Hospital / Specialist hepatitis C only

Telbivudine Chronic hepatitis B 5.3.3 Viral hepatitis Double red Not recommended for routine use / Not commissioned

Temozolomide Malignant glioma (brain cancer) 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Temsirolimus Treatment of relapsed or refractory 8.1.5 Antineoplastic drug - Double red Not recommended for mantle cell lymphoma protein kinase inhibitor routine use / Not commissioned

Temsirolimus First-line treatment of advanced 8.1.5 Antineoplastic drugs - Red Hospital / Specialist and/or metastatic renal cell carcinoma protein kinase only inhibitors

Tenofovir alafenamide HIV in combination with other anti- 5.3.1 Nucleoside reverse Red Hospital / Specialist fumarate retroviral drugs - as per NHS England transcriptase inhibitors only Policy 16043/P

Tenofovir alafenamide Chronic Hepatitis B 5.3.1 Nucleoside reverse Double Red Not recommended for fumarate ▼ transcriptase inhibitors routine use / Not commissioned

Tenofovir disoproxil Treatment of chronic hepatitis B 5.3.1 HIV infection Red Hospital / Specialist only

Teriflunomide ▼ Relapsing remitting multiple sclerosis 8.2 Drugs affecting the Red Hospital / Specialist immune response only

Teriparatide Osteogenesis imperfecta - as per NHS 6.6.1 Calcitonin and Double Red Not recommended for England Policy 16002/P parathyroid hormone routine use / Not commissioned

Printed: 14 September 2021 Page 76 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Teriparatide Secondary prevention of osteoporotic 6.6.1 Calcitonin and Red Hospital / Specialist fragility fractures in postmenopausal parathyroid hormone only women

Teriparatide Male and juvenile osteoporosis 6.6.1 Calcitonin and Double Red Not recommended for parathyroid hormone routine use / Not commissioned

Testosterone management of boys with 6.4.2 Male sex hormones Amber Option for Shared absent/delayed puberty requiring and antagonists Care Prescribing exogenous testosterone therapy

Testosterone - transdermal Hormone replacement in androgen 6.4.2 Male sex hormones Double Red Not recommended for patches deficiency and antagonists routine use / Not commissioned

Testosterone - various Androgen deficiency / treatment of 6.4.2 Male sex hormones Green GP prescribable at formulations except patches transgender patients requiring virilising and antagonists request of endocrine therapy Consultant/Specialist

Tetrahydrobiopterin (BH4, Phenylketonuria (PKU) - Specialist 9.4.1 Tetrahydrobiopterin Red Hospital / Specialist THB) - aka Sapropterin centres only - Highly specialised and derivatives only criteria only

Tezacaftor Cystic Fibrosis 3.7 Mucolytics Double Red Not recommended for routine use / Not commissioned

Tezacaftor, Ivacaftor and treat eligible patients 12 years and 3.7 Mucolytics Red Hospital / Specialist Elexacaftor over who have cystic fibrosis only

Thalidomide Multiple myeloma (first-line) 8.2.4 Other Red Hospital / Specialist immunomodulating only drugss

Thrombin Pseudoaneurysm - as per NICE IPG060 Red Hospital / Specialist IPG060 only

Thyroxine (Levothyroxine Chronic fatigue syndrome/myalgic 6.2.1 Thyroid hormones Double Red Not recommended for sodium) encephalomyelitis (or routine use / Not encephalopathy) - as per NICE CG commissioned 53 - Do Not Do

Thyroxine (Levothyroxine Augmentation of an antidepressant - 6.2.1 Thyroid hormones Double Red Not recommended for sodium) / Liothyronine as per NICE CG 90 - Do Not Do routine use / Not commissioned

Ticagrelor In combination with aspirin for 2.9 Antiplatelet drugs Green GP prescribable at preventing atherothrombotic events request of who had a myocardial infarction and Consultant/Specialist who are at high risk of a further event as per NICE TA 420 Ticagrelor (With aspirin) to prevent 2.9 Antiplatelet drugs Green GP prescribable at atherothrombotic events in patients request of with ACS as per NICE TA 236 Consultant/Specialist

Tildrakizumab Moderate to severe plaque psoriasis in 13.5.3 Drugs affecting the Red Hospital / Specialist adults - as per NICE TA 575 and local immune response only treatment pathway

Tioconazole Fungal nail infections 13.10.2 Antifungal preparations Double Red Not recommended for routine use / Not commissioned

Tioguanine All indications 8.1.3 Antimetabolites Red Hospital / Specialist only

Tiotropium Maintenance treatment of Chronic 3.1.2 Antimuscarinic Double-GreenSuitable for GPs to Obstructive Pulmonary Disease bronchodilators initiate and prescribe

Tipranavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs - as per BHIVA only Guidelines

Tirofiban Prevention of MI in unstable angina 2.9 Antiplatelet drugs Red Hospital / Specialist only

Printed: 14 September 2021 Page 77 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Tisagenlecleucel For treating relapsed or refractory Not listed in the BNF Red Hospital / Specialist diffuse large B-cell lymphoma after 2 only or more systemic therapies - as per NICE 567 (NHSE commissioning responsibility) Tisagenlecleucel Relapsed or refractory B-cell acute Not listed in the BNF Red Hospital / Specialist lymphoblastic leukaemia in people only aged up to 25 years - as per NICE TA 554

Tivozanib Advanced renal cell carcinoma - as 8.1.5 Protein kinase Red Hospital / Specialist per NICE TA 512 inhibitors only

Tobramycin (nebulised) Pseudomonas aeruginosa infection in 5.1.4 Aminoglycosides Red Hospital / Specialist patients with Cystic Fibrosis only

Tobramycin Dry Powder Pseudomonas lung infection in Cystic 5.1.4 Aminoglycosides Red Hospital / Specialist Fibrosis only

Tocilizumab adult patients (aged 18 years and 10.1.3 Drugs affecting the Red Hospital / Specialist older) hospitalised with COVID-19 in immune response only accordance with the criteria set out in the NHS England document.as per ES33

Tocilizumab Systemic juvenile idiopathic arthritis - 10.1.3 Drugs that suppress Red Hospital / Specialist as per NICE TA 238 the rheumatic disease only process

Tocilizumab (monotherapy) 5th line monotherapy in moderate to 10.1.3 Drugs that suppress Red Hospital / Specialist severe rheumatoid arthritis the rheumatic disease only process

Tocilizumab (with Rheumatoid arthritis in adults - as per 10.1.3 Drugs that suppress Red Hospital / Specialist methotrexate) NICE TA 247 the rheumatic disease only process

Tocilizumab IV Juvenile arthritis paediatric (where 10.1.3 Drugs that suppress Red Hospital / Specialist adult TA available - as per TA 247 & the rheumatic disease only 375)) process

Tocilizumab IV Treatment of giant cell arteritis - as 10.1.3 Drugs that suppress Double Red Not recommended for per NHS England Policy 16019/P the rheumatic disease routine use / Not process commissioned

Tocilizumab IV Juvenile arthritis paediatric - as per 10.1.3 Drugs that suppress Red Hospital / Specialist NHS England Policy E03/P/d & NICE the rheumatic disease only TA 373 process

Tocilizumab IV Takayasu arteritis - as per NHS 10.3.1 Drugs that suppress Red Hospital / Specialist England policy 16056/P the rheumatic disease only process

Tofacitinib Active psoriatic arthritis in adults after 10.1.3 Drugs that suppress Red Hospital / Specialist inadequate response to DMARDs the rheumatic disease only under certain conditions - as per NICE process TA 543 and local business application

Tofacitinib Moderately to severely active 10.1.3 Drugs that suppress Red Hospital / Specialist ulcerative colitis in adults - as per the rheumatic disease only NICE TA 547 (option after biosimilar process adalimumab) Tofacitinib ▼ Treatment of moderate to severe 10.1.3 Drugs that suppress Red Hospital / Specialist active rheumatoid arthritis in adults the rheumatic disease only (with and without methotrexate) - as process per NICE TA 480 and local pathway

Tolvaptan Hyponatraemia in cancer - as per NHS 6.5.2 Posterior pituitary Red Hospital / Specialist England Policy 16051/P hormones and only antagonists

Tolvaptan ▼ Autosomal dominant polycystic kidney 6.5.2 Posterior pituitary Red Hospital / Specialist disease in adults - NICE TA 358 hormones and only antagonists

Topotecan Advanced ovarian cancer 8.1.5 Topoisomerase I Red Hospital / Specialist inhibitors only

Printed: 14 September 2021 Page 78 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Topotecan Treatment of advanced recurrent 8.1.5 Topoisomerase I Double Red Not recommended for ovarian cancer inhibitors routine use / Not commissioned

Topotecan Treatment of recurrent and stage IVB 8.1.5 Other antineoplastic Red Hospital / Specialist cervical cancer drugs only

Topotecan (oral) Treatment of relapsed small-cell lung 8.1.5 Other antineoplastic Red Hospital / Specialist cancer drugs only

Total parenteral nutrition Various 9.3 Intravenous nutrition Special Special contract - not for GP prescribing

Total parenteral nutrition Various 9.3 Intravenous nutrition Red Hospital / Specialist only

Trabectedin (In combination with pegylated 8.1.5 Other antineoplastic Double red Not recommended for liposomal doxorubicin HCl) for drugs routine use / Not relapsed ovarian cancer commissioned

Trabectedin Treatment of advanced soft tissue 8.1.5 Other antineoplastic Red Hospital / Specialist sarcoma agents only

Tralokinumab Asthma 3.4.2 Monoclonal Double Red Not recommended for antibodies - allergen routine use / Not immunotherapy commissioned

Tramadol & paracetamol Moderate to severe pain 4.7.1 Non opiod analgesics Double Red Not recommended for combination & compound routine use / Not analgesic preps commissioned

Trametinib (with dabrafenib (Tafinlar®)) for 8.1.5 Other antineoplastic Double Red Not recommended for treating advanced metastatic BRAF agents routine use / Not V600E mutation-positive non-small- commissioned cell lung cancer - as per NICE TA 564

Trametinib ▼ Unresectable or metastatic melanoma 8.1.5 Other antineoplastic Red Hospital / Specialist in adults with a BRAF V600 mutation drugs only (with dabrafenib)

Transanal irrigation /Rectal Bowel dysfunction; Chronic Not listed - Continence Green GP prescribable at Irrigation appliances constipation; Faecal incontinence. care appliances request of Initiation by hospital consultants for Consultant/Specialist adults acro

Transanal irrigation/Rectal Chronic Constipation and Faecal Not listed - Continence Green GP prescribable at Irrigation appliances Incontinence (as recommended by the care appliances request of NCH&C Adult Continence Service only Consultant/Specialist ) - as an option as per agreed treatment pathways

Transanal irrigation/Rectal Chronic Constipation and Faecal Not listed - Continence Green GP prescribable at Irrigation appliances Incontinence in Paediatrics (as care appliances request of recommended by the NNUH Consultant/Specialist Paediatrics Service) - as per agreed treatment pathway

Trastuzumab Advanced breast cancer 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Trastuzumab Adjuvant treatment of early-stage 8.1.5 Other antineoplastic Red Hospital / Specialist HER2-positive breast cancer drugs only

Trastuzumab In combination with an aromatase 8.1.5 Other antineoplastic Double red Not recommended for inhibitor, 1st-line treatment of agents routine use / Not metastatic hormone-receptor-positive commissioned breast cancer that overexpresses HER2

Trastuzumab HER2-positive metastatic gastric 8.1.5 Another antineoplastic Red Hospital / Specialist cancer drugs only

Trastuzumab deruxtecan HER2-positive unresectable or 8.1.5 Other antineoplastic Red Hospital / Specialist metastatic breast cancer after 2 or drugs only more anti-HER2 therapies as per TA704

Trastuzumab emtansine adjuvant treatment of HER2-positive 8.1.5 Other antineoplastic Red Hospital / Specialist early breast cancer as per TA632 drugs only (June 2020)

Printed: 14 September 2021 Page 79 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Trastuzumab emtansine ▼ HER2-positive, unresectable locally 8.1.5 Other antineoplastic Red Hospital / Specialist advanced or metastatic breast cancer, drugs only after treatment with trastuzumab and a taxane (paclitaxel or docetaxel) as per NICE TA 458 Trenonacog alpha Haemophilia B 2.11 Antifibrinolytic drugs Double Red Not recommended for and haemostatics routine use / Not commissioned

Treosulfan with fludarabine for malignant disease 8.1.1 Alkylating drugs Red Hospital / Specialist before allogeneic stem cell transplant only as per TA640

Treosulfan All indications 8.1.1 Alkylating drugs Red Hospital / Specialist only

Treprostinil Peripheral Arterial Hypertension 2.5.1 Vasodilator Double red Not recommended for antihyeprtensive drugs routine use / Not (not listed UK) commissioned

Treprostinil diethanolamine Pulmonary Arterial Hypertension 2.5.1 Vasodilator Double Red Not recommended for antihypertensive drugs routine use / Not (unlicensed) commissioned

Treprostinil sodium Pulmonary Arterial Hypertension - as 2.5.1 Vasodilator Double Red Not recommended for per NHS England policy A11/P/c anithypertensive drugs routine use / Not commissioned

Trientene dihydrochloride Wilson's Disease (where penicillamine 10.1.3 Copper chelators - Double Red Not recommended for not tolerated) rheumatic disease routine use / Not suppressants commissioned

Trifluridine–tipiracil metastatic gastric cancer or gastro- 8.1.5 Other antineoplastic Double Red Not recommended for oesophageal junction adenocarcinoma drugs routine use / Not after 2 or more therapies as per TA669 commissioned

Trifluridine-tipiracil ▼ For previously treated metastatic 8.1 Not listed in BNF Red Hospital / Specialist colorectal cancer only

Trihexyphenidyl hydrochloride NICE Do Not Do - Dyskinesia and/or 4.9.2 Antimuscarinic drugs Double Red Not recommended for motor fluctuations in Parkinson's used in parkinsonism routine use / Not disease - as per NG 71 commissioned

Tri-Luma® Melasma (Chloasma) Not listed Double Red Not recommended for routine use / Not commissioned

Trimipramine Treatment of depressive illness, 4.3.1 Tricyclic and related Double Red Not recommended for especially where sleep disturbance, antidepressant drugs routine use / Not anxiety or agitation are presenting commissioned symptoms

Triptorelin Management of endometriosis; pre- 6.7.2 Drugs affecting Amber Option for Shared operative management of uterine gonadotrophins Care Prescribing fibroids

Triptorelin Treatment of precocious puberty, 8.3.4 Hormone antagonists Amber Option for Shared menorrhagia and dysmenorrhoea in Care Prescribing children

Triptorelin acetate Prostate cancer 6.7.2 Drugs affecting Green GP prescribable at gonadotrophins request of Consultant/Specialist

Turoctocog alfa Haemophilia A - as per BCSH Not listed in the BNF Red Hospital / Specialist Guidelines only

Ulipristal ▼ (Esmya®) First line option for treatment of 6.4.1.2 Progesterone receptor Red Hospital / Specialist symptoms of fibroids ≥ 3cm and with modulators only Hb ≤102g/L

Ulipristal acetate Emergency contraception from 72 to 7.3.5 Emergency Double-GreenSuitable for GPs to 120 hours following unprotected Contraception initiate and prescribe sexual intercourse

Ulipristal acetate ▼ (Esmya®) Pre-operative treatment of moderate 6.4.1.2 Progesterone receptor Red Hospital / Specialist to severe symptoms of uterine fibroids modulators only

Unlicensed drugs Various Not listed Red Hospital / Specialist only

Printed: 14 September 2021 Page 80 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Unloading knee braces Support for knee joint Not listed in BNF Double Red Not recommended for routine use / Not commissioned

Upadacitinib severe rheumatoid arthritis as per 10.1.3 Drugs affecting the Red Hospital / Specialist TA665 immune response only

Uroshield catheter device preventing catheter-related urinary Not listed in the BNF Double Red Not recommended for infections routine use / Not commissioned

Ustekinumab Dose escalation in the treatment of 13.5.3 Drugs affecting the Red Hospital / Specialist severe psoriasis which has responded immune reponse only inadequately to the initial ustekinumab dosage regimen

Ustekinumab Treatment of psoriasis and psoriatic 13.5.3 Drugs affecting the Red Hospital / Specialist arthritis in Paediatrics (where an adult immune response only NICE guidance is available - TAs 180, 340) - NHSE policy Ustekinumab Treatment of active psoriatic arthritis, 13.5.3 Drugs affecting the Red Hospital / Specialist as monotherapy or in combination with immune response only methotrexate, following inadequate response to previous non-biological DMARDs - as per NICE TA 340 and local treatment pathway

Ustekinumab 2nd line (biologic) option for 13.5.3 Drugs affecting the Red Hospital / Specialist moderately to severely active Crohn’s immune response only disease after previous treatment - as per NICE 456 and local treatment pathway

Ustekinumab Plaque psoriasis in children and young 13.5.3 Drugs affecting the Red Hospital / Specialist people - as per NICE TA 455 immune response only

Ustekinumab for treating moderately to severely 13.5.3 Drugs affecting the Red Hospital / Specialist active ulcerative colitis as per TA633 immune response only (June 2020)

Ustekinumab Treatment of adults with moderate to 13.5.3 Drugs affecting the Red Hospital / Specialist severe psoriasis - as per NICE TA 180 immune response only and CG153

Vacuum dressings Healing of chronic wounds Not listed in the BNF - Double red Not recommended for device routine use / Not commissioned

Vacuum pumps / devices for Erectile dysfunction 7.4.5 Erectile dysfunction Red Hospital / Specialist erectile dysfunction treatments only

Vadadustat Anaemia in chronic kidney disease in Not listed in the BNF Double Red Not recommended for dialysis routine use / Not commissioned

Vaginal dilators or trainers Following vaginal reconstruction No BNF entry Red Hospital / Specialist surgery or following pelvic only radiotherapy when recommended by an appropriate Secondary Care Specialist

Valganciclovir Prevention of CMV disease following 5.3.2.2 Cytomegalovirus Red Hospital / Specialist solid organ transplantation infection only

Valsartan / Amlodipine Hypertension 2.6.2 Calcium-channel Double Red Not recommended for blockers routine use / Not commissioned

Vandetanib For treating aggressive and 8.1.5 Protein kinase Double Red Not recommended for symptomatic medullary thyroid cancer inhibitor - Not listed in routine use / Not in adults with unresectable, locally the BNF commissioned advanced or metastatic disease - as per NICE TA 550 Vardenafil Use of regular, daily doses for penile 7.4.5 Drugs for erectile Double Red Not recommended for rehabilitation in prostate cancer/post dysfunction routine use / Not radical prostatectomy commissioned

Printed: 14 September 2021 Page 81 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Varenicline Adjunct to smoking cessation in 4.10 Drugs used in Green GP prescribable at combination with motivational substance dependence request of support - Public Health England Consultant/Specialist commissioning responsibility - as per NICE TA 123 Vedolizumab Paediatric indications (where an adult 1.5.3 Drugs affecting the Red Hospital / Specialist NICE TA is available - TAs 342 & immune response only 352)) - Specialist Centre only

Vedolizumab ▼ 3rd line (biologic) treatment option for 1.5.3 Drugs affecting the Red Hospital / Specialist moderately to severely active immune response only ulcerative colitis in adults - as per NICE TA 342 and the local treatment pathway

Vedolizumab ▼ 3rd line biologic treatment option for 1.5.3 Drugs affecting the Red Hospital / Specialist moderately to severely active Crohn's immune response only disease - as per NICE TA 352 and local treatment pathway

Velaglucerase alfa Type I Gaucher’s disease (specialist 9.8.1 Enzymes used in Red Hospital / Specialist use only) - as per NHS England metabolic disorders only specification

Velcalcetide (aka Etelcalcetide) Secondary hyperparathyroidism in 9.5.1.2 Bone resorption Double Red Not recommended for patients with chronic kidney disease inhibitor routine use / Not on haemodialysis commissioned

Vemurafenib Melanoma (BRAF V600 mutation 8.1.5 Other antineoplastic Red Hospital / Specialist positive, unresectable metastatic) drugs only

Venetoclax with obinutuzumab for untreated 8.1.5 Other antineoplastic Red Hospital / Specialist chronic lymphocytic leukaemia as per drugs only TA663

Venetoclax (with rituximab) for treating chronic 8.1.5 Other antineoplastic Red Hospital / Specialist lymphocytic leukaemia in adults who drugs only have had at least 1 previous therapy - as per NICE TA 561

Venetoclax ▼ Chronic lymphocytic leukaemia 8.1.5 Other antineoplastic Red Hospital / Specialist drugs only

Venlafaxine Depression in children and young 4.3.4 Serotonin & Double Red Not recommended for people - as per NICE CG 28 "Do Not noradrenaline re- routine use / Not Do" uptake inhibitors commissioned

Vernakalant rapid conversion of recent onset atrial 2.3.2 Supraventricular Double Red Not recommended for fibrillation to sinus rhythm (TA675 - arrhythmias routine use / Not terminated appraisal) commissioned

Verteporfin With photodynamic therapy (PDT) - 11.8.2 Ocular diagnostic and Red Hospital / Specialist Chronic Central Serous Chorio- peri-operative only Retinopathy preparations

Vildagliptin ▼ Type 2 diabetes - see specific criteria 6.1.2 Antidiabetic drugs Double-GreenSuitable for GPs to for use initiate and prescribe

Vinflunine Treatment of advanced or metastatic 8.1.4 Vinca alkaloids and Double red Not recommended for transitional cell carcinoma of the etoposide routine use / Not urothelial tract - as per NICE TA 272 commissioned

Vinorelbine Non-small cell lung cancer 8.1.4 Vinca alkaloids Red Hospital / Specialist only

Vinorelbine Advanced breast cancer - as per NICE 8.1.4 Vinca alkaloids Red Hospital / Specialist 81 only

Virulite electronic cold sore Electronic cold sore device Not listed in the BNF - Double Red Not recommended for device device routine use / Not commissioned

Vismodegib ▼ Basal cell carcinoma 8.1.5 Other antineoplastic Double Red Not recommended for drugs routine use / Not commissioned

Vitamin / Multivitamin products Vitamin supplementation for a variety Not listed Double Red Not recommended for of indications routine use / Not commissioned

Printed: 14 September 2021 Page 82 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Vitamin B Co / Co Strong Time-limited use (10 days) only in re- 9.6.2 Vitamin B group Red Hospital / Specialist tablets feeding syndrome only

Vitamin E NICE Do Not Do - Pharmacological 9.6.5 Vitamin (tocopherols) Double Red Not recommended for neuroprotective therapy in Parkinson's routine use / Not disease - as per NG 71 commissioned

Von Willebrand factor, Von Willebrand's disease / factor VIII 2.11 Blood glycoprotein Double Red Not recommended for recombinant - Factor VIII deficiency (coagulation Factor routine use / Not VIII) commissioned

Voriconazole Systemic fungal infections 5.2 Antifungal drugs Red Hospital / Specialist only

Vortioxetine Major depressive episodes in adults 4.3.4 Antidepressants - Double-GreenSuitable for GPs to having a first or recurrent major serotonin modulator & initiate and prescribe depressive episode, if the current stimulator episode has not responded to two antidepressants as per NICE TA 367

Warfarin Various 2.8.2 Oral anticoagulants Double-GreenSuitable for GPs to initiate and prescribe

Warfarin Routine use in combination with 2.8.2 Anticoagulants - Double Red Not recommended for prasugrel or ticagrelor to Coumarins and routine use / Not people who need anticoagulation who phenindione commissioned have had an MI - as per NICE CG 172 - Do Not Do

Wasp / Bee venom extract Wasp / Bee venom allergy - as per 3.4.2 Desensitising vaccines Red Hospital / Specialist (Pharmalgen®) NICE TA 246 only

Yasmin Contraception 7.3.1 Standard strength Double red Not recommended for combined hormonal routine use / Not contraceptive commissioned

Yohimbine Erectile dysfunction Not listed in the BNF Double Red Not recommended for routine use / Not commissioned

Zanamivir Treatment of influenza in at-risk 5.3.4 Antiviral drugs Double-GreenSuitable for GPs to people as per NICE Guidance initiate and prescribe

Zanamivir Prophylaxis of influenza in at-risk 5.3.4 Antiviral drugs Double-GreenSuitable for GPs to people as per NICE Guidance initiate and prescribe

Ziconotide Intrathecal analgesia for severe Analgesics Double Red Not recommended for chronic pain - as per NHS England routine use / Not Policy 16011/P commissioned

Zidovudine (also with HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist lamivudine and Abacavir) antiretroviral drugs only

Zoledronic Acid To prolong survival and prevent 6.6.2 Drugs affecting bone Red Hospital / Specialist skeletal-related events (SREs) in metabolism only patients with plasma cell myeloma

Zoledronic acid 6-monthly infusions for 2 years to 6.6.2 Drugs affecting bone Red Hospital / Specialist improve survival in post-menopausal metabolism only women with breast cancer receiving chemotherapy

Zolpidem Short term treatment insomnia (up to 4.1.1 Non-benzodiazepine Double-GreenSuitable for GPs to 4 weeks) - as per NICE TA 77 hypnotics and initiate and prescribe sedatives

Zonisamide Adjunctive therapy in the treatment of 4.8.1 Control of epilepsy Green GP prescribable at partial-onset seizures with or without request of secondary generalisation in patients Consultant/Specialist with epilepsy aged 18 years and older

Printed: 14 September 2021 Page 83 of 83